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Regulation of chromatin composition and structure is crucial for maintaining genome 
integrity and execution of the wide array of functions related to gene regulation and 
downstream cell signaling. Chemical modifications of chromatin are at the core of these 
processes and include methylation of the primary sequence of DNA, as well as various 
modifications of the proteinaceous chromatin packaging units - the histones. Recent 
genome-wide mapping approaches have been instrumental for characterization of the 
location and distribution of these marks relative to the different functional domains and gene 
regulatory elements in chromatin. The majority of the characterized chromatin modifications 
function as signaling platforms for recruitment of various protein complexes. Therefore, it is 
of equal importance to describe these sets of proteins for dissection of the functional 
consequence of their binding. More importantly, global analysis of the interactomes of 
functionally associated chromatin modifications might shed light on the proteins required for 
establishment and operation of specific chromatin domains. 
In this study, a novel approach for identification of chromatin modification-dependent 
protein binding was established. In vitro reconstituted oligonucleosomal templates with 
homogeneous and defined modification status were used for affinity purification from SILAC-
labeled nuclear extracts. The interactomes of ten individual chromatin species were 
investigated and the results provided valuable insight into chromatin biology on several 
levels. Investigation of the nature of the subproteomes recruited by single modifications 
provided evidence for their functional role. Additionally, the results offer a comprehensive 
catalogue of candidate proteins for further dissection of specific chromatin modification 
molecular readout. This was exemplified here with the demonstration of the recruitment of 
the SWI/SNF complex to monoubiquitylated H2B-containing chromatin for regulation of 
transcription of a specific set of genes. Investigation of the interactome of doubly modified 
chromatin identified a large number of factors whose recruitment presumably depends on 
the cooperative action of two modifications. Furthermore, the comparative analysis of 
individual datasets revealed novel relationships between the different modifications. On a 
global scale, this resulted in the identification of a limited set of proteins that likely play an 
important role for the function of heterochromatin domains. Lastly, the chromatin affinity 
purification approach was used for developing a SILAC internal standard method for direct 








The genomic DNA of eukaryotes is confined within the membranes of the cell nucleus. 
Its physiological structural and functional form – chromatin, is an intricate 
deoxyribonucleoprotein complex that is at the core of regulation of virtually all DNA-
templated processes. These are carried out by a large number of chromatin proteins and 
macromolecular complexes. An important feature of many of these complexes is their 
recruitment or regulation by chemical modifications of the chromatin structural proteins and 
the DNA itself. The chromatin modifications are crucial for reading and translating the 
information within the genome in a programmed and organized fashion, resulting in tightly 
regulated, specific and selective gene expression during different stages of development or 
in different cell types. Moreover, there is evidence for the involvement of these modifications 
in epigenetic phenomena – the propagation of heritable traits “coded” beyond the sequence 
of the DNA. 
 
2.1 Chromatin structure and organization 
2.1.1 The nucleosome core particle 
The length of the DNA molecules in eukaryotic cells far exceeds the dimensions of 
the nucleus and therefore mechanisms exist that allow its compaction. This compaction can 
result in up to 10 000-fold decrease in size and is achieved at several structural levels. The 
basic structural unit of chromatin is the nucleosome core particle. It consists of 147 base 
pairs (bp) DNA wrapped around two copies of each histones H2A, H2B, H3 and H4 (Figure 
2.1 A) [1]. The histones are relatively small (11-15 kDa) and basic proteins that are highly 
conserved among all eukaryotes. Despite having no apparent sequence homology, the four 
histones share high degree of structural homology – namely the histone fold motif. It 
consists of two short α-helices flanking a third long helix, which are connected by two loops. 
These structural motifs take part in the protein-protein, as well as in the protein-DNA 
interactions that form the nucleosome core particle. The histone proteins interact with each 
other as heterodimers. H2A interacts with H2B, and H3 – with H4. In addition, and under 
higher concentrations in vitro, two H3/H4 dimers form a tetramer (Figure 2.1 B) [3]. Two 
H2A/H2B dimers and one H3/H4 tetramer constitute the histone octamer, around which the 
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147 bp of in DNA is wrapped in a 1.65 tight superhelical turn (Figure 2.1 A). However, both 
in vivo and in vitro, these interactions are executed in a stepwise fashion. First, the H3/H4 
tetramer interacts with the central stretch of DNA, followed by the H2A/H2B dimer. 
Importantly, the protein-DNA interactions within are not nucleotide-, and therefore sequence-
specific [4]. Nevertheless, because of greater bending properties, A-T-rich sequences facing 
the histone octamer in the minor groove of DNA are preferred [3]. Within the structure of the 
nucleosome core particle, more than 75% of the DNA surface remains free and available for 
additional protein-DNA interactions [3]. The N-terminus of all four histones, as well as the C-
terminus of H2A, are far less structured than the histone fold motif. They are arginine- and 
lysine-rich and are responsible for the majority of the sequence variability between different 
species. They protrude outwards from the nucleosome core and are not visible in any of the 
3D crystal structures determined to date. Nevertheless, they are crucial for interactions with 




Figure 2.1  Nucleosome core particle structure  
A. Crystal structure of the nucleosome core particle with front and side views (PDB ID 1KX5) [2] 
visualized using MacPyMol (http://pymol.org). Histone proteins are coloured as indicated, DNA is 
coloured gray. Alpha-helical regions are represented as cylinders. B. As in A, but only the histone 





Apart from the four canonical types of histones, there are a number of major non-
allelic histone variants that bring about structural and functional heterogeneity in different 
nucleosome core particles. They are expressed in all tissue types and can be incorporated 
in chromatin during different stages of development and the cell cycle. All histones, but H4, 
have such variants and while some are differing from the canonical form by only a few amino 
acids (for example H3.1 and H3.3), others have additional domains (for example H2A and 
macroH2A) [3]. 
 
2.1.2 Higher order structures and chromatin domains 
The nucleosome core particle is the fundamental unit of chromatin. The linear 
arrangement of these structures along the DNA constitutes the first level of DNA compaction 
– the 10-11 nm wide “beads on a string” form of chromatin (Figure 2.2 A). Individual 
nucleosome core particles are separated by 10-60 bp of linker DNA. The nucleosome core 
DNA, linker DNA and the histone octamer together form the nucleosome. A fifth class of 
histones – the linker histone H1, interacts extensively with the linker DNA and the 
nucleosome core particle, forming a structure called chromatosome, and is essential for 
higher levels of chromatin compaction [7]. Under physiological salt conditions the 
nucleosome beads on a string chain can fold into a higher order structure – the 30 nm fiber 
[7]. Several models of the architecture of this structure have been proposed [7, 8], however 
it’s exact organization and physiological significance remain controversial [9]. The higher 
levels of chromatin organization are even more elusive and presumably involve long-range 
chromatin loop interactions. 
Cytologically, chromatin can be divided in two main categories – euchromatin and 
heterochromatin. Historically, heterochromatin was described as the distinct part of 
chromatin that remained compacted throughout the cell cycle and was visible as more 
densely stained regions of the nucleus using dyes with affinity for DNA under light 
microscopy (and later observed as more electron-dense regions using electron microscopy, 
Figure 2.2 B), unlike euchromatin that undergoes general decondensation during interphase 
[10, 11]. Generally, heterochromatin is characterized with lower gene density, high content 
of repetitive sequences and late replication [7]. The centromeres and telomeres are part of 
constitutive heterochromatin, which is present in all cells at all times, while regions that are 
specifically compacted and silenced during development and differentiation are termed 
facultative heterochromatin. Euchromatin, on the other hand, is more relaxed, replicates 
early in S-phase and mostly includes gene-rich regions of the genome. Even though this 
near-century old classification of chromatin domains is backed up by molecular and 
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biochemical evidence, it is now clear that upon closer look, there are more chromatin 





Figure 2.2  Higher order chromatin structures and domains 
A. Several levels of chromatin condensation. Nucleosomes are arranged as “beads on a string”, 
which interact to form the “30 nm fiber”. These are then condensed by yet unknown mechanisms 
and interactions into mitotic chromosomes. Adapted from [13] with permission from the publisher. 
B. Electron micrograph of a C. elegans neuronal cell body. Arrows indicate darker regions of the 
nucleus, scale bar represents 1 µm. The micrograph was acquired on U/Pb-contrasted 
ultramicrotom sections of high-pressure frozen C. elegans in the laboratory of Dr. Stefan Eimer, 































2.2 Chromatin modifications and their readers 
The fundamental unit of chromatin – the nucleosome, is not only a static structural 
component with DNA-compaction functions. It is highly dynamic throughout the cell cycle 
and can exist in different forms. One degree of diversity is achieved by incorporation of 
histone variants. Additionally, differential and specific positioning of nucleosomes along the 
DNA molecule is possible from the action of multiple chromatin remodeling complexes [14]. 
The dynamics of these processes reflects the changing requirements for execution of 
different genetic programs at different stages of the cell cycle or variable environmental 
conditions. Post-translational modifications (PTM) of histones and modifications of DNA are 
an enormous source for such variability and play central role in regulating virtually all DNA-
templated processes [15].  
 
2.2.1 Types of chromatin modifications and associated functions 
General properties and establishment of histone modifications 
The fact that the histone proteins are chemically modified in vivo was recognized for 
the first time nearly 50 years ago [16]. However, especially with the advancements in mass 
spectrometry-based proteomics [17-19], it has only recently been possible to site-specifically 
identify (and quantify) the wide array of histone modifications. Virtually every known type of 
protein PTM has been found on histones. There are nearly 200 detected sites of 
modification and the number is still growing [20]. While the majority of these PTMs are found 
in the flexible N- (or C-) terminal tails, there are a number of modified sites in the histone 
core regions as well. There is functional evidence only about a fraction of those 
modifications, and while some types of PTM have been widely studied, there are only single 
reports for the existence of whole classes of others (e.g. tyrosine hydroxylation [20]). 
Methylation and acetylation of lysine comprise the most abundant classes of histone 
modifications. Additionally, methylation of arginine, phosphorylation of serine and threonine, 
are well studied. Other classes of PTMs include crotonylation, glycosylation, hydroxylation, 
ADP-ribosylation, deimination, proline isomerization, citrulination and H3 tail clipping. 
Furthermore, the conjugation of whole proteins is also well documented, with the examples 
of monoubiquitylation and to a lesser extent – sumoylation [21]. The tremendous degree of 
diversity comes not only from the different positions of the modifications, but also from their 
degree. Methylation can be found in three varieties for both lysine (mono-, di- and tri-) and 
arginine (mono-, symmetric and asymmetric di-) residues. 
The establishment of histone modifications is a highly dynamic process and the 
majority of them have a high turnover [15]. This is regulated by the opposing activities of the 
enzymes responsible for depositing or erasing these PTMs. The process of histone 
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acetylation and deacetylation is arguably most well studied [22, 23]. The enzymes depositing 
acetyl marks on histones are known as histone acetyl transferases (HATs), and those 
erasing the modification – histone deacetylases (HDACs). There are many different 
enzymes that catalyze these processes, and they are specific for certain histone residues or 
distinct molecular processes. High sequence and function specificity is even more evident 
for lysine methylation [15]. The enzymes catalyzing this modification are termed lysine 
methyl transferases (KMTs) and those erasing it – lysine demethylases (KDMs). Additional 
level of complexity stems from the finding that many lysine HMTs show specificity only for a 
certain degree of methylation, while others are capable of mono-, di- and trimethylation. The 
same holds true for the histone demethylases [15].  
 
Functional consequences 
Because of the wide variety and degrees of histone modifications they hold an 
enormous potential for functional responses. While histone hyperacetylation is generally 
associated with active transcription and hypoacetylation with repressed transcription [16, 
24], the functional consequence of the majority of other modifications is specifically 
dependent on the site, degree and timing of modification. Generally, histone modifications 
have been linked to transcriptional regulation, DNA repair, cell cycle progression, alternative 
splicing, chromosome segregation, epigenetic silencing, nucleosome remodeling and other 
major cellular processes [25-27]. A brief description of the main functional consequences 
and modifying enzymes for more prominent histone modifications is given in Table 1. 
Histone modifications exert their function by two major mechanisms. The first mechanism 
relies on direct disruption of contacts between individual nucleosomes or between the 
histones and DNA. The best characterized such effect is by histone acetylation. Deposition 
of acetyl group has a strong effect as it neutralizes the positive charges of lysine residues. 
For example acetylation of lysine 16 in the N-terminal histone tail of H4 can significantly 
affect internucleosomal contacts and completely disrupt higher order chromatin 
condensation [28]. On the other hand, acetylation of H3K56 can affect (H3/H4)2 tetramer 
contacts with DNA, but this does not contribute to destabilization of nucleosomes [29]. 
Lastly, ubiquitylation of H2B can interfere with chromatin compaction and results in more 
accessible chromatin arrays [30]. The second mode of action is by recruiting specific non-
histone proteins to chromatin. In such manner, the histone modifications function as 
molecular beacons and depending on the site, type and degree of the modification, can 
recruit a wide variety of proteins and affect virtually all DNA-templated processes. The 






Table 1  Selected histone modifications, their functions and deposition enzymes 
Representative histone modifications, their functions and deposition enzymes. ac – acetylation, 
me1/2/3 – mono-/di-/trimethylation, me2a – asymmetric dimethylation, me2s – symmetric 
dimethylation, ph – phosphorylation, ub – monoubiquitylation, sumo – sumoylation. Based on [21, 










H2B H2BK12ac Transcriptional,activation p300/CBP
H2BK120ub Transcriptional,activation,and,elongation BRE1
























Chromatin modifications and their readers 
 
 10 
Distribution in chromatin and the genome 
Taking together the functions of individual histone modifications (Table 1) and the 
concept of active euchromatin and inactive heterochromatin, it is not surprising that 
individual PTMs have specific distribution along the genome. There are modifications 
specific for one type of chromatin and excluded from the other type. The most prominent 
histone modifications for constitutive heterochromatin, are H3K9me3, H4K20me3 and to a 
lesser degree H3K27me3 [33]. Additionally, dimethylation of H3K9 and H3K27 are often 
found together with the respective trimethylation marks. High resolution mapping of histone 
modifications at these regions is, however, very difficult owing to the repetitive nature of the 
underlying DNA sequence. Nevertheless, advances in computational approaches for 
analysis of high-throughput sequencing data have shown that different regions of 
constitutive heterochromatin, including gene deserts, subtelomeres, centromeres and 
pericentromeric regions are not monolithic and can have varying levels of histone 
modifications, with prevalence for one or another mark (Figure 2.3 A) [34, 35]. A hallmark 
modification for facultative heterochromatin is H3K27me3, along with the associated 
Polycomb repressor complexes [36]. An important feature of chromatin are the boundary 
elements, or insulators, that prevent spreading of heterochromatic regions [37]. They contain 
high levels of the protein CTCF, as well as the H3K9me1 mark [38]. CTSF, in particular, has 
also been implicated in mediating higher order chromatin organization and regulating the 
dynamics and localization of heterochromatic domains [39]. 
Transcriptionally active euchromatin contains a large number of characteristic 
histone modifications. However, these are not distributed equally. There are regions, 
especially those employed at different stages of transcriptional regulation, that are 
particularly modification-rich. The general modification landscape of an active gene is 
represented in Figure 2.3 B. The transcriptional start site (TSS) contains high levels of 
methylated H3K4, particularly H3K4me3, as well as acetylation of H3K9. Methylated H3K79 
is characteristic for the 5’-region of the active gene, while H3K36me3 – for the 3’-region. 
H3K9me2/3 and H3K27me2/3 are excluded from the active gene bodies [15]. Silent genes, 
on the other hand, contain high levels of H3K9me2/3 and H3K27me2/3 and are depleted 
from active marks, such as H3K4me and H3K9ac (although these could be found at low 
levels at the TSS) (Figure 2.3 C) [40]. Interestingly, a specific pattern consisting of H3K4me3 
and H3K27me3 is present at genes that are expressed at low levels but poised for activation 
in ES cells. Upon differentiation, the modification status resolves in either H3K4me3 and 






Figure 2.3  Distribution of histone modifications along the genome or at representative genes. 
Levels of different histone modifications along different chromatin domains (A), active (B) inactive 
(C) and bivalent-poised (D) genes. A illustrates the distribution along the genome length and 
does not represent a mitotic chromosome. Transcriptional start site (TSS) is marked with an 
arrow and gene body with dark rectangle. This is a cartoon illustration and does not represent the 
true complexity and variability of the levels at different genes. A is based on information from 
[35]. B is adapted from [15] with permission from the publisher; C and D are based on data from 
[38, 40, 42];  
Recent studies mapping the high-resolution profile of all known (at that time) sites of 
histone methylations and acetylations [38, 43] have significantly expanded our 
understanding of the chromatin landscape. It was shown that histone acetylation in general 
is associated only with active genes. It appears that the histone modification landscape of 
active genes is more complex than previously appreciated (Figure 2.4). Multiple methylation 
and acetylation marks have specific positions with respect to gene controlling elements. 
While H3K4me3 and H3K9ac are associated mainly with the TSS, H3K4me2, H3K9me1, 
H3K27me1, H4K20me1 are characteristic also for the gene body. Strikingly, the distribution 
of the monomethyl modification level of H3K9 and H3K27 is in stark contrast to the 
distribution of their di- and tri-methyl counterparts, mainly associated with silent loci. 
H3K4me1, on the other hand, has highest levels at enhancer elements. Insulators show 























































































































































































Figure 2.4  Distribution of fourteen histone modifications and CTCF in the region of an active 
gene 
Distribution of the indicated histone modifications and CTCF in the enhancer, insulator and TSS 
regions and the gene body of an active gene. This is a cartoon representation and does not show 
the true complexity and variability of the modification levels within individual genes. Based on 
data derived from CD4+ T-cells [38, 43] and adapted from [44] with permission from the 
publisher. 
DNA methylation 
In addition to the plethora of histone post-translational modifications, DNA can also 
be chemically modified post-replicationaly. Methylation of the C5’ position of cytosines, 
mainly in CpG dinucleotides, is the most prominent and widely studied DNA modification in 
mammals [45]. Its existence has been proposed more than 100 years ago, and it was 
detected and unambiguously identified shortly afterwards [46]. In mammals, this modification 
is deposited by a class of enzymes – DNA methyl transferases (Dnmts), with differing 
activities. Dnmt3a and Dnmt3b establish the de novo methylation pattern, while Dnmt1 is a 
maintenance methyl transferase during replication and repair and has a preference for 
hemimethylated DNA [45]. CpG dinucleotides are found throughout the genome, but are 
concentrated at gene-rich regions. Moreover, even though 60-80% of the CpG sites in the 
mouse and human genomes are methylated [47], CpG methylation is found at higher levels 
























sequences like promoters and enhancers are methylated to a lower level [48]. Sequences 
with higher than average CpG content are termed CpG islands and are found often 
unmethylated at promoters of constitutively expressed genes [46]. Methylation is associated 
with gene silencing, as well as with repression of transposable elements and transcriptional 
noise in general [49]. Interestingly, DNA methylation at CpG island promoters correlates very 
well with reduced gene expression, however methylation of promoters with low CpG content 
does not influence transcription significantly [46, 50, 51]. It is thought that the mechanisms of 
DNA methylation-regulated gene expression depend on either direct loss of transcription 
factor binding site on DNA, or on recruitment of proteins binding to methyl-CpG (meCpG) 
[46] 
 
2.2.2 Functions of chromatin modification-binding proteins 
The distribution of histone and DNA modifications throughout the genome and their 
association with differential gene expression or with particular chromatin domains are well 
established for a number of model organisms and cell types. Mounting evidence suggests 
that the main mechanism of localized action of these modifications is by recruitment of 
specific proteins and protein complexes [25]. It is clear that for the majority of modifications 
not only the exact chemical group, but also its precise position and surrounding residues are 
determinant for different functional consequences. While some acetylation positions are 
interchangeable [52], this is not the case for others [28, 29]. Methylation shows even higher 
level of specificity, where different degrees of modification, as well as the exact position 
could have profoundly different impact [43, 53]. The possibility of combinatorial effects of 
different modifications expands the signaling potential tremendously. It has been postulated 
that the protein “readers” and “effectors” associated with these marks are part of a “histone 
code” where specific combinations of PTMs exert specific functions that determine the 
functional status of the underlying DNA [27, 54]. However, while there are examples of 
cross-talk between different modifications and combinatorial recruitment, evidence for a true 
code-like behaviour with high levels of specificity on protein level is scarce. 
 
Recognition of chromatin modifications by “reader” domains 
Translation of the signals from individual modifications requires specialized molecular 
recognition of the recruited proteins. Indeed, chromatin mark-binding proteins contain  
“reader” domains that bind specifically to modified (or unmodified) residues, as well as DNA. 
In the majority of cases, they are found in multiple copies or together with other domains, 
creating specific recognition modular assemblies [53]. Most prominent histone modification-
binding domains are bromodomains, tudor domains, plant homeodomains, MBT repeats, 
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PWWP, chromodomains and 14-3-3 domains. The first identified example of histone 
modification binding domain is the bromodomain, which binds acetyl-lysine residues with 
remarkable sequence specificity [55]. It is found in many transcriptional regulators, including 
HAT enzymes. It is often positioned near another histone-binding domain – the plant 
homeodomain (PHD) Zn-finger [53]. It was recently demonstrated that PHD fingers can also 
recognize acetylated lysines [56]. However, they are best known as general protein-protein 
interaction domains, and in particular - methylated lysine recognition motifs. There are 
numerous reports, as well as 3D structures, indicating the interaction of PHD domains with 
methylated H3K4 [57, 58]. Tudor domains are often found in tandem (TTD), where one of 
the folds interacts with a methylated lysine and the other is free for potential ligands [59, 60]. 
Tudor domains have also been shown to recruit proteins to methylated arginines [61, 62]. 
The MBT repeats bind preferentially to monomethyl, or in some cases dimethyl lysines [63], 
while often having no particular sequence context specificity [64]. PWWP domains have not 
been investigated as extensively as the other chromatin binding folds. There are several 
reports demonstrating their binding to mono- [65] and trimethyl lysines [66]. Chromodomains 
are well characterized as methyl recognition domains both structurally and functionally. They 
are divided into several subclasses, including the chromobox and HP1-type, the CHD 
chromodomains, and the chromo shadow and chromo barrel domains [58]. HP1 and 
chromobox chromodomains have been found to interact with methylated H3K9 and H3K27. 
CHD-type of chromodomains appear in tandem and several 3D structures including 
recognition of H3K4me have been determined [67]. The chromoshadow domains, on the 
other hand, do not interact with histones. In HP1 proteins they act as dimerization domain, 
and as such, create a platform for protein-protein interactions with factors containing a 
conserved PxVxL motif [68, 69]. The tudor, PWWP, MBT and chromodomains are 
structurally related and are part of the so called Royal family of methyl-lysine recogntition 
domains [53]. 
Phosphorylation of serine and tyrosine are recognized by distinct protein domains - 
BRCT and 14-3-3, respectively [70, 71]. Phosphoserine is often found next to another 
modified residue and can function in disruption or weakening of the recognition of the 
adjacent modification [72]. 
Proteins binding to methylated cytosine also contain specific recognition domains. 
meCpG-interacting proteins can be divided in three different groups – the meCpG-binding 
domain (MBD), Uhrf and Kaiso families [46]. The MBD group of proteins bind meCpG via 
their MBD domain and often recruit HDAC and KDM proteins for gene silencing. However, 
there are examples where these proteins are recruited independently from meCpG and not 
exclusively linked to gene repression [46]. The two members of the Uhrf family – Uhrf1 and 
Uhrf2, recognize meCpG via an SRA domain [73, 74]. Uhrf1 can also recruit HDAC and 
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KDM enzymes, suggesting involvement in gene silencing [73]. The members of the Kaiso 
family of meCpG binders contain BTB/POZ motif and their recruitment is mediated by a 
Krüpel-like C2H2 zink finger [46]. 
 
Functional consequence, modes of chromatin modification binding and cross-talk 
There are numerous chromatin-associated proteins that show specific recruitment by 
histone and DNA modifications. Some have been identified by large-scale approaches [75-
78], while others have been targeted following known functional association or by educated 
guesses [79]. These proteins and their recruitment have been implicated in a wide range of 
cellular functions. More prominent examples of proteins binding to specific histone 
modifications, the recognition modules, the influence of other modifications and the known 
associated functional consequence are summarized in Table 2 
From the provided examples it is clear that while there are paradigms where only a 
single protein is known to recognize a particular modification, in the majority of cases there 
are multiple different factors, and the associated complexes, binding to a chromatin mark 
with similar, divergent or opposing functional consequences. Moreover, these interactions 
can in addition be dependent on the recognition of the surrounding amino acids sequence, 
as well as the surface of the histone proteins and DNA within the same or adjacent 
nucleosomes (Figure 2.5 and examples below). Therefore, it is not surprising that the 
chromatin associated proteins or complexes often are modular assemblies of several 
functional domains. On one hand, multivalent interaction could enhance specificity, and on 
the other – multiple weak interactions could contribute to overall stronger binding [6]. For 
example, the TAFI subunit of TFIID recognizes two acetylation marks on histone H3 
(H3K5acK12ac) via double bromodomains [80]. Moreover, another subunit of TFIID, TAF3, 
specifically recognizes the H3K4me3 mark [81]. The interaction of the complex with 
H3K4me3 is thus stronger when this modification is flanked by the two acetyl marks [75]. 
Another level of combinatorial recruitment might be provided by a third TFIID subunit – TBP 
binds the TATA box DNA sequence and is important for recognition of TSS [82]. 
Multivalent interaction can also be achieved by a single multidomain chromatin 
factor. TRIM24 recognizes the nonmethylated H3K4 residue (H3K4me0) and at the same 
time H3K23ac [83]. UHRF1 is a multidomain protein that interacts with several H3 residues 
and in addition with DNA [84]. While the contribution of each binding event towards the 
overall strength of recruitment remains to be quantified accurately, it has been established 
that the protein recognizes the unmodified H3 tail, methylation of H3K9 and/or DNA, and its 
binding is antagonized by methylation of H3K4 and H3R2 [84]. Multivalent interaction can 
also be achieved by binding multiple targets from different histones within the same 
 




Mark Histone Position Protein Recognition0
domain +/50effect0from Functions
H3 K4me0 WDR5 WD40 HAT
UHRF1 PHD H3R2me1/2

















PHF80(3) PHD H3K9/14ac Histone0demethylation
JMJD2A0(2,3) Tudor H3T3ph Hystone0demethylase
Sgf290(3) Tudor H3K9/14ac Histone0acetylation
K9 HP10(2,3) Chromo Y41ph,0S10ph Heterochromatin
Tip600(2/3) Chromo DNA0damage
CDYL Chromo S10ph Represor0of0REST




K27 EED0(2,3) WD40 PRC0mediated0repression




K36 Eaf30(2/3) Chromo Histone0deacetylation
NSD1/2/3 PWWP Histone0methylayion
K79 53BP10(2) Tudor DSB0response






H3 R2me WDR50(2s) WD40 HAT
R17 TDRD30(2a) Tudor Transcriptional0activation
H4 R3 TDRD30(2a) Tudor Transcriptional0activation
Dnmt3a0(2s)
PCAF/p3000(2) H30acetylation
H3 S10 145353 145353 Transcriptional0activation
Gcn5 Histone0acetylation
S28ph 145353 145353
H2B K120 WDR82/Cps35 H3K40methylation
H3 K14 DPF3b Tandem0PHD K4me Remodeling
K23 TRIM24 Bromo Chromatin0activation
H4 K5,8 Brdt Bromo Chromatin0compaction














nucleosome. In this sense, BPTF recognizes H3K4me3 via a PHD finger and H4K16ac via a 
bromodomain, and this trans-histone recruitment shows remarkable selectivity [85]. There is 
also evidence for proteins and protein complexes interacting in trans-nucleosome fashion 
[6]. L3MBTL1 can compact nucleosomal arrays dependent on H4K20me1/2 and 
H1bK26me1/2, and the MBT domains of this protein can interact with at least two 
nucleosomes simultaneously [86]. Lastly, long non-coding RNAs (lncRNAs) can also 
function in targeting chromatin proteins. This has been shown for the polycomb repressive 
complexes PRC1 and PRC2 [6]. lncRNAs have also been implicated in targeting HP1, a 
prominent H3K9me binder, to pericentromeric heterochromatin [87]. Examples of several 
possible binding modes are illustrated in Figure 2.5, however, different combinations and 




Figure 2.5  Binding modes of proteins recruited to chromatin 
Several scenarios of binding modes depending on histone and/or DNA modifications. Different 
modifications are represented as coloured circles on the histone tails or triangle on DNA. A 
protein can interact with one modification and be ejected by another (Repulsion); binding can be 
achieved via histone modification and DNA (+DNA) or meCpG (+meCpG) interacting domains; 
recruitment by two identical (Double homo) or different (Double hetero) modifications; a protein 
can bind unmodified residue (Unmodified) or a single modification (Single); a homodimer can be 
stabilized by two modifications (Homodimer); the recruitment of a factor can depend on 





ç  Table 2  Histone modifications and their binding proteins  
Examples of the most widely studied histone modifications and their binding proteins. The 
recognition domain, known cross-talk with other modifications and functional relevance are 
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Besides in binding of factors to multiple chromatin modifications, a different level of 
“cross-talk” can be achieved by recruitment of effector proteins via secondary interactions. 
Importantly, these effector proteins can function as “erasers” or “writers” of additional 
chromatin modifications. An example of this is the recruitment of H3K4 and H3K79 methyl 
transferases by recognition of ubiquitylation of H2B [88, 89]. In the case of repressive marks, 
methylation can recruit enzymatic activities for heterochromatin spreading. In the first 
example, the EED subunit of the polycomb complex PRC2 is recruited by trimethylated 
repressive marks and the binding results in allosteric activation of H3K27 methylation activity 
[90]. Methylation of H3K9, on the other hand, can recruit different HP1-containing complexes 
and result in DNA methylation and histone deacetylation [91, 92]. Another link between 
histone modification and DNA methylation are the examples of HDAC recruitment by 
meCpG binding proteins discussed in the previous section. 
Thus, it is clear that the chromatin readout by modifications of histones and DNA is a 
complex process where multiple synergistic or antagonistic levels of interaction can exist. 
While there are systematic efforts to catalog the proteins binding to individual or limited sets 
of modifications [32, 75-78, 81], the examples given above are among the few available 
where cross-talk between individual modifications has been demonstrated. Examples for 
recognition of multiple modifications in a code-like manner by individual proteins or protein 
complexes are even scarcer. There is more and more evidence regarding the transcriptional 
control of gene-rich areas of the genome, however, it is still far from clear what is the 
function of the discovered complex patterns of modifications (Figure 2.3 and 2.4). Even 
though these patterns are thought to be less complex in heterochromatic regions, there is a 
clear difference in the distribution of individual chromatin marks among separate 
subdomains. On a more global scale it remains to be revealed how these subdomains 
function differentially, what is the interactome of a chromatin domain as determined by its 
modification signature and what is the interplay and connections between the proteomes of 
multiple modifications and combinations thereof. 
 
Methods for systematic analysis of chromatin modification readout 
Several array-based technologies have been used to screen the interaction of 
modified histone peptides with immobilized reader domains [63, 100], or vice versa using 
immobilized peptides to screen for a library of interaction partners [101]. However, these 
methods are restricted to the use of libraries of prey molecules and cannot identify 
unpredicted interactions. Therefore, affinity approaches for purification of proteins from 
cellular sources have become the method of choice for de novo identification of histone and 
DNA binding proteins and complexes. Like array-based assays, these methods can function 
in two ways. In one example, the chromatin protein 53BP1 was used as bait to screen native 
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purified histones. Mass spectrometric analysis then revealed that H3 carrying methylation at 
K79 was preferentially bound [102]. On the other hand, affinity approaches using N-terminal 
modified histone peptides have proven extremely useful for identification of multiple 
modification-dependent interactions of proteins and protein complexes [103]. In peptide pull-
downs a chemically synthesized modified peptide is incubated with isolated nuclear extracts, 
the bound proteins are analyzed by mass spectrometry, and the results compared to a 
control experiment using an unmodified counterpart peptide. This approach is 
straightforward and easy to implement, and has recently been coupled to quantitative mass 
spectrometry and used for cataloguing the interaction partners of several histone 
modifications [32, 75, 76]. However, as the peptides in this type of assay can only be 
synthesized in limited size, they reflect the local environment of the histone modification and 
cannot replicate additional interactions with histones, DNA or other non-adjacent 
modifications. Therefore, affinity approaches using recombinant chromatin templates are of 
great interest. Uniformly and homogeneously modified histones can be created by one of 
several available approaches [29, 104, 105] and can be reconstituted into 
mononucleosomes or nucleosomal arrays [106-108]. These complexes not only mimic the 
native chromatin in vivo, but also allow for the incorporation of multiple histone and DNA 
modifications in combination. Therefore, affinity purification using homogeneously modified 
in vitro reconstituted chromatin species is a promising candidate assay for the elucidation of 
the complex interactions and cross-talk between different chromatin modifications and their 
binding partners. Moreover, coupled with state-of-the-art quantitative mass spectrometry, it 
will allow unbiased and sensitive interrogation of the chromatin modification associated 
interactomes. 
 
2.3 Mass spectrometry for protein identification and quantification 
2.3.1 Protein identification by mass spectrometry 
Proteins are one of the major classes of macromolecules in living cells and 
participate in virtually every molecular process. Unambiguous protein identification is 
therefore crucial for all areas of life science research. A classical approach for establishing 
protein identity is immuno-detection with antibodies. However, this method is targeted and 
therefore biased and also with low-throughput. One of the pioneering methods for unbiased 
protein sequence determination is Edman degradation [109]. It relies on chemical cleavage 
of N-terminal amino acid residues in a step-wise manner. The technique has significantly 
pushed forward protein-centered research, however, it requires a large amount of 
homogeneous samples, free N-termini and even in an automatized manner is still very time-
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consuming. Because of these limitations, protein analytical methods based on mass 
spectrometry have been developed. The routine exploitation of these methods for large 
nonvolatile molecules became possible after the advent of the soft ionization techniques of 
matrix-assisted laser desorption/ionization (MALDI) [110, 111] and electrospray ionization 
(ESI) [112]. Instrumental for the wide adoption of these approaches was the knowledge of 
the genome sequence, and hence the proteome sequence, of multiple organisms. The 
general workflow of a typical proteomics experiment consists of several steps (Figure 2.6): 
a) hydrolysis of the analyzed proteins into peptides; b) determination of the peptide mass-to-
charge ratio (m/z) by MS analysis; c) selection of precursor peptide ions and their 
fragmentation using MS/MS; d) determination of the peptide sequence and identification of 
the peptides, and consequently the proteins, by comparing the experimentally derived 





Figure 2.6  MS-based protein identification workflow 
Proteins are hydrolyzed using specific endoproteases, the resulting peptides are analyzed by MS 
and selected for fragmentation by MS/MS. The precursor and fragment m/z values are compared 























































Depending on the size of the protein, the standard proteomics workflow can result in 
a complex mixture of peptides. As the mass spectrometers can analyze only a limited 
number of peptides at a time, even for single protein analysis a peptide separation step for 
reducing the sample complexity is beneficial. For complex proteomics samples with 
hundreds or thousands of proteins, separation of the peptides is usually not sufficient and 
reducing the complexity of the sample at protein level is required. Proteins can be separated 
using standard SDS-PAGE, followed by excision of protein bands and in-gel proteolysis 
[114]. This approach is very robust and has been the method of choice for numerous 
proteomics studies. Alternatively, proteins can be separated by isoelectric focusing, size 
exclusion or ion exchange chromatography followed by in-solution protease digestion. 
After protein digestion, the resulting peptides can be separated by different 
approaches. The most routine one relies on reversed-phase (RP) C18 chromatography and 
direct elution of the separated peptides into an ESI mass spectrometer. Additionally, peptide 
pre-fractionation can be done using strong cation exchange (SCX) chromatography. Often 
the separation at the level of proteins can be circumvented by using high performance 
peptide separation. This can be achieved by two-dimensional separation, e.g. SCX followed 
by RP chromatography [115], or peptide isoelectric focusing followed by RP chromatography 
[116]. Alternatively, novel filter-assisted sample preparation methods [117] and ultra high 
performance chromatography can be optimized for single step near complete proteome 
coverage [118]. 
Regardless of the separation technique used, the resulting peptides are further 
analyzed by mass spectrometry. In case of MALDI, the peptides are spotted and co-
crystalized together with a matrix on a stainless steel target and analyzed “off line”. This has 
the advantage that the peptides can be stored at room temperature and analyzed several 
times at different time points. For high-throughput identification, however, ESI offers 
immediate and fast analysis by directly coupling the last chromatography step to the mass 
spectrometer. Capillary or nano liquid chromatography methods use very low flow rates and 
sample amounts and are ideally suited for coupling to ESI mass spectrometers. 
After elution of the peptides through the ESI source into the mass spectrometer, their 
m/z ratio is measured using different physical approaches depending on the specific mass 
analyzer. Nevertheless, most mass spectrometers used in routine proteomics research 
operate by data-dependent-acquisition (DDA). A DDA analysis cycle consists of several 
steps. First, a complete MS scan over a specific mass range (e.g. 350-1600 m/z) detects the 
m/z ratios of all peptides eluting at that particular moment. The most intense precursor ions 
are then selected consecutively and fragmented independently in a MS/MS experiment. The 
number of selected peptides per MS scan depends on the speed of the mass analyzer and 
can range from 2-3 to over 20. Typically, the two stages of analysis are performed one after 
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another. Therefore, a faster mass analyzer can measure a higher number of peptides during 
the length of their LC elution profile and detection of peptides eluting later is not disturbed. 
Apart from speed, important features for high sensitivity are the accuracy and resolution of 
the mass analyzers. Higher accuracy results in more confident m/z and therefore mass 
assignment and better identification. The resolution is typically measured as the full peak 
width at half maximum intensity (FWHM). Higher resolution allows better m/z accuracy and 
the distinction between peaks with similar m/z. Resolutions of 60,000 and above and 
accuracy in the low ppm to sub-ppm range are now routine, additionally, accuracy can be 
further improved by software post-processing [119, 120]. 
 
2.3.2 MS-based quantification of peptides and proteins 
The application of mass spectrometry for identification of proteins is well established. 
These approaches allow the analysis of individual proteins or almost entire proteomes within 
single experiments [118], mapping and localization of post-translational modifications, 
elucidation of three-dimensional structure and contact sites within macromolecular 
complexes [121]. The use of mass spectrometry to identify interaction partners of specific 
baits is also well documented. However, the use of protein identity when comparing bait and 
control has several disadvantages. First, proteins binding in both experiments but with 
higher affinity for the bait cannot be identified as specific binders, thus resulting in a high 
false negative rate. Furthermore, it is difficult to determine whether bait-prey interaction is 
strong or weak. Therefore, in the last decade, much effort has been invested in developing 
various MS-based quantitative approaches. The applications of these methods range from 
focused analysis of the subunit stoichiometry of individual protein complexes [122], to almost 
entire proteome comparison between cell types [123]. 
 
General overview of MS-based quantification 
Mass spectrometry is not a quantitative method per se. Due to different 
physicochemical properties of different peptides and proteins, their signals within the mass 
spectrometer cannot be used for comparison. Quantification can be done only on chemically 
identical species between measurements or, if they differ in isotope composition, and 
therefore in mass, within the same measurement. The first group of methods is termed label-
free quantification. It relies on comparison of the signals from identical peptides and proteins 
between different measurements. The second group is based on stable isotope labeling 
techniques. Here, the peptide or protein species to be compared are differentially labeled 
with stable heavy isotopes and measured simultaneously. This results in chemically identical 
molecules that have different mass when measured by MS. In both label-free and label-
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based approaches the signals between the investigated molecules are compared. This 
comparison can be relative – direct measurement of the relative amounts of each species, or 
absolute – determination of the absolute amount of analyte based on spiked-in standards. 
The most widely used methods for label-free and label-based relative or absolute 





Figure 2.7  Approaches for label-free and label-based relative or absolute MS quantification 
Most widely used methods for relative (left) and absolute (right) MS-based quantification. 
Adapted from [124] with kind permission from Springer Science and Business Media. 
Label-free approaches [124, 125] have the advantage of comparing virtually 
unlimited number of samples, without additional cost for labeling procedures. They can be 
based on counting the number of peptides or spectra per peptide in each measurement, or 
comparing the intensities of precursor peptides on the MS detector. However, these 
methods rely on highly reproducible sample handling and chromatography separation, and 
usually require multiple technical replicates. Additionally, quantification of PTMs between 
different experiments can be very unreliable. These limitations encouraged the development 
of more accurate methods for direct quantitative comparison within the same mass-
spectrometric measurement using stable isotope labeling. Due to their natural occurrence, 
each peptide/protein contains a certain proportion of stable heavy isotopes of carbon, 
nitrogen, oxygen and hydrogen (e.g. 13C, 15N, 18O, 2H, respectively) that produce a mass 
shift and thus – the characteristic isotope envelope seen in MS measurements. The 
difference in signal intensities between the individual peaks of this envelope reflect 
accurately the natural abundance of the heavy isotopes contained therein. Therefore, 
artificial incorporation of such heavy isotopes can be used for protein or peptide labeling and 
quantification. In this way, a heavy labeled peptide will produce a specific mass shift 
compared to a light labeled species. The intensities of both isotopomers can be measured 



























Mass spectrometry for protein identification and quantification 
 
 24 
analyte. Stable isotope labeling can be established both in vivo, by metabolic labeling [126, 
127], or in vitro, by chemical [128, 129] or enzymatic [130] labeling. The label-based 
techniques offer high accuracy but rely on additional sample preparation steps for labeling. 
This also increases the costs, compared to label-free approaches. Moreover, only a limited 
number of samples can be compared within one experiment (from two to eight, depending 
on the method) [124]. However, recent reports describe significant increase in the 
multiplexing power of combinations of chemical and metabolic labeling [131]. This requires 
sophisticated computational analysis but seems to be extremely useful for large-scale 
multiplexing experiments. 
 
Stable isotope labeling by amino acids in cell culture 
Stable isotope labeling by amino acids in cell culture (SILAC) [126] is one of the most 
widely used methods for relative quantification by MS. SILAC, and metabolic labeling in 
general, introduces heavy isotopes during cellular or organismal growth. This offers a 
significant advantage over chemical labeling approaches where the isotopes are 
incorporated later in the experimental workflow. Early labeling and mixing of the samples 
reduces separate and potentially differential handling steps of the analytes to be compared. 
On the other hand, the requirement for metabolic labeling limits the type of samples that can 
be used for comparison. There are hybrid approaches that successfully use SILAC samples 
for spike-in comparison of samples that cannot be labeled [132]. A typical workflow of a 
SILAC experiment is shown in Figure 2.8. A cell population is divided in two and cultured in 
light and heavy SILAC medium, respectively. The two medium preparations are identical, 
apart from the fact that all arginine and lysine sources are depleted and replaced with amino 
acids containing a specific number of light (12C, 14N, 1H) or heavy (13C, 15N, 2H) carbon 
and/or nitrogen and/or hydrogen atoms. After complete incorporation of the heavy isotopes, 
the SILAC experiment is performed (e.g. differential treatment, overexpression of a protein, 
immunoprecipitation or pull-down) and the light and heavy samples are mixed and 
processed for MS analysis. Here, each peptide will be represented as a SILAC pair with a 
certain mass shift (depending on the number of heavy atoms used for labeling). Comparison 
of the intensities between the heavy and light peaks of each SILAC pair gives the relative 






Figure 2.8  Schematic representation of a SILAC experimental workflow 
Workflow of a typical SILAC experiment. First, two cell populations are labeled with light or heavy 
SILAC medium, then an experiment is performed (e.g. differential treatment of the cells, isolation 
of extract and immunoprecipitation, etc.), the samples are mixed and measured by MS. Here in 
the MS spectrum each peptide is represented by SILAC pair peaks with different intensity in light 
(green) or heavy (red), depending on the relative abundance of the specific protein. 
All large-scale MS-based quantification approaches are greatly dependent on software 
tools for identification and quantification of the proteins within the compared samples [133]. 
Apart from the straightforward experimental design, another key aspect in the success of the 
SILAC approach has been the availability of an advanced and semi-automatic software 
environment for data analysis and interpretation. MaxQuant [119] implements complex 
algorithms for all steps of data analysis, starting with raw MS data and finishing with 
statistical evaluation and visualization. The first step in the data analysis is feature detection 
and processing. This includes 3D peak (intensity, m/z, elution time) detection, de-isotoping 
and SILAC pair identification. Furthermore, this step allows for software peptide mass 
recalibration improving accuracy. This information, together with the deconvoluted MS/MS 
spectra, is used for peptide identification with a built-in database search engine [120]. After 
peptide identification, the protein identities are inferred. Next, the enrichment ratio for each 
individual SILAC pair is calculated, normalized and used for estimation of the protein 
enrichment ratio. In cases where only one of the SILAC pairs is detected, a re-quantification 
step estimates enrichment ratio based on the baseline noise in the spectrum. Furthermore, 























































































































Mass spectrometry for protein identification and quantification 
 
 26 
modification sites. The latest versions of MaxQuant allow for data analysis of label-free, as 




2.4 Aims and objectives of the presented thesis 
The role of histone modifications and their binding partners is undoubtedly at the 
center of genome biology and chromatin regulation. The plethora of identified modifications 
and their specific patterns of genome distribution is striking. However, little is known about 
the proteomes of individual chromatin domains. Are there exclusively unique proteins 
recruited to each distinct modification? What is the set of proteins specific for functionally 
related chromatin modifications? Which factors are recruited to chromatin as a function of a 
combinatorial modification signature? Research in this direction led to cataloguing the 
interactomes of several individual modifications, however these questions are still open. The 
majority of the approaches used in the field of chromatin modification proteomics are based 
on in vitro assays using isolated modified or unmodified histone N-terminal peptides. 
Therefore, the first aim of this study was to establish a novel affinity purification approach for 
the identification of chromatin modification binding proteins from mammalian cell nuclear 
extracts using homogeneous in vitro reconstituted chromatin templates. False positive hits 
are a major problem in all pull-down experiments, therefore the assay needed to be set up 
utilizing SILAC-labeled extracts for quantitative mass spectrometry. In order to validate the 
novel approach, it had to be compared to classical peptide pull-down using the two most 
widely studied histone modifications – H3K4me3 and H3K9me3. Following successful 
validation, the chromatin affinity purification was to be applied to describe the interactomes 
of a set of heterochromatic modifications, in addition to several euchromatic ones. The 
binding proteins of each modification were then to be used to deduce novel functional 
features and relationships within and between the interactomes. Similar analyses were also 
intended to be applied for identification of proteins binding to combinations of modifications. 
Lastly, the functional consequences of recruitment of selected factors needed to be 
interrogated using in vitro and in vivo approaches. 
 
  
Aims and objectives of the presente  thesis 
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3 Material and Methods 
 
 
3.1 Material and reagents 
3.1.1 Laboratory equipment and instruments 
ÄKTA Explorer/Purifier GE Healthcare, Buckinghamshire (UK) 
Balances Metler-Toledo, Giesen (DE) 
BBD 6220 CO2 incubator Heraeus, Hanau (DE) 
Bioreactor 5L with ez-Control Applikon, Schiedam (NL) 
Centrifuge Cryofige 6000i Heraeus, Hanau (DE) 
Centrifuge Sorvall Evolution RC Thermo Scientific, Braunschweig (DE) 
Centrifuges tabletop 5415R/5810R Eppendorf, Hamburg (DE) 
Electrophoresis power supplies Bio-Rad, München (DE) 
Gel Doc 2000 gel documentation system Bio-Rad, München (DE) 
HP1100 and HP1200 LC systems Agilent, Santa Clara (USA) 
Kodak X-Omat 2000 processor Carestream Health, New York (USA) 
Laminar flow clean bench Heraeus, Nahau (DE) 
LTQ Orbitral XL Thermo Fischer Scientific, Bremen (DE) 
LTQ Orbitrap Velos Thermo Fischer Scientific, Bremen (DE) 
LTQ XL Thermo Fischer Scientific, Bremen (DE) 
Mini Trans-Blot system Bio-Rad, München (DE) 
Mini-PROTEAN Tetra PAGE cell Bio-Rad, München (DE) 
NanoDrop ND-1000 Peqlab, Erlangen (DE) 
Perfection V700 PRO scanner Epson, Nagano (JP) 
Peristaltic pump Ismatec, Glattburgg (CH) 
pH meter Metler-Toledo, Giesen (DE) 
Sonication bath SONOREX Super BANDELIN Electronic, Berlin (DE) 
Sorval SA600 rotor Thermo Scientific, Braunschweig (DE) 
Sorval SS34 rotor Thermo Scientific, Braunschweig (DE) 
SpeedVac Savant SPD121P Thermo Scientific, Braunschweig (DE) 
Sub-Cell-GT agarose gel electrophoresis Bio-Rad, München (DE) 
Thermocycler epgradientS Eppendorf, Hamburg (DE) 
Thermomixer Comfort Eppendorf, Hamburg (DE) 
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UV Transiluminator Bio-Rad, München (DE) 
Water bath TW12 Julabo, Selbach (DE) 
XCell Sure Lock Mini NuPAGE cell Invitrogen, Karlsruhe (DE)  
  
3.1.2 Chemicals and reagents 
(2-chloroethyl)-methylammonium chloride Karl Industries, Aurora (USA) 
2-mercaptoethanol Sigma-Aldrich, Steinheim (DE) 
4-(2-Hydroxyethyl)-1-piperazineethanesulfonic 
acid (HEPES) 
VWR, Poole (DE) 
Acetic acid Merck, Darmstadt (DE) 
Acetonitrile, LiChrosolv Merck, Darmstadt (DE) 
Acrylamide/Bisacrylamide (37.5:1) Merck, Darmstadt (DE) 
Agarose Serva, Heidelberg, (DE) 
Ammonium hydrogen carbonate Fluka, Buchs (CH) 
Ammonium peroxodisulfate AppliChem, Darmstadt (DE) 
Boric acid Merck, Darmstadt (DE) 
Bovine serum albumin (BSA) Sigma-Aldrich, Steinheim (DE) 
Bromophenol blue Serva, Heidelberg (DE) 
Cleland’s reagent (DTT, for MS analysis) Calbiochem, Darmstadt (DE) 
Coomassie Briliant Blue G-250 Fluka, Buchs (CH) 
D/L-Methionine Sigma-Aldrich (DE) 
Deoxynucleotide-5’-phosphate (dATP, dCTP, 
dGTP, dTTP) 
Roth, Karlsruhe (DE) 
Dithioerythrol (DTE) Roth, Karlsruhe (DE) 
Dithiothreitol (DTT) Alexis Biochemicals, Farmingdale (USA) 
Ethanol Merck, Darmstadt (DE) 
Ethidium bromide (solution 10ml/ml) Roth, Karlsruhe (DE) 
Ethylendiamine tetraacetate (EDTA) Roth, Karlsruhe (DE) 
Formic acid (FA) Fluka, Buchs (CH) 
Glycerol Merck, Darmstadt (DE) 
Guanidine hydrochloride Sigma-Aldrich, Steinheim (DE) 
Hydrochloric acid (37% HCl) Merck, Darmstadt (DE) 
Iodacetamide (IAA) Sigma-Aldrich, Steinheim (DE) 
Magnesium chloride (MgCl2) Merck, Darmstadt (DE) 
Methanol, LiChrosolv Merck, Darmstadt (DE) 
N,N,N’,N’-Tetramethylethylendiamid (TEMED) Sigma-Aldrich, Steinheim (CH) 
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Non-fat dry milk powder Regilait, Saint-Martin-Belle-Roche (FR) 
Ortho-Phosphoric acid Merck, Darmstadt (DE) 
Phenol:Chlorophorm:Isoamil alcohol (PCI) 
[25:24:1] 
Roth, Karlsruhe (DE) 
Phenyl-methylsulfonyl fluoride (PMSF) Roche, Mannheim (DE) 
Poluethylene glycol 6000 Merck, Darmstadt (DE) 
Ponceau S Sigma-Aldrich, Steinheim (DE) 
Potassium chloride (KCl) Merck, Darmstadt (DE) 
Potassium dihydrogen phosphate (KH2PO4) Roth, Karlsruhe (DE) 
S-(5’-adenosyl)-L-methionine (SAM) New England Biolabs, Ipswitch (USA) 
Sodium acetate  Roth, Karlsruhe (DE) 
Sodium azide (NaN3) Alfa Aesar, Massachusetts (USA) 
Sodium chloride (NaCl) Merck, Darmstadt (DE) 
Sodium dodecyl sulfate  VWR, Poole (DE) 
Sodium hydrogen phosphate (Na2HPO4) Merck, Darmstadt (DE) 
Sodium hydroxide (NaOH) Merck, Darmstadt (DE) 
Triethanolamine VWR, Poole (DE) 
Tris(hydroxymethyl)amino ethane (Tris base) Roth, Karlsruhe (DE) 
Triton X-100 Merck, Darmstadt (DE) 
Tween-20 Sigma-Aldrich, Steinheim (DE) 
Urea Merck, Darmstadt (DE) 
Water, LiChrosolv Merck, Darmstadt (DE) 
  
3.1.3 Cell culture media and materials 
DMEM High Glucose (w/o Lys, w/o Arg) PAA Laboratories, Colbe (DE) 
Foetal bovine serum, dialyzed PAA Laboratories, Colbe (DE) 
L-Arginine (Arg0) Sigma-Aldrich, Steinheim (DE) 
L-Arginine, 13C6 (Arg6) Euriso-top, Saarbrücken (DE) 
L-Arginine, 13C6, 15N4 (Arg10) Euriso-top, Saarbrücken (DE) 
L-Lysine (Lys0) Sigma-Aldrich, Steinheim (DE) 
L-Lysine, 13C6, 15N2 (Lys8) Euriso-top, Saarbrücken (DE) 
L-Lysine, 2D4 (Lys4) Euriso-top, Saarbrücken (DE) 
Penicillin/Streptomycin 100x PAA Laboratories, Colbe (DE) 
 
3.1.4 Cell lines 
HeLa S3 (human cervical cancer, Computer cell culture centre, BE) were kindly 
provided by Thomas Conrad (Facility for Cell Production, Max Planck Institute for 
Biophysical Chemistry, Göttingen, DE). 
 
Material and reagents 
 
 32 
3.1.5 Commercial kits, buffers and solutions 
1 Kb Plus DNA ladder Invitrogen, Karlsruhe (DE) 
Amersham Hyperfilm ECL GE Healthcare, Buckinghamshire (UK) 
ECL Pus Western Blotting Detection System GE Healthcare, Buckinghamshire (UK) 
ECL Western Blotting Detection System GE Healthcare, Buckinghamshire (UK) 
Hybond ECL nitrocellulose membrane GE Healthcare, Buckinghamshire (UK) 
Hybond N+ membrane GE Healthcare, Buckinghamshire (UK) 
Imperial Protein Stain Pierce/Thermo Scientific, Rockford (USA) 
Mini-PROTEAN 4-12% TGX gels Bio-Rad, München (DE) 
Mini-PROTEAN 4-20% TGX gels Bio-Rad, München (DE) 
NucleoSpin Extract II Machery&Nagel, Düren (DE) 
NuPAGE Antioxidant Invitrogen, Karlsruhe (DE) 
NuPAGE LDS Sample Buffer (4x) Invitrogen, Karlsruhe (DE) 
NuPAGE MOPS SDS Running Buffer (10x) Invitrogen, Karlsruhe (DE) 
NuPAGE Novex 4-12% Bis-Tris gels, 1mm Invitrogen, Karlsruhe (DE) 
NuPAGE Sample Reducing Agent (10x) Invitrogen, Karlsruhe (DE) 
Plasmid Giga Kit Qiagen, Hilden (DE) 
QIAquick PCR purification kit Qiagen, Hilden (DE) 
SeeBlue Plus2 Protein Standard Invitrogen, Karlsruhe (DE) 
 
3.1.6 Chromatography and affinity media 
HiLoad 10/300 Superdex200 GE Healthcare, Buckinghamshire (UK) 
HiLoad 16/60 Superdex200 GE Healthcare, Buckinghamshire (UK) 
PD-10 columns GE Healthcare, Buckinghamshire (UK) 
Reprosil AQ-3/5µm / 300Å Dr.Maisch, Ammerbuch (DE) 
SilicaTip emmiters New Objective, Woburn (USA) 
Streptavidin MagneSphere particles Promega, Mahhneim (DE) 
 
3.1.7 Consumables and plasticware 
Amicon Ultra centrifugal filter devices 
(MWCO 3 and 10 kDa) 
Millipore, Billerica (USA) 
Phase Lock Heavy Tubes (2, 15, 50 ml) 5PRIME, Hamburg (DE) 
Slide-A-Lyzer dialysis units and cassettes 
(MWCO 3500 and 10,000) 
Pierce/Thermo Scientific, Rockford (USA) 
Spectra/Por dialysis membrane (MWCO Spectrum Laboratories, Rancho Domingues 
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3500 and 10,000) (USA) 
 
3.1.8 Enzymes, proteins and inhibitors 
Antarctic phosphatase New England Biolabs, Ipswitch (USA) 
Benzonase Calbiochem, Darmstadt (DE) 
H2Bub1 Moshe Oren (WIS, Rehovot, IL) 
M.SssI CpG methyltransferase New England Biolabs, Ipswitch (USA) 
Micrococcal nuclease Calbiochem, Darmstadt (DE) 
Proteinase Inhibitor Cocktail Complete, 
EDTA free 
Roche, Mannheim (DE) 
Restriction endonuclease enzymes New England Biolabs, Ipswitch (USA) 
SWI/SNF complex (INI1-FLAG) Eric Allemand (Institut Pasteur, Paris, FR) 
T4 DNA ligase New England Biolabs, Ipswitch (USA) 
Taq polymerase Winfried Lendeckel (MPIbpc) 
Trypsin Roche, Mannheim (DE) 
Trypsin Promega, Mannheim (DE) 
Ubiquitin-biotin Stefan Kopperman (Max Planck Institute for 
Biophysical Chemistry, Göttingen, DE) 
 
3.1.9 Peptides 
N-terminal histone H3 peptides for pull-down experiments were synthesized in 
unmodified or modified form using Fmoc-based solid-phase synthesis. C-terminal non-native 
lysine was used for biotinylation. The peptides obtained from the Department of NMR-based 
Structural Biology at the Max Planck Institute for Biophysical Chemistry, Göttingen, DE. 
 
H3 unmodified  NH2 - ARTKQTARKSTGGKAPRKQL - biotin 
H3K4me3  NH2 - ARTKme3QTARKSTGGKAPRKQL - biotin 
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3.1.10 Antibodies and sera 
Reagents and their dilutions used for immunodetection of proteins in Western Blotting: 
Name Host Supplier, catalog number Dilution 
α-beta-tubulin mouse, monoclonal Sigma-Aldrich,  1:20,000 
α-BRG1 mouse, monoclonal Santa Cruz, sc-17796 1:2,000 
α-BRM rabbit, polyclonal Eric Allemand (Institut 
Pasteur, Paris, FR) 
1:500 
α-DYRK1A rabbit, polyclonal Cell Signaling, 2771 1:1,000 
α-FLAG M2 mouse, monoclonal Sigma-Aldrich, F1804 1:1,000 
α-H2A rabbit, polyclonal Abcam, ab13923 1:1,000 
α-H3 rabbit, polyclonal Abcam, ab1791 1:20,000 
α-H3K4me3 rabbit, polyclonal Active Motif, 39159 1:2,000 
α-H3K9me3 rabbit, polyclonal Upstate/Millipore, 07-442 1:1,000 
α-H4 rabbit, polyclonal Upstate/Millipore, 07-108 1:500 
α-INI1 rabbit, polyclonal Eric Allemand (Institut 
Pasteur, Paris, FR) 
1:500 
α-INTS3 rabbit, polyclonal Abcam, ab91419 1:1,000 
α-MORC2 rabbit, polyclonal Bethyl, A300-149A 1:2,000 
α-NELFA rabbit, polyclonal Yuki Yamaguchi (TIT, Tokyo 
JP) 
1:2,000 
α-RCC1 mouse, monoclonal Abcam, ab54600 1:1,000 
α-RECQL5 rabbit, polyclonal Abcam, ab91419 1:1,000 
α-BAF155 rabbit, polyclonal Abcam, ab22355 1:400 
α-SMCHD1 rabbit, polyclonal Abcam, ab31865 1:1,000 
α-SUPT5H rabbit, polyclonal Yuki Yamaguchi (TIT, Tokyo 
JP) 
1:2,000 
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α-rabbit-HRP swine, polyclonal Dako, P0399 1:5,000 
α-mouse-HRP goat, polyclonal Dako, P0447 1:5,000 
 
3.1.11 Plasmids 
Name Promotor Resistance Application Source 
pUC18_12x200-
601 







3.1.12 DNA oligonucleotides 
Oligonucleotides were purchased from Eurofins MWG Operon (Edersberg, DE) and 
kindly provided by Alexandra Stützer (Chromatin Biochemistry Group, Max Planck Institute 
for Biophysical Chemistry, Göttingen, DE). 
 
Primers for PCR amplification of scavenger DNA for chromatin array reconstitution: 
Forward  5’ GTTATCCGCTCACAATTCCACACAACATAC 3’ 
Reverse  5’ TAATGCAGCTGGCACGACAGGTTTC 3’ 
 
Oligonucleotides for labeling of 12x200-601 template for chromatin array reconstitution: 
EcoRI_3’P  5’-GGGGGGGGATCCGGGGGGGp-3’ 
EcoRI_5’P_3’bio 5’-pAATTCCCCCCCGGATCCCCCCCC-biotin-3’ 
 
3.1.13 Commonly used buffers 
10x DNA loading dye 30 % [v/v] 
10 mM 
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10x SDS running buffer 250 mM 
1.92 M 















EDTA NaOH (pH 8.0) 
 
1x PBS-T 1x 









Colloidal Coomassie stain 0.08 % [w/v] 
20 % [v/v] 
1.6 % [v/v] 
8 % [w/v] 





PD150 (pull-down wash buffer) 20 mM 
10 % [v/v] 
150 mM 
0.1 % [v/v] 









Tris-HCl (pH 7.5) 








Tris-HCl (pH 7.5) 
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EDTA NaOH (pH 8.0) 
 















Western Blotting blocking solution 1x 




Non-fat dry milk powder 
1 M Tris.HCl buffer 1 M Tris base, desired pH adjusted 
with 37 % [w/w] HCl 
1 M HEPES buffer 1 M HEPES, desired pH adjusted 
with 5 M NaOH or 5 M KOH 
 
3.1.14 Software 
Adobe Creative Suite 4 Adobe Systems, San Hose (USA) 
Cytoscape Cytoscape Consortium [134] 
GProX CEBI [135] 
Lasergene 7 DNASTAR, Madison (USA) 
MaxQuant and Andromeda Max Planck Institute for Biochemistry [119, 
120] 
Microsoft Office Microsoft Corporation, Redmont (USA) 
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3.2 Molecular biology methods 
3.2.1 Analysis of nucleic acids 
3.2.1.1 Determination of nucleic acid concentration 
DNA concentration was determined by measuring the absorbance of aqueous 
solutions against a reference at 260 nm using a Nanodrop ND-1000 spectrophotometer. The 
following equation was used to calculate DNA concentrations [137]: 
 
1 OD260nm = 50 µg/ml double-stranded DNA 
 
3.2.1.2 Agarose gel electrophoresis 
Agarose gel electrophoresis was carried out for visualization and small-scale 
purification of DNA according to standard protocols [137]. Gels were prepared with 0.5 – 2 % 
[w/v] agarose in 1 x TBE buffer. DNA samples were diluted with 10x DNA loading dye and 
separated using a horizontal electrophoresis system (Bio-Rad, München, DE) in 1 x TBE 
buffer at 80-120 V for 40 – 80 min. 1 kb Plus DNA Ladder (Invitrogen, Karlsruhe, DE) was 
used as size reference. Gels were stained post-run in 0.5 µg/ml ethidium bromide solution 
for 20 min at RT, and subsequently destained in ddH2O for 30 min. DNA was visualized on a 
UV transiluminator or gel documentation system (Bio-Rad, München, DE). 
 
Agarose gel solution: 
0.5 – 1 % [w/v] agarose 
1 x TBE 
 
3.2.2 Preparation of DNA templates for chromatin array assembly 
3.2.2.1 Isolation of 12-mer ‘601’ DNA template 
The DNA template used for chromatin array reconstitution was a kind gift of Daniela 
Rhodes (MRC, Cambridge, UK) [107]. The template, consisting of 12 repeats of the ’601’ 
nucleosome positioning sequence (147 bp) [138, 139] flanked with a linker sequence (200 
bp in total), was within the pUC18 plasmid backbone. The plasmid DNA was amplified in and 
isolated from transformed dam-/dcm- E.coli using a plasmid Giga kit (Qiagen, Hilden, DE) 
(isolation performed by Winfried Lendeckel, Max Planck Institute for Biophysical Chemistry, 
Göttingen, DE). For excision of the template from the plasmid backbone, the isolated DNA 
was digested with DdeI, BfuCI, HaeII and EcoRI restriction endonucleases overnight at 37° 
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(300 U of enzyme per 1 mg of DNA) in NEB4 buffer provided by the manufacturer (New 
England Biolabs, Ipswitch, USA). The resulting digest, containing the 2.4 kb template and 
various vector backbone fragments (<400 bp) was fractionated by precipitation with PEG-
6000 [140]. The restriction digest was incubated for 10 min at RT with 0.5 M NaCl and 2 % 
[v/v] PEG-6000. The mixture was centrifuged at 16,000 g for 15 min (4°C). The supernatant 
was collected and the PEG-6000 concentration stepwise adjusted from 3 % to 12 % [v/v] in 
1 % steps. The supernatant was centrifuged at each step as described above. The pellets 
resulting from each fraction were washed once with 70 % [v/v] ethanol, air-dried and 
dissolved in Tris-HCl (pH 7.9). Equal amount of DNA from each fraction was analyzed using 
agarose gel electrophoresis (3.2.1.2). The 12x200-601 template precipitated reproducibly at 
PEG-6000 concentration of 6-7 % [v/v] with high purity. 
 
3.2.2.2 Biotinylation of 12-mer ‘601’ DNA template 
The 12x200-601 template (3.2.2.1) contains a 5’ EcoRI overhang sequence (5’-
GATC-3’) which was used for ligating to a biotinylated oligonucleotide (3.1.12). The 
“EcoRI_3’P” and “EcoRI_5’P_3’bio” oligonucleotides were mixed in equimolar amounts at 
100 µM and denatured at 95°C for 10 min in a thermocycler (Eppendorf). Annealing was 
achieved by slow cooling from 95°C to RT for 30 min. In order to allow ligation of the 
oligonucleotide (phosphorylated at the EcoRI overhang) to the 12-mer template, the latter 
was dephosphorylated using typicaly 1 U Antarctic phosphatase (New England Biolabs, 
Ipswitch, USA) per 2µg of DNA for 2 hours at 37°C in the corresponding buffer provided by 
the manufacturer. The phosphatase was deactivated by incubation at 65°C for 10 min. 
Following dephosphorylation, the DNA was extracted by addition of equal volume of 
phenol:chlorophorm:isoamyl alcohol (CIP) [25:24:1] in a phase lock heavy tubes (5PRIME, 
Hamburg, DE). The aqueous phase was precipitated with 0.3 M (final) sodium acetate (pH 
5.2) and 3 volumes cold ethanol (99% [v/v]) [137]. The pellet was dissolved in 10 mM Tris 
buffer (pH 7.9). Ligation of the biotinylated oligonucleotide was performed with T4 DNA 
ligase. Ten times molar excess of oligonucleotide was ligated for 2 hours at RT using 2.5 U 
of ligase per 1µg of DNA in buffer supplied by the manufacturer (T4 DNA ligase buffer, New 
England Biolabs, Ipswitch, USA). The biotinylated  DNA template was precipitated by 
addition of 0.5 M NaCl and 7% [v/v] PEG-6000 as described above (3.2.2.1). 
 
3.2.2.3 Methylation of 12-mer ‘601’ DNA template 
The DNA template was methylated specifically at CpG sites using bacterial M.SssI 
methyltransferase (New England Biolabs, Ipswitch, USA). Typically, 500 µg DNA was 
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incubated for 4 h at 37°C with 250 U of M.SssI in 500 µl buffer containing 0.32 mM SAM, 1 
mM DTT, 1 mM EDTA (pH 8.0), 50 mM NaCl and 10 mM Tris buffer (pH 7.9). To ensure 
complete methylation, the amount of SAM was doubled and half the original enzyme amount 
was added to the reaction for additional 4 hours (or overnight). Completion of the 
methylation was tested by digesting a 0.5 µg DNA aliquot of the reaction mixture with a 
restriction endonuclease with blocked cleavage at methylated CpG sites (e.g. BstUI, NotI, 
using buffer supplied by the manufacturer, New England Biolabs, Ipswitch, USA). Cleavage 
of non-methylated DNA and absence of cleavage of methylated DNA indicated complete 
methylation. 
 
3.2.2.4 Preparation of scavenger DNA 
Scavenger DNA was used to prevent oversaturation of chromatin arrays during 
reconstitution [107]. The scavenger DNA represents a 147 bp fragment from the 
pUC18_12x200-601 plasmid backbone without specific nucleosome positioning properties. 
The fragment was amplified by PCR in 96x100 µl volume using Taq polymerase (purified in-
house by Winfried Lendeckel, Max Planck Institute for Biophysical Chemistry, Göttingen, 
DE). The PCR mix and PCR cycle program were as follows: 
 




0.2 mM (each) 
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3.3 Protein biochemistry methods 
3.3.1 Detection and analysis of proteins 
3.3.1.1 Protein concentration determination 
Concentration of histone proteins was determined by UV adsorption at 276 nm on a 
NanoDrop ND-1000 using published molar extinction coefficients [106]. Molar extinction 
coefficient of ubiquitinated H2B (H2Bub1) was calculated by adding the extinction coefficient 
of ubiquitin (calculated by sequence using ProtParam [141]) to this of H2B. 
 
Protein Molecular weight [Da] Molar extinction coefficient [M-1cm-1] 
H2A 13960 4050 
H2B 13774 6070 
H2Bub1 22172 7320 
H3 15273 4040 
H4 11236 5400 
 
Concentration of nuclear extract was roughly estimated for comparison between 
preparations by adsorption at 280 nm and assuming 1OD280 = 1 mg/ml. 
 
3.3.1.2 Denaturing polyacrylamide gel electrophoresis (SDS-PAGE) 
For visualization, histone proteins were separated using discontinuous 
polyacrylamide gel electrophoresis in the presence of SDS [142] according to standard 
protocols [143]. Typically, Tris-Glycine gels using 12-15 % resolving gel and 4 % stacking 
gel were prepared and run using Mini-PROTEAN Tetra system (Bio-Rad, München, DE). 
 
Resolving gel: Stacking gel 
12-15 % [w/v] 
 
0.4 M 
0.1 % [w/v] 
0.1 % [w/v] 
0.04 % [v/v] 
Acrylamide:bisacrylamide 
(37.1:1) 




4 % [w/v] 
 
0.68 M 
0.1 % [w/v] 
0.1 % [w/v] 
0.1 % [v/v] 
Acrylamide:bisacrylamide 
(37.1:1) 





Prior to loading on gels, protein samples were heated at 70°C for 10 min in 1x NuPAGE LDS 
sample buffer and 1x NuPAGE reducing agent (Invitrogen, Karlsruhe, DE). SeeBlue Plus2 
pre-stained protein standard (Invitrogen, Karlsruhe, DE) was used as reference (6 µl per gel 
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lane) [144]. Samples were run in 1x SDS running buffer at constant current (30 mA per gel) 
for the aspired time (typically 50 – 80 min). 
Unless otherwise stated, all protein samples for Western Blotting immunodetection 
were analyzed on 4-12 % or 4-20 % gradient Mini-PROTEAN TGX gels (Bio-Rad, München, 
DE) using 1x SDS running buffer and constant voltage of 200 V for 30 min. 
All samples for mass spectrometry analysis were separated on 4-12 % gradient NuPAGE 
Novex Bis-Tris gels (Invitrogen, Karlsruhe, DE) using 1 x MOPS SDS running buffer 
supplemented with NuPAGE antioxidant for 50 min at constant 200 V according to 
instructions provided by the manufacturer (Invitrogen, Karlsruhe, DE). 
 
3.3.1.3 Staining of protein SDS-PAGE gels 
SDS-PAGE gels were stained using Imperial Protein Stain (Pierce/Thermo Scientific, 
Rockford, USA) according to instructions provided by manufacturer, or alternatively by using 
Colloidal Coomassie staining solution [145] overnight and destaining by rinsing with water 
for 2 h. 
 
3.3.1.4 Western Blot transfer and immunodetection 
For immunoblot detection, proteins from SDS-PAGE gels were transferred on 
nitrocellulose membrane using the Mini Trans-Blot system (Bio-Rad, München, DE). Gels 
were sandwiched between a stack of fiber pad/Whatmann paper/nitrocellulose membrane, 
equilibrated in 1 x transfer buffer according to instructions by manufacturer. Proteins were 
blotted onto the membrane electrophoretically in 1 x transfer buffer at 100 V, for 1 h at 4°C. 
The membrane was washed with ddH2O and for visualization of higher abundant proteins, 
stained with Ponceau S solution (0.5 % [w/v] in 5 % [v/v] acetic acid) for 10 min at RT. The 
membrane was destained in 5 % [v/v] acetic acid, washed with 1 x PBS-T and blocked with 
PBS-T non-fat dry milk blocking solution for 1 h at RT. Then the membrane was rinsed with 
PBS-T and incubated with primary antibody solution in blocking buffer (3.1.10) overnight at 
4°C. After three washes with PBS-T (10 min at RT), the membrane was incubated with 
secondary antibody solution in blocking buffer (3.1.10). The membrane was washed three 
times in PBS-T (10 min at RT) and the immunoblot was developed for chemiluminescence 
detection using ECL or ECL Plus kits (GE Healthcare, Buckinghamshire, UK). Photography 
films were overlaid on the developed membrane and exposed for 1 s to 20 min. 
For reprobing the blots with additional primary antibodies, the membrane was 
washed with stripping buffer for 30 min at 60°C. After extensive washing with ddH2O and 
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PBS-T, the membrane was blocked with milk solution and probed again with a different 
primary antibody using the procedure described above. 
 
3.3.2 Introduction of specific histone chemical modifications 
3.3.2.1 Native protein ligation 
Native protein ligation for generation of H3K4me3, H3K9me2 and H3K9me3 modified 
histones was performed as described [104] by Szabolcs Sörös (Max Planck Institute for 
Biophysical Chemistry, Göttingen, DE). The ligation was performed between N-terminally 
truncated histone H3 (H3 A21C Δ1-20) and chemically synthesized 20 amino acid-long N-
terminal H3 peptide bearing a C-terminal thioester (synthesized by Peter Henklein, Charité, 
Berlin, DE). 
 
3.3.2.2 Incorporation of methyl lysine analogues. 
H3K27me1 modified histone protein was prepared with mono-methyl lysine mimick 
as described [105, 146]. Histone H3 protein containing K27C and C110A mutations was 
prepared by Alexandra Stützer (Max Planck Institute for Biophysical Chemistry, Göttingen, 
DE). 10 mg freeze-dried histone protein was dissolved in alkylation buffer (4 M Guanidine 
hydrochloride, 1 M HEPES pH 7.8, 10 mM D/L-Methionine, filtered), supplemented with 10 
µl fresh 1 M DTT and incubated for 1 h at 37°C in a sealed tube with occasional mixing by 
inverting the tube. Next, the solution was quantitatively transferred to a new tube and mixed 
with 100 µl of 3 M (2-chloroethyl)-methylammonium chloride and incubated for 2.5 h at RT in 
the dark under a fume hood (toxic intermediates!). The reaction was incubated for another 
2.5 h after addition of 10 µl fresh 1 M DTT. The reaction was quenched with 50 µl 2-
mercaptoethanol for 30 min at RT. The modified histone protein was purified using PD-10 
columns (GE Healthcare, Buckinghamshire, UK) equilibrated with 25 ml ddH2O. The reaction 
mixture (1 ml) was loaded on the column and washed with two consecutive volumes of 750 
µl 2 mM 2-mercaptoethanol. The protein was eluted with 3.2 ml 2 mM 2-mercaptoethanol. 
The identity of the modification was verified after analysis by ESI-MS on LTQ XL (Thermo 
Fisher Scientific, Bremen, DE) (3.5.3.4) by the specific +58 Da mass shift. H3K27me2 and 
H3K27me3 proteins were kindly provided by Alexandra Stützer (Max Planck Institute for 
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3.3.3 Recombinant chromatin 
3.3.3.1 Histone octamer assembly 
Close to equal amounts (typically 1-3 mg) of freeze-dried histone proteins (H2A, H3, 
H4 and H2B or H2Bub1) were dissolved separately in Unfolding buffer at ~2 mg/ml and 
incubated at 4°C for 1 h as described [106]. Equimolar amounts of the four proteins (3.3.1.1) 
were mixed and the total protein concentration was adjusted to 1 mg/ml with Unfolding 
buffer. The histone proteins were refolded and the octamer complex assembled after dialysis 
against RB High buffer at 4°C (3 changes of 2 l of buffer each, for minimum of 30 h in total). 
The assembled complex mixture was concentrated to 500 µl (using Amicon Ultra, Millipore, 
Billerica, USA) and the complex species (octamers, H3/H4 tetramers and H2A/H2B dimers) 
were separated using HiLoad 10/300 Superdex200 size exclusion chromatography column 
connected to ÄKTA Explorer/Purifier FPLC system according to instructions provided by the 
manufacturer (GE Healthcare, Buckinghamshire, UK) and using RB High buffer as mobile 
phase. The octamer peak fractions (typically eluting 11-12 ml after injection) were pooled 
and concentrated to 2-3 mg/ml. For long-term storage at -20°C, the octamer solution was 
supplemented with 50 % [v/v] glycerol. 
 
3.3.3.2 Chromatin 12-mer array reconstitution 
Chromatin array reconstitution was achieved by decreasing salt dialysis as described 
[106, 107]. Histone octamers were dialyzed against RB High buffer for minimum of 6 h and 
concentration was determined by UV spectroscopy (0.45 OD276 = 1 mg/ml). Octamers and 
template DNA (3.2.2.2) were mixed in a molar ratio of 1:1 (octamers:DNA) with final buffer 
concentrations identical to RB High. The reconstitution mixture was dialyzed for 1 h against 
RB High at 4°C. RB High buffer was then exchanged gradually for RB Low buffer over a 
period of 36 h using a peristaltic pump, yielding a final NaCl concentration of ~25 mM. 
Successful reconstitution of chromatin arrays was visualized on native agarose gel 
electrophoresis (3.2.1.2) using 0.2 x TB running buffer and Chromatin loading buffer. Quality 
of the reconstitution was also monitored by digestion with micrococcal nuclease (3.3.3.3). 
The chromatin arrays were stored at 4°C for up to 6 months. 
 
3.3.3.3 Digestion with micrococcal nuclease 
Micrococcal nuclease (MNase) digestion was performed as described [147]. 500 µl of 
free DNA or chromatin array solution at 5µg/ml was incubated with 0.1 U MNase in MNase 
buffer (20 mM Tris-HCl (pH 7.2), 5 mM MgCl2, 3 mM CaCl2) at RT for 0 s, 10 s, 30 s, 2 min 
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and 10 min. At each time point a 100 µl aliquot was transferred in PB buffer (QIAquick PCR 
purification kit, Qiagen, Hilden, DE) to stop the reaction. DNA was purified according to 
instructions provided by the manufacturer. Samples were analyzed by agarose gel 
electrophoresis (3.2.1.2). 
 
3.4 Cell culture, metabolic labeling and cell-based assays 
3.4.1 Cell culture and metabolic labeling of HeLa S3 cells 
HeLa S3 cells were grown in custom High Glucose Dulbecco’s Modified Eagle’s 
Medium (DMEM) medium (PAA Labratories, Colbe, DE) lacking Arginine and Lysine. Light 
(Arg0 and Lys0) or heavy (Lys4 and Arg6, Lys8 and Arg10 or Lys6 and Arg10) amino acids 
(3.1.3) were supplemented to final concentration of 50 mg/ml. 1/10 volume of foetal bovine 
serum (FBS) and 1 X Penicillin/Streptomycin were added before culturing of the cells. 
Typically, a cryostock of 108 cells was used for starting culture of 100 ml in spinner flasks. 
The cells were cultivated at 37°C, 5 % CO2 and 95 % relative humidity. The culture was 
expanded to 1.5 L over at least 6 passages and then inoculated in a 5 L bioreactor 
(Applikon, Schiedam, NL) and grown under standard conditions (2 x 106 cells/ml, with 
barbutation of synthetic air and dissolved oxygen level kept at pO2 = 20 using a feedback 
monitoring system). 
 
3.4.2 Transgenic cell lines for microscopy, ChIP and qRT-PCR 
Transgenic cell lines (expressing exogenous FLAG-tagged ACTL8, ADNP, FANCF, 
SPIN1 or ZMYM3) for immunofluorescence microscopy or specific chromatin or peptide pull-
down experiments were prepared by Kerstin Mosch (Max Planck Institute for Biophysical 
Chemistry, Göttingen, DE) [78]. 
Cell lines used for ChIP and qRT-PCR (siBrg1, siBAF155, siBrm) were prepared by 
Efrat Shema (Weizmann Institute of Science, Rehovot, IL). 
 
3.4.3 Nuclear extract isolation 
Light and Heavy-labeled cells were used for preparation of nuclear extracts (NE) as 
described [148]. Typically, 1010 Cells were harvested from the bioreactor by centrifugation at 
2,000 rpm for 5 min (Cryofuge 6000i, Heraeus, Hanau, DE) and washed with ice-cold 1 x 
PBS. Cells were washed with 1.25 volumes of MC buffer supplemented with 1/500 vol. 0.25 
M DTE and EDTA-free protease inhibitor cocktail according to instructions by the 
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manufacturer (Roche, Mannheim, DE). After incubation on ice for 5 min, the cell suspension 
was lysed by 50 ml Dounce homogenizer (18 strokes). Nuclei were pelleted by centrifugation 
for 5 min at 18,000 x g (Sorval SS34 rotor) and then resuspended in 1.3 vol. Röder C buffer 
(supplemented with 1/500 vol. 0.25 M DTE and 1/200 vol. 0.1 M PMSF) and dounced (20 
strokes). Nuclear debris were pelleted by centrifugation for 30 min at 16,000 rpm (Sorval 
SS34 rotor). The supernatant was flash-frozen in liquid nitrogen (LN2) and stored at -80°C. 
The nuclear extract was thawed in water bath (37°C) and dialyzed 3 x 2 hours against 50 
vol. Röder D buffer. The dialysate was centrifuged for 2 min at 9,000 x g (Sorval SA600 
rotor) and the supernatant aliquoted and flash-frozen in LN2. The isolated NE was stored at -
80°C. Typical protein concentration of the isolated nuclear extracts was 10-12 mg/ml. 
 
3.5 Biochemical binding assays 
3.5.1 Peptide affinity purification of histone modification-binding proteins 
Peptide pull-down experiments were performed as described [78, 103, 108, 149]. 
Typically, 10 µg of peptide solution was incubated with 40 µl streptavidin coated 
paramagnetic beads (Promega, Mannheim, DE) in PD150 buffer overnight at 4°C. Peptide-
bound beads were washed three times with PD150 buffer and incubated with 0.2 to 0.5 ml 
pre-cleared nuclear extracts for 4 hours on head-over-tail shaker at 4°C. Non-specifically 
bound proteins were removed by three washes with PD150 buffer (5 min each on head-
over-tail shaker). Bound proteins were eluted by heating the beads in LDS sample buffer 
(Invitrogen, Karlsruhe, DE) at 70°C for 10 min. The eluted proteins were separated on SDS-
PAGE and transferred on nitrocellulose membrane for immunodetection (3.3.1.4). For SILAC 
pull-down experiments, unmodified peptides were incubated with light and modified with 
heavy NE (forward experiment), and unmodified peptides with heavy and modified with light 
NE (reverse experiment). Protein eluates from unmodified and modified peptides within each 
forward or reverse experiment were mixed and separated by SDS-PAGE, protein bands 
were excised and subjected to proteomics analysis (3.6.1, 3.6.2 and 3.6.3). 
 
3.5.2 Chromatin affinity purification 
Chromatin affinity purification experiments were performed as described for the 
peptide pull-down experiments (3.5.1) [78, 108] with some modifications. For SILAC 
experiments, typically 40-50 µg of chromatin arrays were immobilized on 160-200 µl 
paramagnetic beads suspension (1 µg chromatin per 4 µl bead suspension) per 
experimental condition. Following pull-down, bound proteins were eluted with 1 x NuPAGE 
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LDS sample buffer (containing 2 mM MgCl2, 10 mM Tris-HCl pH 7.9), light and heavy 
samples were mixed and incubated with 1,000 U benzonase nuclease (Calbiochem, 
Darmstadt, DE) for 45 min at 37°C. After addition of 1 x NuPAGE reducing agent, the 
samples were heated at 70°C for 10 min and separated on gradient SDS-PAGE gels as 
described above (3.3.1.2 and 3.5.1). Chromatin pull-down experiments for Western Blot 
immunodetection were performed with 2-10 µg chromatin immobilized on 20-40 µl beads 
suspension. 
 
3.5.3 Affinity purification experiments using internal standard 
Chromatin or peptide pull-down experiments were performed as described above 
(3.5.1 and 3.5.2) with the following modification. For forward experiment, proteins originating 
from Light nuclear extract pull-downs were eluted in LDS sample buffer and quantitatively 
mixed. The pooled eluate was divided equally among the Heavy nuclear extract pull-downs 
and each of them was analyzed separately on SDS-PAGE (3.3.1.2). Reverse experiment 
was performed alike, but with pooling the Heavy samples and distributing them between the 
Light pull-down eluates. 
 
3.6 Mass spectrometry methods 
3.6.1 In-gel proteolysis of proteins 
In-gel digestion of proteins was performed as described [114, 150] with 
modifications. Unless otherwise stated, all incubation steps were performed at 26°C in 
thermomixer (Eppendorf, Hamburg, DE) at 1050 rpm for 15 min. All solutions were prepared 
with LiChrosolv H2O (Merck, Darmstadt, DE). Solutions were removed after each incubation 
step. SDS-PAGE gel lanes were cut into 22 equal slices using in-house designed device 
[129]. Each gel slice was cut into 1 mm x 1 mm cubes, washed with 150 µl water and 
dehydrated with 150 µl acetonitrile (ACN). Gel pieces were dried and then rehydrated with 
100 µl reducing solution (100 mM DTT in 50 mM ammonium hydrogen carbonate pH 8.0). 
After incubation at 56°C for 50 min, the gel pieces were dehydrated with 150 µl ACN. 
Reduced protein cysteine residues were alkylated with 100 µl 60 mM iodoacetamide (IAA, in 
50 mM ammonium hydrogen carbonate pH 8.0) for 20 min at 26°C in the dark. The gel 
pieces were washed with 150 µl ammonium hydrogen carbonate (pH 8.0), followed by 
addition of 150 µl ACN. After dehydration with 150 µl ACN, the gel pieces were dried and 
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rehydrated with 15-20 µl digestion buffer for 30 min on ice. The rehydrated gel pieces were 
overlaid with digestion buffer without trypsin and incubated at 37°C ON. 
 
Digestion buffer: 
15 µl Trypsin (0.1 µg/ml) 
50 µl Ammonium bicarbonate (50 mM, pH 8.0 
50 µl H2O 
 
3.6.2 Extraction of peptides 
Peptides from in-gel digestion were extracted as described [114, 150] with 
modifications. All incubation steps were performed using a thermomixer (1050 rpm) at 37°C 
for 15 min. Gel pieces were incubated with 30 µl water followed by addition of 100 µl ACN. 
The solution was transferred to new tubes and the dehydrated gel pieces were incubated 
with 50 µl 5 % [v/v] formic acid (FA), followed by addition of 50 µl ACN. The solution from the 
second extraction step was pooled with the solution from the first and additional 50µl ACN 
were added to the gel pieces to ensure complete extraction. The supernatant from the third 
extraction step was pooled with the solution from steps one and two, dried in vacuum 
centrifuge (Thermo Scientific, Braunschweig, DE), re-dissolved and analyzed by LC-MS/MS 
(3.6.3) or stored at  -20°C. 
 
3.6.3 LC-MS/MS analysis of peptides 
Peptides from in-gel digestion (3.6.1 and 3.6.2) were re-dissolved in 20 µl 5 % [v/v] 
ACN/1 % [v/v] FA by extensive vortexing and brief sonication (3 min, maximum power). 5 µl 
aliquots were separated by reverse-phase nanoflow chromatography (HP1100 or HP1200 
equipped with autosampler, Agilent, Santa Clara, USA). Peptides were loaded on in-house 
packed trap (desalting) column (fused silica, 3 cm, 360µm o.d., 150 µm i.d., Reprosil AQ-3/5 
µm / 300 Å, Dr.Maisch, Ammerbuch, DE) and separated at flow rate 250 nl/min on C18 
analytical column in-house packed in the electrospray emitter (SilicaTip, New Objective, 
Woburn, USA, 15 cm, 360 µm o.d., 75 µm i.d., Reprosil AQ-3/5 µm / 300 Å, Dr.Maisch, 
Ammerbuch, DE). The applied gradient was 3 % - 37 % buffer B (buffer A: 0.1 % [v/v] FA; 
buffer B: 98 % [v/v] ACN / 0.1 % [v/v] FA) for 35 min, followed by column wash (90 % buffer 
B) and equilibration (3 % buffer B). Peptides eluting from the LC were analyzed by ESI-
MS/MS (spray voltage 1.5 kV) on a LTQ-Orbitrap XL mass spectrometer (Thermo Fischer 
Scientific, Bremen, DE) operating in data-dependent mode. Survey full scan MS spectra 
were acquired in the orbitrap mass analyzer (m/s range 350-1600, resolution of 30,000 or 
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60,000 at 400 m/z and automatic gain control target at 106). The five most intense peaks 
were selected for collision-induced dissociation (CID) in the LTQ linear ion trap with 
normalized collision energy of 37.5 %, activation q = 0.25 and activation time 30ms. 
Precursors with single or unknown charge state were excluded. Previously selected 
precursors were dynamically excluded for 60 s. Unless otherwise stated, samples were 
analyzed in triplicate. LC-MS/MS analysis on LTQ-Orbitrap Velos was performed alike, but 
with the 15 most intense ions selected for CID fragmentation and 30 sec dynamic exclusion 
time. 
 
3.6.4 Molecular weight determination of intact proteins 
Intact proteins were dissolved in 20 % [v/v] ACN / 0.1 % [v/v] FA and manually 
injected and analyzed on LTQ XL linear ion trap (Thermo Fischer Scientific, Bremen, DE) in 
full scan mode (350-2000 m/z). Spectra were extracted and deconvoluted with ProMass 
(Thermo Fischer Scientific, Bremen, DE) using Small Protein analysis mode as suggested 
by the manufacturer. 
 
3.6.5 MS raw data processing 
Raw MS data from LTQ-Orbitrap XL and Velos were analyzed using MaxQuant 
software [119, 120] (version 1.2.2.5). The following settings were used: initial MS mass 
tolerance 8 ppm, MS/MS tolerance 0.6 Da, false discovery rate (FDR) at both peptide and 
protein level 1 %, maximum peptide posterior error probability (PEP) 0.05, minimum peptide 
length 5 amino acids, minimum ratio count 1 (further increased after analysis, 3.7.1), 
maximum number of modifications per peptide 4, maximum precursor charge 5, “re-quantify” 
on, “keep low-scoring versions of identified peptides” off, “use razor and unique peptides” 
on. Processed raw files were searched using International Protein Index (IPI) Human protein 
database (version 3.87, September 2011, containing 91,464 entries, 
http://www.ebi.ac.uk/IPI/) supplemented with 179 common contaminants (e.g. keratins, 
serum albumin). Carbamidomethylation of cysteine and oxidation of methionine were used 
as variable modifications. Trypsin specificity with no proline restriction and up to 2 missed 
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3.7 Data analysis and statistics 
3.7.1 Data filtering and visualization in R 
Tab-delimited text file output from MaxQuant (proteinGroups.txt) was imported in R 
[136] without pre-processing. All “Reverse” and “Contaminant” entries were deleted. 
Additionally, for individual chromatin modification experiments within each Forward (F) and 
Reverse (R) experiments the following ratio count (RC) minima were required: RCF > 1 AND 
RCR > 1 AND RCF + RCR >3. 
Total summed peptide intensities were plotted in log10 scale, normalized enrichment ratios in 
log2 scale. Hierarchical clustering was performed within the heatmap.2 function using 
Euclidean distance and combined linkage method. R scripts were previously published in 
[78].  
 
3.7.2 Protein-protein interaction analysis 
For protein-protein interaction network analysis, the STRING database [151] was 
queried for known protein-protein structural and functional interactions (based on 
experimental, curated database and text-mining evidence and with confidence level higher 
than 0.4) using the leading UniProt knowledgebase IDs as reported by MaxQuant. 
Interaction information was saved as tab-delimited text files and imported in Cytoscape 
(version 2.8.1, [134]). Proteins without known interactions within the datasets were imported 
as individual nodes. Nodes were coloured according to experiment origin, with overlapping 
nodes having multi-colour annotation. The network was clustered using force-directed 
layout. Network analysis was performed using the NetworkAnalyzer plug-in [152]. 
 
3.7.3 GRproX 
MaxQuant results from experiments using spiked-in internal standards were imported in 
GProX (version 1.1.7, [135]), where the enrichment ratios were reversed and plotted for 






DNA and histone modifications play a central role in regulating virtually all genome 
functions. While some chromatin marks exert their function at a structural level, the 
majority of the studied modifications serve as molecular beacons to recruit various 
proteins and protein complexes that bring about different functional consequences. 
Single or multiple interacting partners of several modifications have been described, 
however the overlap, interplay and correlation between chromatin marks with similar 
or divergent functional outcomes have not yet been analyzed. To gain more insight 
into the chromatin modification interactome, a novel affinity purification strategy 
combined with quantitative mass spectrometry was established. Using recombinant, 
uniformly modified chromatin, the interaction partners of ten chromatin templates 
differing in their modification status were described. Apart from global analysis, the 
particular molecular function of the recruitment of the SWI/SNF complex to chromatin 
containing monoubiquitylated histone H2B was also elucidated. 
 
 
4.1 Chromatin affinity purification assay for identification of modification-
specific binding proteins 
4.1.1 Preparation of recombinant uniformly modified chromatin template 
General reconstitution strategy 
The first step towards the goal of identification of chromatin modification binding 
proteins was establishment of a suitable affinity template. Several studies, some of which 
originating from our research group, successfully report the use of short modified or 
unmodified peptides that can recruit specific interaction partners [149, 153] including 
examples in the context of chromatin [81, 103, 108]. In order to bring the approach closer to 
the native state of chromatin, the novel method was based on homogeneous recombinant 
chromatin that consists of nucleosome octamers positioned uniformly on a defined DNA 
template [107, 108]. Recombinant Xenopus laevis histone proteins [106] were utilized as 
they have been widely used for structural and functional characterization of recombinant 
nucleosome core particles and chromatin [1, 30, 107, 154]. In addition, they have high 
sequence similarity to their human orthologues (93-100% sequence identity). The DNA 
template used for in vitro reconstitution was based on the non-natural “601” nucleosome 
 




Figure 4.1  General scheme of chromatin array reconstitution. 
Unfolded recombinant histone proteins were mixed in equimolar amounts and assembled into a 
histone octamer via dialysis against 2 M NaCl (step 1). The resulting octamer was mixed with a 
DNA template in a defined molar ratio (step 2) and gradually dialyzed against a buffer with 
decreasing NaCl concentration from 2 M to 20 mM (step 3). 
positioning sequence [138, 139]. An array of twelve 601 sequences separated by 53 bp of 
linker DNA was used. This allowed for the reconstitution of uniform and evenly spaced 
nucleosome core particles along a 2.4 kb long DNA template. Nucleosomal arrays, rather 
than mononucleosomes, were chosen in order to capture proteins requiring the interaction 
surfaces offered by multiple or neighbouring nucleosomes. The DNA template and histone 
octamers were assembled into chromatin arrays using the salt dialysis approach [106] as 
outlined in Figure 4.1. The basis of the reconstitution approach has been established by 
Szabolcs Sörös [155]. 
The salt dialysis method for reconstitution of oligonucleosomes [107] differs from the 
classical mononucleosome reconstitution method [106] in the addition of a 148 bp DNA 
fragment with random sequence that prevents oversaturation of the array by scavenging free 
histone octamers. An octamer to DNA molar ratio of 1.1 was previously found to be optimal 
for obtaining ~90% saturation of the DNA template [155] as revealed by single molecule 
atomic force microscopy analysis (Figure 4.2 A, courtesy of Stefan Winter, Max Planck 
Institute for Biophysical Chemistry, Göttingen, Germany). This molecular ratio resulted in 
uniformly saturated chromatin arrays as seen by native agarose gel shift (Figure 4.2 B, 
compare lane 2 with lanes 4 and 7). Regular digestion pattern over time in micrococcal 
nuclease (MNase) digest assay indicated evenly distributed nucleosomes (Figure 4.2 C).  
 
Incorporation of specific chromatin modifications 
Three separate approaches were used for obtaining site-specifically homogeneously 
modified histones depending on the type of modification and its localization within the protein 
sequence. The modifications within the first 20 amino acids of the H3 N-terminus were 














Figure 4.2  Quality control of reconstituted nucleosomal arrays. 
A. Atomic force microscopy imaging of a 12x601 nucleosomal array (courtesy of Stefan Winter, 
Max Planck Institute for Biophysical Chemistry, Göttingen, Germany). B. Native agarose gel shift 
analysis of free DNA and nucleosomal arrays reconstituted using the indicated molar ratios of 
DNA (calculated per 200 bp repeat) and histone octamer. The samples were separated using 
0.2x TB buffered agarose gel electrophoresis and stained with ethidium bromide. C. Micrococcal 
nuclease digestion of nucleosome array reconstituted using a 12x601 DNA template. Samples 
loaded in lanes 2 - 6 were incubated with the enzyme for 0 s, 10 s, 30 s, 2 min and 10 min, 
respectively. DNA was extracted and analyzed by agarose gel electrophoresis and stained with 
ethidium bromide. Ladder-like pattern indicates specifically positioned octamers. Mono-, di- and 
12-mer DNA fragments are indicated. M: DNA size marker in kb. 
transesterification reaction between a C-terminal thioester on a synthetic histone peptide 
consisting of amino acids 1-20, and a N-terminal cysteine from a truncated (Δ1-20) 
recombinant histone H3 protein (Figure 4.3 A). Thus, a ligated histone protein can be 
created bearing any modification that can be synthesized chemically as part of a short 
peptide. The native chemical ligation, purification of the products and quality control by SDS-
PAGE (Figure 4.3 B) and mass spectrometry (data not shown) were performed by Szabolcs 
Sörös (Max Planck Institute for Biophysical Chemistry, Göttingen, Germany) for 
modifications H3K4me3, H3K9me2 and H3K9me3. 
A second strategy, used for preparation of K120-ubiquitinylated H2B (H2Bub1), was 
based on an approach combining orthogonal protection and native chemical ligation [156]. 
The synthesis of H2Bub1 was done in the group of Ashraf Brink (Ben Gurion University of 
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Figure 4.3  In vitro incorporation of specific chromatin modifications. 
A. Schematic representation of the native chemical ligation reaction (H3K9me3 as an example). 
The synthetic peptide bearing the chemical modification and C-terminal thioester is coupled to the 
cysteine thiol group of recombinant H3 Δ1-20, A21C. The intermediate product rearranges 
spontaneously to form a native peptide bond. Adapted from [157]. B. SDS-PAGE analysis of 
recombinant H3 Δ1-20, A21C, as well as mutant full length H3 A21C and ligated H3K9me3 A21 
(courtesy of Szabolcs Sörös). C. Schematic representation of the incorporation of methyl lysine 
analog H3K27mec1 on H3 K27C, C110A recombinant protein. The native H3K27me1 residue is 
shown on the right for comparison. Based on [105]. D. ESI-LTQ MS analysis of unmodified H3 
K27C, C110A mutant protein (upper panel) and the product of the alkylation reaction H3K27mec1 
(lower panel). E. Agarose gel electrophoresis analysis of non-methylated and methylated DNA 
treated with different restriction endonucleases sensitive (AvaI, BsaAI, BstUI, NotI) or non-























































































H3K27me 1, C110AcH3 K27C, C110A H3K27me1
.
M   +   +   +   +   +   +































































The third strategy, used here for methylation of lysine 27 on histone 3, was based on 
chemical alkylation of a cysteine residue resulting in mono-, di- or trimethyllysine analogs 
(MLA) [105] (Figure 4.3 C). To this aim, a mutated recombinant histone 3 (H3 K27C, C110A) 
was used for selective alkylation with 2-chloro-N-mehylethanamine, 2-chrloro-N,N-
dimethylethanamine or 2-bromo-N,N,N-trimethylethanaminium for mono-, di or trimethylated 
product, respectively. The product of the alkylation reaction mimics a native methylated 
lysine residue [105] with the difference of a thioether group replacing the γ-methylene group 
of the modified amino acid. In each case, upon completion of the alkylation reaction the 
mass of the product was measured by ESI-MS (Figure 4.3 D). As shown before [105], the 
methylation reaction for production of monomethyl analogues is very sensitive and residual 
unmethylated protein was observed after the reaction (Figure 4.3 D, lower panel). 
Nevertheless, this strategy is more cost-efficient than native protein ligation and allows for 
selective methylation of virtually any mutated cysteine residue within a protein sequence. 
The recombinant protein used for preparation of H3K27mec1, as well as the alkylated 
H3K27mec2 and H3K27mec3 proteins were a kind gift from Alexandra Stützer (Max Planck 
Institute for Biophysical Chemistry, Göttingen, Germany). 
Commercially available and highly active bacterial CpG methyltransferase M.SssI 
(New England Biolabs, Ipswitch, USA) was utilized for specific methylation of cytosines in 
CpG sequences of the DNA template used for reconstitution. Agarose gel electrophoresis 
analysis showed complete cleavage of non-methylated DNA using all tested restriction 
endonucleases (Figure 4.3 E), while the M.SssI-treated DNA was not cleaved by the 
enzymes whose activity is blocked by CpG methylation (AvaI, BsaAI, BstUI and NotI). 
 
4.1.2 Optimization of the chromatin affinity purification approach 
General strategy and representation of SILAC results 
Several publications have reported the use of affinity purification followed by mass 
spectrometry for identification of histone modification binding proteins (see for example refs. 
[108, 158]). Franz et al. used short biotinylated peptides bearing the H3K9me3 modification 
in pull-down experiments and identified CDYL as a direct H3K9me3-binding partner. The 
identification of CDYL as an H3K9me3-associated protein was inferred from the notion that it 
was not identified in parallel pull-down experiments using unmodified biotinylated peptides. 
However, among the proteins with general chromatin binding properties (or proteins that 
show high non-specific binding to the matrix used in such experiments) there could be 
examples that nevertheless are specific for H3K9me3 but would be eliminated from the list 
of putative H3K9me3 binders using this analysis. While this approach is suitable for the  
 





Figure 4.4  Workflow and results representation of the SILAC chromatin affinity purification. 
A. Unmodified and modified chromatin templates were immobilized on magnetic beads and 
incubated with light and heavy SILAC extracts, respectively. The beads were washed and the 
bound proteins eluted, mixed and separated via SDS-PAGE. The proteins were then in-gel 
digested and the resulting peptides analyzed by LC-MS/MS. The enrichment ratios of each 
peptide (and consecutively, each protein) were calculated from the ratio of the light and heavy è  
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dissection of the binding of individual factors, it would restrict the comprehensive large-scale 
characterization of the chromatin modification interactomes. Therefore, a straightforward and 
semi-automatic approach for relative quantification of the proteins binding to unmodified and 
modified chromatin arrays in pull-down experiments was applied here. Stable isotope 
labeling with amino acids in cell culture (SILAC) [126] was chosen because of its accuracy 
and readily available software for advanced data processing [119]. 
A general workflow of the SILAC-based chromatin affinity purification is shown in 
Figure 4.4 A. Biotinylated chromatin arrays were immobilized on streptavidin-coated 
paramagnetic beads. This ensured stable interaction and facilitated washing and handling 
steps. After immobilization, the unmodified and modified chromatin was incubated with light 
and heavy SILAC nuclear extracts, respectively. Following three mild washing steps, the 
bound proteins were eluted using SDS sample buffer and mixed. For in-depth proteomics 
analysis the proteins were separated via SDS-PAGE, the gel lanes were excised into 21-23 
equal slices and the proteins therein subjected to in-gel digestion using trypsin. The 
extracted peptides were analyzed on nano LC-coupled hybrid linear ion trap-orbitrap mass 
spectrometer. Here, peptides originating from proteins binding to the modified chromatin 
would show higher intensity heavy peaks, while those originating from background proteins 
or proteins binding irrespectively from the modification would show close to equal intensity 
peaks. Large-scale identification and quantification of the analyzed peptides and proteins 
was done using the MaxQuant software suite [119]. 
In order to visualize the results, the enrichment ratios were plotted as scatter plots 
correlating the values from two independent experiments and representing each quantified 
protein as a circle (Figure 4.4 B). The normalized enrichment ratios were plotted in log2 
scale, positive values indicating higher heavy/light (H/L) ratio (higher abundance of the 
heavy protein), negative values denoting H/L ratios below 1/1 (higher abundance of the light 
protein). A protein showing similar behavior in both experiments would appear in the upper 
right or lower left quadrant, while a protein enriched in one and de-enriched (depleted) in the 






ç peak intensities. B. Representative scatterplot showing the correlated enrichment ratio results 
from two experiments (e.g. forward and reverse experiments or two individual modifications, see 
main text) in log2 scale. Proteins enriched or excluded (depleted) in both experiment appear in 
the upper right or lower left quadrants, respectively. Proteins enriched in one and excluded in the 
other experiment would appear in the upper left or lower right quadrants. 
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The significance of label swap experiments 
For each investigated modification, two pull-down experiments in parallel were 
performed – one as described above, and the second one identical but with swapping the 
heavy and light extracts for incubation with unmodified and modified chromatin, respectively. 
The first experiment was termed “forward” and the second – “reverse”. Positive correlation of 
the enrichment ratios from the forward experiment with the inversed enrichment ratios from 
the reverse experiment indicates modification-dependent specific binding. Negative 
correlation implies false positive interaction where high enrichment ratio correlates with the 
type of extract used (light or heavy) and not with the modification status of the affinity 
template. Figure 4.5 shows the result from a representative SILAC experiment. The 
correlation between the enrichment ratios from forward and reverse experiments is plotted in 
panel A, and in panel B – the enrichment ratios relative to the total summed peptide 
intensities (indicative of protein abundance). Proteins coloured in orange and blue show 
average enrichment ratio between forward and reverse experiment higher than 2 (log2 
scale). The proteins coloured in orange appear to have opposite enrichment ratios between 
the two experiments, nevertheless their average ratios exceed the enrichment thresholds 
that were set. If only one of the label swap experiments was performed, these proteins 
would have been indistinguishable from the true hits specific for the chromatin modification 
used. Thus, in order to exclude false positive hits, each SILAC pull-down was performed in 





Figure 4.5  Correlation between forward and reverse label swap experiments. 
A. Normalized ratios from representative forward and reverse experiments were plotted as 
scatterplot. All proteins showing average enrichment ratios higher than 2 (log2 scale) were 
coloured in red or blue. B. Average enrichment ratios of the proteins from panel A were plotted 




















































Nuclear extract preparation and quality control. 
SILAC nuclear extracts (NE) used for chromatin affinity purifications were prepared 
from HeLa S3 human cervical cancer cells. This cell line has modest culturing requirements 
allowing large yields. The HeLa S3 cells for SILAC labeling were cultured in a 5 L bioreactor 
with environmental controller (Figure 4.6 A). Near gram amounts of nuclear extract were 
prepared in a single experiment, with the advantage of having a controlled and reproducible 
growth environment. Additionally, the optimized culturing conditions within the bioreactor 
allowed for growing the cells to higher densities (2-3 x 106 cells/ml), reducing the time and 
SILAC medium needed. A single bioreactor run resulted in typically 30-50 g of HeLa cells. 
The nuclear extracts were prepared at higher protein concentration (typically 10-15 mg/ml), 
thus mimicking the natural environment in the cell nucleus during the pull-down experiments 
more closely (typical protein concentration range in the interchromatin compartment of the 
nucleus is around 100 mg/ml [159]). Mixing equal amounts of each extract, followed by 
standard SILAC sample preparation and data analysis, was used to compare the difference 
in abundance of the proteins between the light and heavy extracts. An example of light and 
heavy extracts prepared by two different lab members is shown in the left panel of Figure 4.6 
B, and an example of light and heavy nuclear extracts prepared by the same person in 
parallel is shown in the left panel of Figure 4.6 C. The enrichment ratios in the case where 
the extracts were not prepared in parallel showed wider distribution, indicating broader 
differences in protein abundance. Additionally, a pull-down experiment using the first pair of 
extracts resulted in even more pronounced spread of the enriched and false positive 
interactors (Figure 4.6 B and C, middle and right panels). Thus, the performance of each 
extract preparation was monitored by using control pull-downs and by determining the 
difference in protein abundance. 
 





Figure 4.6  Nuclear extract preparation and quality control. 
A. HeLa S3 cells used for SILAC labeling and nuclear extract preparation were cultured at high 
densities in a bioreactor with controlled environment. B-C. Comparison of the protein distribution 
of light and heavy nuclear extracts prepared independently (A, left) and in parallel (B, left). 
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Removal of DNA by benzonase digestion 
A typical chromatin affinity purification experiment utilized 40-50 µg of chromatin per 
condition, resulting in a total of 80-100 µg of chromatin (after mixing light and heavy 
samples) per gel lane for SDS-PAGE analysis. Such large amount of DNA resulted in 
blocking the porous structure of the gel [160] and decreased the resolution and protein 




Figure 4.7  Removal of DNA from affinity purification eluates. 
A. SDS-PAGE analysis of a pull-down reaction using 100 µg chromatin in total. B. 12x601 DNA 
aliquots were sonicated for 10, 20 and 30 min and analyzed by agarose gel electrophoresis (left 
panel). The treatment did not remove the large DNA fragment completely. Sonication of nuclear 
extract aliquots (middle) or chromatin pull-down reaction (right panel) resulted in loss of high 
molecular weight proteins as observed after SDS-PAGE analysis. C. Control DNA samples in 
SDS or LDS sample buffer were treated with benzonase with or without addition of 4 mM MgCl2 
and visualized by agarose gel electrophoresis. The presence of Mg2+ clearly improved digestion 
efficiency. D. Chromatin pull-down reactions with or without benzonase treatment were analyzed 
by SDS-PAGE (left, benzonase band marked with an arrow) and agarose gel electrophoresis 
(right). Benzonase improved SDS-PAGE resolution tremendously and resulted in near complete 
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reduced the amount of intact DNA species only moderately, even after 30 min treatment 
(Figure 4.7 B, left panel, lane 4). Treating a nuclear extract aliquot under the same 
conditions resulted in loss of large molecular weight proteins (Figure 4.7 B, middle panel, 
lane 5, see arrow). This effect was even more pronounced after identical treatment (30 min 
sonication) of a chromatin pull down reaction (Figure 4.7 B, right panel). Thus, other 
methods for removal of DNA from the samples were tested. Benzonase is a commercially 
available genetically engineered promiscuous endonuclease [161] that is active in wide 
range of conditions. The activity of the enzyme in SDS- or LDS- sample buffers (SB) was 
tested, as the later is used for elution in the final step of the chromatin pull-down. The 
enzyme was only moderately active under these conditions (Figure 4.7 C, left panel, 
compare lane 1 to 4 and 5). However, both SB used contain EDTA which could deplete the 
Mg2+ required for optimal enzymatic activity. Indeed, supplementing the reactions with 4 mM 
MgCl2 improved the cleavage efficiency substantially (Figure 4.7 C, left panel, compare 
lanes 1, 4 and 5 to 6 and 7). Incubating the chromatin pull-down eluate with 1000 U 
benzonase for 45 min at 37°C improved significantly the SDS-PAGE resolution (Figure 4.7 
D, left panel, compare lanes 2 and 3) and cleaved the 12x601 DNA template completely 
(Figure 4.7 D, right panel, compare lanes 1 and 2). As the enzyme is sensitive towards 
higher concentrations of DTT or 2-mercapto ethanol, these components were added to the 
SB only after incubation with benzonase. 
 
The effect of saturation of the affinity matrix 
The amount and immobilization efficiency of the bait complex on affinity matrix beads 
could be an important parameter in pull-down experiments. Therefore, the immobilization 
efficiency of the recombinant chromatin on the streptavidin beads used was tested. Varying 
amounts of 1-11 µg chromatin in 2 µg steps were immobilized on 20 µl beads suspension, 
then the equivalent of 1 µg chromatin was loaded on SDS-PAGE, transferred on 
nitrocellulose membrane and detected with polyclonal αH3 antibodies. As shown in the left 
panel of Figure 4.8 A, the high immobilization efficiency remained similar regardless of the 
amount of chromatin used (compare lane 1 with lanes 2-7). With higher chromatin per beads 
ratios, the beads aggregated noticeably (Figure 4.8 A, right panel, e.g. compare tubes 1 and 
7). This aggregation is likely due to higher order chromatin inter-bead interactions, promoted 
by the higher chromatin density on the beads. The influence of the different beads saturation 
was further tested by comparing two chromatin SILAC pull-downs, one using 20 µg 
chromatin/200 µl beads (experiment labeled “20 µg”) and a second one using 50 µg 
chromatin/200 µl beads (experiment labeled “50 µg”). The interaction partners of unmodified 






Figure 4.8  Influence of chromatin saturation level. 
A. One to eleven µg chromatin was immobilized on 20 µl magnetic beads and the equivalent of 1 
µg chromatin was loaded on SDS-PAGE and then transferred on nitrocellulose membrane for 
immunodetection with polyclonal αH3 antibodies (left panel). The samples of immobilized 
chromatin showed higher bead aggregation with increasing chromatin amounts (right panel). B. 
20 µg and 50 µg of chromatin were used for immobilization on 200 µl beads suspension for pull-
down experiments. The SILAC results show higher number of background proteins for the “50 µg” 
experiment (left). C. Correlation between the enrichment ratios from the “20 µg” and the “50 µg” 
experiments. 
of CpG sequences (meCpG chromatin) were compared between both experiments. Nearly 
1900 proteins were identified in the “20 µg ” experiment and 1300 proteins in the “50 µg ” 
experiment, of which 679 and 79 proteins were unique, respectively. Interestingly, the 
proteins unique for the “20 µg ” experiment showed enrichment ratios very close to 1:1 
(Figure 4.8 B, left panel, note that only quantified proteins are plotted), indicating that the 
lower saturation level of the beads promotes more prominent background protein binding. Of 
the proteins unique for the “50 µg” experiment, a few showed higher enrichment ratios in one 
or the other directions (Figure 4.8 B, right panel). Notably, two of those proteins appear to be 
significant interaction partners in the context of this modification (HOMEZ and KDM2B, 
discussed later). The two experiments reported similar enrichment ratios of the proteins 
binding to either meCpG or unmodified chromatin (Figure 4.8 C). However, larger number of 
background binding proteins could lead to lower dynamic range of detection of the MS 
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of background proteins and constant sampling rate, the chances of sequencing peptides 
from true interaction partners become lower. Thus, in order to maximize the sampling rate 
and avoid identification of excess background proteins, for further chromatin affinity 
purification experiments a chromatin/beads ratio offering higher saturation level and identical 
to the “50 µg” experiment was used. 
 
4.1.3 Validation of the chromatin affinity purification approach 
 
As a proof-of-principle the proteins enriched to recombinant modified chromatin were 
compared with those enriched using modified histone peptides. For these experiments two 
hallmark histone modifications were used – trimethylation of lysine 4 and lysine 9 on histone 
3 (H3K4me3 and H3K9me3, respectively), as there are a number of already known binding 
proteins [58, 162-164]. Additionally, these modifications have very different functional roles 
in chromatin biology and an overlap between the proteins they recruit was not likely [27, 43, 
54]. In total 16 experiments were performed, four for each modification using both chromatin 
or peptide as affinity matrix (including label swap, and using two independent nuclear extract 
preparations). A total of more than 2100 proteins, out of 5000 present in the HeLa nuclear 
extract (Ilian Atanassov, manuscript in preparation), were identified. The distribution of the 
enrichment ratios of all quantified proteins is shown in Figure 4.9. In order to exclude 
proteins behaving non-reproducibly between forward and reverse experiments, a threshold 
of minimum 1 (log2 scale) in each experiment, and in addition for the average of both 
experiments minimum 1.5 (log2 scale) was set. Using this threshold, 61 proteins were 
identified as recruited to the H3K4me3 modification in the context of chromatin, and 67 in the 
context of the N-terminal histone peptides. For the H3K9me3 modification the number of 
proteins associated with modified chromatin and peptide settings was 25 and 42, 
respectively. Interestingly, a number of proteins associated specifically with unmodified 
chromatin and peptides in each of the experiments (termed here excluded or repelled by the 
respective modification). 14 proteins were excluded by chromatin-embedded H3K4me3 and 
18 in the parallel peptide experiment. The H3K9me3 experiments revealed less proteins 
excluded by the modification – 3 for chromatin and 5 for peptide. Importantly, the datasets 
reveal a number of factors that have already been shown to interact directly with H3K4me3 
and H3K9me3. TAF3 [81], CHD1 [67], PHF8 [165], WDR5 [98] and ING2 [166] are known to 
be directly recruited by H3K4me3. The isoforms of HP1 – CBX1, CBX3 and CBX 5 [167], 
UHRF1 [168] and MPP8 [169] are known H3K9me3 binders. Additionally, proteins known to 
be recruited to these modifications via secondary interactions though direct binders were 
also identified. For example, DNMT1 [170, 171] and HAUSP [172] were recruited by UHRF1, 
Results 
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while POGZ is a known binding partner of CBX5 [173]. Several subunits of TFIID were 
recruited to H3K4me3 by TAF3 [81]. Additionally, UHRF1 bound preferentially unmodified 
chromatin and histone tail, compared to those bearing the H3K4me3 modification, which is 





Figure 4.9  Enrichment ratios of proteins recruited by H3K4me3 and H3K9me3 chromatin and 
peptides. 
Scatterplots representing the correlation between the enrichment ratios from forward and reverse 
experiments for H3K4me3 chromatin (A) and peptide (B) experiments, and H3K9me3 chromatin 
(C) and peptide (D) experiments. Proteins above threshold level (+/-1 in each F and R 
experiment, +/-1.5 average in log2 scale, see main text) are coloured in blue. 
H3K4me3 and H3K9me3 recruit distinct sets of protein factors 
Notably, there was a very limited overlap when comparing the results for each 
modification (Figure 4.10). In the chromatin context the death-associated protein 6 (DAXX) 
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The same was true for PHF8, which showed very strong enrichment with H3K4me3 and only 
moderate enrichment in the context of H3K9me3. Interestingly, the peptide experiment 
revealed four proteins excluded by both modifications, three of which were the meCpG 
associated proteins MTA1, MBD3 and GATAD2B [174]. All three proteins showed moderate 
exclusion from H3K4me3 chromatin, and near 1:1 binding with H3K9me3 chromatin. As 
already mentioned above, UHRF1 was enriched with H3K9me3 and excluded by H3K4me3 
in both affinity matrices. The ACTL8 protein (discussed later and in the following chapters) 
followed the same trend in the chromatin experiments. Furthermore, in the chromatin 
experiment the UHRF1-binding proteins DNMT1 and HAUSP showed similar enrichment 
behaviour but slightly below the set thresholds. The second protein showing high enrichment 
with H3K9me3 peptides and exclusion from H3K4me3 peptides was CHD4, a factor involved 
in nucleosome remodeling and histone deacetylation [175]. Notably, neither the chromatin 
nor the peptide affinity purification identified proteins that associate with the H3K4me3 




Figure 4.10  Comparison between H3K4me3 and H3K9me3 interactomes. 
Scatterplots correlating the average enrichment ratios from H3K4me3 (x-axis) and H3K9me3 (y-
axis) in the context of chromatin- (A) or peptide- (B) based experiments. 
Comparison of the chromatin- and peptide-based approaches 
As demonstrated in the comparison of the enrichment ratios between the two tested 
modifications, the chromatin- and peptide-based assays showed only a limited overlap, with 
several examples of proteins enriched to higher degree with one or the other matrix. This 
becomes even more evident after direct comparison of the two approaches (Figure 4.11). 
Both methods produced similar number of enriched factors, slightly higher in the case of the  
 
A BChromatin Peptide










































































Figure 4.11  Comparison of chromatin- and peptide-based affinity purification approaches. 
Correlation between the average enrichment ratios from peptide- (x-axis) and chromatin- (y-axis) 
based assays for H3K4me3 (A) and H3K9me3 (B). The overlap between the enriched (blue) or 
excluded (red) proteins is shown as inlay Venn diagrams (note that the number of dots is lower 
than the numbers in Venn diagrams as only proteins identified independently in both experiments 
are plotted). Proteins above threshold level in both approaches are presented as crossed-out 
circles. C. Venn diagrams representing the overlap of the enriched proteins for both approaches 
in H3K4me3 (left) and H3K9me3 (right) experiments using lower ratio threshold (+/-1 in each 
experiment, +/-1 average in log2 scale, see main text). 
peptide pull-downs (Figure 4.11 A and B, inlay Venn diagrams for enriched (blue) or 
excluded (red) proteins). Additionally, there was a clear distribution of proteins identified as 
enriched with one of the affinity templates and as background (1:1) binders with the other  
(solid blue or orange circles near the x- or y-axes). Interestingly, as seen from the 
distribution of the proteins identified as enriched in both approaches (crossed out circles), 
the absolute values of the enrichment ratios for the chromatin experiments were lower 
compared to the peptide-based assay. Lowering of the ratio threshold (to average from F 
and R experiments 1, log2 scale) resulted in somewhat higher overlap of enriched proteins 
(Figure 4.11 C). Strikingly, the number of proteins enriched with the chromatin templates 
increased more than twofold, while the effect for the peptide-based experiment was only 
moderate (compare the Venn diagrams in panels A and B to panel C). Thus, a large number 
of putative novel H3K4me3 and H3K9me3 interaction partners were identified using the two 
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enriched with each modification, in addition to a set of factors unique for each individual 
affinity matrix. 
 
Validation of novel histone-modification interaction partners 
Transfection and harvesting of 293T HEK and NIH3T3 cells, as well as 
immunofluorescence microscopy, presented in the following paragraph, were 
performed by Kerstin Mosch (Max Planck Institute for Biophysical Chemistry, 
Göttingen, Germany). 
 
The analysis of the chromatin and peptide pull-down results for H3K4me3 and 
H3K9me3 recapitulated the majority of the known interaction partners of both modifications 
tested. To validate the method, the interaction of several novel factors was further tested 
using orthogonal approaches. To this end, candidate proteins with engineered FLAG-tag 
were transiently expressed in 293T HEK cells. Nuclear extracts were isolated and used for 
peptide or chromatin affinity purification experiments with Western Blot detection using 
αFLAG antibodies. SPIN1, a protein implicated in regulation of the cell cycle [176] was 
enriched with the H3K4me3 modification using both pull-down methods (Figure 4.12 A), 
confirming the results from the SILAC-based experiments. Importantly, SPIN1 was only 
recently also shown to be a direct H3K4me3 interaction partner using orthogonal 
approaches [177]. FANCF [178] was recruited by the same modification in the chromatin 
context, but not in the peptide-based assay, again verifying the MS results. For the 
H3K9me3 modification the interaction was similarly confirmed for ADNP and ZMYM3 [179] 
(Figure 4.12 B). The interaction of ADNP with H3K9me3 (mediated by HP1) was further 
dissected in a recent publication from our group [180]. In contrast to these results, ACTL8 
showed no or very little enrichment with H3K9me3. However, the protein contains a PxVxL 
motif, known to be present in proteins recruited to chromatin by HP1 – a direct H3K9me3 
binder [181]. Moreover, the overexpressed protein showed exclusion from the nucleus as 
seen by immunofluorescence imaging (data not shown). Importantly, ACTL8 was identified 
as a prominent binder in several other affinity purification experiments using heterochromatic 
modifications (presented below). Finally, the recruitment of SMCHD1 was also verified using 






Figure 4.12  Validation of proteins recruited by H3K4me3 and H3K9me3. 
A-B. The indicated proteins containing C-terminal FLAG-tag were transiently expressed in 293T 
HEK cells, which used for preparation of nuclear extracts. Chromatin and peptide affinity 
purification with H3K4me3 (A) and H3K9me3 (B) modifications was performed, the bound 
proteins were separated on SDS-PAGE and transferred on nitrocellulose membrane and 
immunoblotted using αFLAG antibodies, except for SMCHD1 where wt cells and αSMCHD1 
antibodies were used. C-D. The indicated proteins containing C-terminal FLAG-tag were 
transiently expressed in NIH3T3 cells. Immunofluorescence was performed using αFLAG, 
αH3K4me3 (C) and αH3K9me3 (D) antibodies. DNA was stained with DAPI. Scale bar 
corresponds to 7.5 µm. The figure originally appeared in [78]. 
In addition to the biochemical validation discussed above, the cellular localization of 
the selected factors was also tested in comparison with H3K4me3 and H3K9me3 nuclear 
distribution (Figure 4.12) in NIH3T3 cells. Both transiently expressed SPIN1 and FANCF 
showed diffuse pattern, similar to the distribution of H3K4me3 (Figure 4.12 C). ZMYM3 and 
ADNP showed enrichment in discrete nuclear foci, which were also marked by H3K9me3 
and were DNA-dense (panel D). In summary, the findings from the MS-based screen were 


































































































4.2 Analysis of the interactome of different chromatin modifications 
Following the validation of the novel chromatin affinity purification approach, it was 
used to define the interactomes of a set of histone and DNA modifications. In this chapter 
the proteins specific for each individual modification will be briefly described, then analyzed 
comparatively and globally. The focus was on the heterochromatin-associated modifications 
H3K9me2, H3K9me3, H3K27me2, H3K27me3, meCpG, a combination of two of them 
(H3K9me3 and meCpG), the euchromatic H3K4me3, and the more poorly understood 
H3K27me1, which has been implicated both with euchromatin and heterochromatin 
functions [182]. Furthermore, monoubiquitylation of H2B (H2Bub1) was also tested, in 
addition to the difference between unmodified and H3Δ1-20 containing chromatin. Lastly, the 
H2Bub1-dependent recruitment of the SWI/SNF chromatin remodeling complex and its 
effect on transcription of selected genes was investigated. 
 
4.2.1 Proteins recruited by distinct chromatin modifications 
Overview and thresholds 
More than 4900 proteins were identified in total in all performed experiments – a 
value close to the number of proteins identified in the HeLa nuclear extract (Ilian Atanassov, 
manuscript in preparation). Of these, a varying number of highly enriched factors were 
specific for each modification. Since there is no consensus in the proteomics community 
which values reflect clear enrichment in a SILAC experiment, a fixed enrichment ratio 
threshold within two independent experiments was applied in the following studies. First, the 
limit of +/- 1 (log2 scale) for each forward and reverse experiments within individual SILAC 
pull-downs was set. This ensured that false positive proteins showing opposite ratios in both 
experiments (i.e. being identified as enriched only in light or only in heavy form, e.g. the 
exclusively light histone proteins part of the affinity matrix) would be excluded. Additionally, 
this threshold would also discard factors showing generally non-reproducible enrichment 
between the two experiments. Next, an additional threshold of +/-1.5 (log2 scale) for the 
average enrichment ratio between the forward and reverse experiments was set, resulting in 
a flat borderline between the putative background and specifically enriched proteins (Figure 
4.13, dark grey boundaries). All proteins above threshold levels for each modification are 
listed in Table 3 (a detailed list of the proteins with identifiers and enrichment ratios is 
included in Appendix 1). Nevertheless, as some proteins could be specifically enriched with 
lower ratios, the threshold level was decreased for some global analyses (as indicated) but 
enrichment in more than one experiment was required. 
 





Figure 4.13  Enrichment ratio threshold boundaries. 
Scatterplot representing the boundaries of the enrichment ratio threshold used for analysis of the 
individual interactomes (+/-1 in each F or R experiment, +/-1.5 average, log2 scale). Proteins 
















èTable 3  Proteins enriched or excluded within each chromatin affinity purification. 
A list of the proteins enriched (green arrow) or depleted (red arrow) in each of the performed 
experiments sorted according to their enrichment ratios (top – highest enrichment, bottom – 
highest depletion). Proteins occurring in more than one experiment are colour-coded as indicated 








































OCR C1orf103 ZHX2 UHRF1 DEK PHF1 PHF1 SPT4H BAZ1B UHRF2
KIAA1111 CBX5 ZHX1 ACTL8 CTCF POLR3D LRWD1 C1orf193 UHRF1 CBX5
CHD1 CBX1 HOMEZ CBX5 DDX36 C14orf151 ORC2 C9orf80 ACAC ZHX2
C17orf1 NIRF ZHX3 ARFIP2 POLR3D MYH10 UHRF1 LP3587 KIAA0783 HOMEZ
TAF2F CBX3 KAISO A2D IFI16 USP3 ENO1 PPP2CA JADE3 UHRF1
C6orf61 KIAA0650 ZNF787 KDP POLR3G G2E3 ORC5 INTS2 BRD2 MECP2
KIAA1523 ADNP INRF2 EDC4 POLR3C FKSG13 INTS12 C10orf12 KIAA1584
TAF3 C13orf8 A8K4Q3 NIPBL FBL6 LATHEO SPT5 BCLAF1 ZHX1
KIAA0700 POGZ MBD2 AIM KIAA1452 CBX5 RSBN1L CBX1
KIAA1227 RNF95 FOSL2 GARNL1 IFI16 EIF2G INTS5 FIZ1
GTF2A1 KIAA0892 MAFF NUP358 AAG POLR3D INTS9 CBX3
TAF2C CAF CDK2AP1 AKAP13 NSEP1 CMAS INTS1 ACTL8
TAF2D CAF1A MTA1L1 ATX NFIA TCF13 KIAA0852 ZHX3
C20orf154 UHRF1 MAFK HAUSP SRBD1 DP1 A-152E5.7 ADNP
MBTD1 ZMYM3 POGZ TRIO POLR3A PAF53 INTS4 UBCH5C
hCG_1810992 NIPBL JUND KIAA1057 C20orf167 PCL3 OBFC2A HAUSP
ESYT1 KIAA0425 ACTL8 hCG_1812148 POLR3F TFAP2A C1orf73 HSPC189
TAF2E ACTL8 FBL12 GMDS C14orf117 RBAP48 C7orf26 LRWD1
ARID4A HSPC189 MAFG HSP75 H1FX DDX47 DBI1 KIAA0414
ARID4B KIAA1205 ATF7 SCML2 POLR3B RING1 RSBN1 MBD2
KIAA0764 GTF3C1 DMAHP EDC3 C16orf88 BHLHB2 KIAA0459 ZNF580
C11orf30 AIM GATAD2B SP3 NFIC LYT10 POLR2B ORC2
JARID1A GTF3C5 GATAD2A POLR2 MUTYH ACTL8 C12orf11 KIAA1231
BRMS1L GTF3C3 RBAP46 CREM HARP SAP49 CPSF3L NIPBL
FANCF BBAP CHD4 INO80 POLR2E C21LRP C8orf35 CDYL
KIAA1291 ACAC CHD3 E2F3 CCDC86 TAB3 C8orf52 ZNF787
C17orf53 BAL2 UHRF1 POLR3D KIAA1649 KIAA1978 PPP2R1A POGZ
GTF2A2 PCNA DR1 PURB PSMB2 POLR2G LATHEO
KIAA0886 BAP1 ZBTB14 MUS81 LIG1 C19orf62 CHD3
HARP DPY30 MAFF POLR1C C14orf125 PPP2CB SCML2
PRO2134 BRD2 CIC CMAS KIAA1797 POLR2 MUTYH
NOC4L DP1 POLR2E ZFP276 COPG RECQL5 HMBOX1
FACE MTF2 KIAA1452 KIAA1665 GRL PPP2R1B AOF1
TAF12 E2F3 BANP PAF53 KIAA1741 ABRA1 MBD4
C6orf90 KIAA1798 ATF1 ANKT RTTN NELFA CHD4
EPC2 KIAA0309 DP1 DNAJC9 AMPK RAP80 MTA1L1
SAP45 MEN1 KIAA0997 KIAA1227 PSME3 BRCC3 A8K4Q3
HSPC301 BHLHB12 CREM TCF13 ARH BTBD12 C20orf88
TAF9B ZFP38 ASYIP E4F KIAA0791 C15orf44 FBL6
TAF2G TIM13B FOSL2 ZBTB14 PLEKHG4 DYRK MAFG
IPO12 SAMD1 CEBPB E2F3 ADTB1 KIAA0211 RBAP46
PPP1R10 BHLHB2 ERCC2 DP1 BAT2D1 POLR2J1 MAFF
C11orf23 BHLHB11 TIGD1 HMBOX1 TBC1D15 DCAF7 GATAD2A
CHD8 BCOR FOXK2 TRIP12 FIGNL1 KIAA1125 ATF7
BA2R RBBP5 BTEB3 TCF6 PI4KA POLR2D KIAA0892
COPA EMC19 BRD4 PUR1 NUBP2 POLR2 NRF1
RNF114 ASH2L CANPL1 TRIP12 WDR3 HSPC130 KIAA1196
C20orf158 NSPC1 ELF4 C20orf1 AKAP10 BRCC45 IFI16
TAF10 BHLHB39 POLR3F TAF1C DNMBP RNF168 TAF2D
KIAA1429 BEND3 WEE1 MSH2 CRM1 AD-009 GATAD2B
SIN3A WDR75 AIDD KIAA1196 CNOT3 KIAA1991 IFI16
GTF2D1 CIRH1A KIAA1227 POLR2L GYG COBRA1 TFAP2A
TOP3 UTP15 CREB1 DP2 GMIP NELFE TCHH
SAP130 L14 JUND ATF7 EIF4E2 KIAA1441 KIAA1266
TOX4 ALL1 JUN RB1 IRAK2 C19orf7 PUR1
CAGH32 BAP28 IFI16 CSDA STX5 GPN1 ORC5
POLR2B KIAA0007 ZBP89 AUF1 ESP1 ERCC1 NFIB
TGIF HRX2 BHLHD3 INO80S RAD54B C20orf94 LSF
ING1 ZNF131 IFI16 MBD4 C10orf46 ANP32B NFIA
BRD8 C17orf53 BTEB4 TFAP2A RCD1 ERCC11 SRBD1
SPK DEAF1 CTCF ZBTB9 C9JYP6 LAP2 PURB
CHET9 CXXC8 E4F ATAD5 CDC36 ANCO1 NFIC
JNKK2 TAF2E ARID4B PYCR1 ANCO2 KIAA1090
C17orf96 BHLHC41 GLYR1 C5orf7 TOX4 MAFK
HSPC144 HMBOX1 POLM ARHGAP29 GRWD ZMYM3
MGMT TFAP2A ZFP64 TMCO4 POLR2L LBP1
HMG20A NFIA MECP2 C22orf18 RAD18 IGKJRB
BRAF35 ATF7 AHCTF1 C1orf112 WDR82 HDAC2
KIAA0783 KIAA0414 NR2C2 WDR36 POLR2E AIM
UHRF1 NFIB UHRF1 PKN2 KPNA1 HDAC1
HAUSP NFIC RFX5 PPT1 BAF155 C18orf37
PCL3 KIAA0886 AD-005 KIAA0035 INO80S
ACTL8 CAF1 EPC1 EZF
SCML2 CALIF CPSF1 SIX4



































where the protein was enriched




The affinity purification using H3K4me3 chromatin identified a large number of 
putative interaction partners (Figure 4.14 A). The major group of proteins of the interactome 
of the H3K4me3 modification were the multiple subunits of the TFIID complex (e.g. TAF3, 
TBP). This complex binds directly to H3K4me3 (via TAF3) and the interaction is required for 
transcriptional activation [81]. Additionally, several subunits of another known H3K4me3 
interactor – the SAGA complex (e.g. the chromatin remodeling factor CHD1) [75], were 
identified. The SAGA subunit binding directly to this modification (CCDC101/SGF29) [183] 
was also detected, however with a ratio in one of the experiments slightly lower than the set 
threshold. SPIN1 was another example of a protein known to be directly recruited by 
H3K4me3 [177]. Other proteins than exert positive transcriptional regulation were the 
components of the NuA4 histone acetyl-transferase (HAT) complex – EP400, KAT5, ING3 
and BRD8 [184]; the mono- and dimethyl lysine-specific demethylase PHF8, known to 
demethylate e.g. H3K9me1/2 and H4K20me1 [185]; several subunits of the general 
transcription factor TFIIA [186]. Interestingly, several proteins with transcriptional repression 
functions were also part of the H3K4me3 interactome – the HDAC-associated BRMS1L, 
SUDS3 [187] and ING2 - a known H3K4me3 binder [166], and importantly - the H3K4me2/3-
specific lysine demethylase KDM5A [188]. Furthermore, several factors were excluded by 
this modification and bound preferentially to unmodified chromatin. The protein UHRF1 





Figure 4.14  Enrichment ratio distribution of the interactomes of H3K4me3 and H3K9me3. 
Enrichment ratios (log2 scale) from forward (x-axis) and reverse (y-axis) experiments for 
H3K4me3 (A) and H3K9me3 (B) chromatin. Proteins enriched or repelled by the modifications 
with ratios higher than the set threshold (+/-1 in each F or R experiment, +/-1.5 average, log2 
scale) are coloured in blue. 
A BH3K4me3 H3K9me3






























































R2 or K4 residues of H3 are modified [84]. Additionally, several UHRF1 interacting partners, 
including DNMT1/AIM and HAUSP/USP7 [189], were also detected. Another example of a 
protein from this group was ACTL8, which was already tested in the validation experiments 
for H3K9me3 (see 4.1.3). 
 
H3K9me3 
Among the known interactions partners of H3K9me3 (Figure 4.14 B) identified here 
were the three isoforms of the hallmark heterochromatin protein HP1 (CBX1/3/5) [167], as 
well as their interaction partners ADNP [180] and POGZ [173]. UHRF1, ACTL8 and DNMT1, 
which were excluded by H3K4me3, were strongly enriched with H3K9me3. UHRF2 was 
another example of a protein that was recently shown to bind H3K9me3 with high affinity 
[190]. Several zink-finger domain proteins (ZMYM3, ZMYM4, ZNF828, ZNF581) were also 
identified as specifically enriched, together with three subunits of the general RNA 
polymerase III transcription factor TFIIIC [191]. Of the proteins repelled by the H3K9me3 
modification were the ubiquitin ligase DTX3L, responsible for H4K91 ubiquitylation, and the 
functionally related poly(ADP-ribose) polymerase PARP14 [192]. 
 
H3K9me2 
The interactome of the heterochromatic modification H3K9me2 [43] is far less 
studied than the one of its trimethyl counterpart. The H3K9me2 chromatin pull-down showed 
asymmetrical enrichment ratio distribution with only a few proteins enriched above the set 
threshold (Figure 4.15 A). The only known H3K9me2 binder - PGC7, was not identified in 
the dataset. However, the interaction of PGC7 with H3K9me2 was shown only in mice and in 
the context of early embryogenesis [193]. Interestingly, ACTL8, UHRF1, UHRF2, CBX5, 
NIPBL, DNMT1, HAUSP – all of which were already described in the H3K9me3 dataset, 
were identified with H3K9me2. Additionally, enriched were the ubiquitin ligase HECTD1 
[194] and the ubiquitin-specific peptidase USP24 [195]. The proteins excluded by this 
modification represented a larger set. These included a large number of sequence-specific 
activating transcription factors - several subunits of the transcription factor nuclear factor I 
(NFI) [196], E2F3 [197], ELF4 [198], ATF7 [199]. On the other hand, DR1 [200], CTCF [201] 
and ZNF148 [202] were among the proteins related to transcriptional repression. Two 











Figure 4.15  Enrichment ratio distribution of the interactomes of H3K9me2 and meCpG. 
Enrichment ratios (log2 scale) from forward (x-axis) and reverse (y-axis) experiments for 
H3K9me2 (A) and meCpG (B) chromatin. Proteins enriched or repelled by the modifications with 
ratios higher than the set threshold (+/-1 in each F or R experiment, +/-1.5 average, log2 scale) 
are coloured in blue. 
Methylated DNA (meCpG) 
The interactome of DNA methylated at 5’C in CpG context (meCpG) revealed a 
similar number of proteins recruited and repelled by this modification (Figure 4.15 B). Among 
the known meCpG binders [203] MBD2 and KAISO were faithfully identified as enriched, 
while MBD3, MBD4, ZBTB4 and MECP2 showed ratios slightly lower than the set threshold 
or were found with very low ratio counts only in forward or reverse experiments. UHRF1, 
which was described in the context of H3K4me3 and H3K9me3, was also enriched here, 
supporting previous reports about its binding to methylated DNA [73]. Other proteins 
enriched in this dataset include ACTL8, POGZ, the homeobox leucine zipper protein 
HOMEZ [204] and most prominently - the three members of the zink fingers and 
homeoboxes (ZHX) family – ZHX1, ZHX2, ZHX3, implicated in transcriptional co-repression 
[205]. Of the proteins repelled by DNA methylation, KDM2A - a H3K36 demethylase, was 
previously shown to bind non-methylated CpG sequences [206]. Other proteins binding 
preferentially to unmodified chromatin in this context were WBP7 (or MLL4), MLL and 
ASH2L - components of H3K4-specific methyltransferase complexes [207-209]; multiple 
transcription factors, including USF1, USF2 [210], E2F3 [197], MTF2 [211]; the polycomb 




































































Monomethylation of Lys27 on H3 has been generally associated with transcriptional 
repression [213]. However, several reports also indicate roles in actively transcribed genes 
[182]. The interactome of H3K27me1 (Figure 4.16 A) revealed nearly 70 specifically 
enriched proteins, including a large number of subunits of RNA polymerases II and III. 
Additionally, recruited were proteins implicated in both positive and negative transcriptional 
regulation. Members of the former include E2F3 [197], ATF7 [199], NFIA/C [196], TEAD1 
[214]. Proteins with known negative transcriptional functions include for example the meCpG 
binding protein MECP2 [203], ARID4B and RB1 [215], the chromatin insulator protein CTCF 
[216]. Additionally, UHRF1 was identified with this modification as well. The only protein 
found to be excluded by the modification was the reticulon protein RTN4 [217]. 
 
H3K27me2 
This modification is associated with transcription repression, however not much is 
known about its direct functions in recruiting chromatin proteins [43]. Surprisingly, only two 
proteins appeared enriched here (Figure 4.16 B). The first, and highly enriched was PHF1 – 
a polycomb group protein involved in response to DNA double-strand breaks [218], and the 
second and with much lower ratio – the RNA polymerase III subunit POLR3D. Interestingly, 
both proteins were identified in the H3K27me3 dataset, and POLR3D was also present in 
the H3K27me1 interactome. The proteins repelled by the modification included the E3 
ubiquitin ligase G2E3, required for early embryonic development [219], and USP3 – a 
H2A/H2B deubiquitinating enzyme [220]. 
 
H3K27me3 
Trimethylation of Lys27 on H3 is a well-studied histone modification implicated in 
polycomb-mediated transcriptional silencing [221], X-chromosome inactivation [222] and 
establishment of bivalent chromatin domains, poised for transcriptional activation or 
silencing [41]. Among the highly enriched factors here (Figure 4.16 C) were LRWD1 and 
origin recognition complex (ORC) subunits, known to be associated with the repressive 
H3K9me3 and H4K20me3 modifications [223]. The only polycomb group proteins above the 
enrichment ratio threshold were the H2AK119-specific ubiquitin ligase RING1 – a subunit of 
PRC1 [224] and PHF1 [218]. Additionally, several other polycomb group proteins were 
identified, but either with lower ratios, or not quantified (e.g. BMI1, CBX4, CBX8, EZH1, 
EZH2, PHC2, SUZ12). Other proteins include the already descibed UHRF1, ACTL8, TEAD1, 
CBX5, as well as the splicing factor SF3B4 [225] and the transcription factor DP-1 [226]. 
 





Figure 4.16  Enrichment ratio distribution of the interactomes of H3K27me1, H3K27me2 and 
H3K27me3. 
Enrichment ratios (log2 scale) from forward (x-axis) and reverse (y-axis) experiments for 
H3K27me1 (A), H3K27me2 (B) and H3K27me3 (C) chromatin. Proteins enriched or repelled by 
the modifications with ratios higher than the set threshold (+/-1 in each F or R experiment, +/-1.5 
average, log2 scale) are coloured in blue. 
Interestingly, among the proteins excluded by H3K27me3 were six subunits of CCR4-NOT – 
a protein complex involved in various aspects of mRNA metabolism, including transcriptional 
regulation, mRNA decay and transport [227], the H3K9-specific histone demethylase 





































































































Ubiquitination of H2B on K120 (H2Bub1) has been linked to transcriptional 
activation/elongation, nucleosome assembly/disassembly and DNA damage [230, 231]. The 
analysis of the H2Bub1 pull-down revealed more than 90 enriched proteins (Figure 4.17 A), 
many of which are members of multiprotein complexes. Importantly, one of the identified 
factors was WDR82, a known H2Bub1-binding partner [89]. Remarkably, the list included all 
subunits of the negative elongation complex NELF [232], the elongation complex DSIF [233], 
11 subunits of the snRNA processing Integrator complex [234], multiple subunits of RNA 
polymerase II and the SWI/SNF chromatin remodeling complex [235]. Additionally, enriched 
with H2Bub1 were the DNA helicase RECQL5, a putative tumor suppressor involved in 
maintaining genome stability [236] and the DYRK1A kinase, implicated in neuronal 
development [237]. Several of the identified proteins have been implicated in 
heterochromatin related roles, including the CW zinc finger protein MORC2, involved in 
histone deacetylation [238] and ADNP - a HP1 interacting partner linked to silencing of major 
satellite repeats [180]. The most prominent H2Bub1 excluded factors were the regulator of 






Figure 4.17  Enrichment ratio distribution of the interactomes of H2Bub1 and H3 Δ1-20. 
Enrichment ratios (log2 scale) from forward (x-axis) and reverse (y-axis) experiments for H2Bub1 
(A) and H3 Δ1-20 (B) chromatin. Proteins enriched or repelled by the modifications with ratios 
higher than the set threshold (+/-1 in each F or R experiment, +/-1.5 average, log2 scale) are 
coloured in blue. 
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In addition to the presented chromatin modifications, the proteins binding to the 
unmodified H3 N-terminus per se were also investigated. To this aim, an affinity purification 
experiment comparing the interaction partners of chromatin containing wt H3 to chromatin 
reconstituted with H3 lacking 20 amino acids from the N-terminus (H3 Δ1-20) was 
performed. Several proteins indeed bound stronger to the chromatin containing full length 
H3 (Figure 4.17 B), including the already described UHRF1 [84], the bromodomain-
containing proteins BAZ1B [241] and BRD2 [242], and the PHD finger proteins PHF14 and 
PHF16 [243]. The only protein enriched with the H3 Δ1-20 chromatin was BCLAF2, a 
transcriptional repressor interacting with members of the BCL-2 family of apoptosis 
regulatory proteins [244]. 
 
 
H3K9me3 and meCpG, comparison of single against a combination of modifications 
In order to study potential synergistic effects of two chromatin modifications, the 
interactomes of unmodified chromatin and doubly modified H3K9me3/meCpG chromatin 
(meCpG.H3K9me3) were compared. Nearly 100 proteins were associated specifically with 
meCpG.H3K9me3 chromatin (Figure 4.18 A). Interestingly, the overlap between this 
experiment and the interactomes of the individual H3K9me3 (Figure 4.14 B) and meCpG 
(Figure 4.15 B) modifications was relatively limited. The chromatin carrying both 
modifications recruited larger number of proteins than the factors from the two single 
modification experiments taken together (Figure 4.18 B). The proteins enriched in all three 
experiments were UHRF1, ACTL8 and POGZ. Additionally, several of the factors that were 
enriched in meCpG.H3K9me3 were also present with high ratios in one of the other two 
modifications (see crossed out circles in Figure 4.18 C and D) – these represented proteins 
identified as prominent binders in meCpG (e.g. ZHX1) or H3K9me3 (CBX5). In both 
comparisons, a number of proteins were enriched with the combination of modifications and 
present near background level in the other (see solid blue and green circles). The majority of 
those were the factors specific for the meCpG experiment (in the comparison of 
meCpG.H3K9me3 with H3K9me3, panel C) or H3K9me3 experiment (in the comparison of 
meCpG.H3K9me3 with meCpG, panel D). Surprisingly, a large number of proteins excluded 
by meCpG were not influenced by the combination of meCpG and H3K9me3 (green circles 
on the negative x-axis in Figure 4.18 D), while only two were uniquely enriched by meCpG. 
Interestingly, one of the later was the known meCpG binder KAISO [203]. 
Next, the three datasets were analyzed together in order to identify proteins that 




Figure 4.18  The interactome of H3K9me3 in combination with meCpG. 
A. Enrichment ratios (log2 scale) from forward (x-axis) and reverse (y-axis) experiments for 
meCpG.H3K9me3 chromatin. Proteins enriched or repelled by the modifications with ratios higher 
than the set threshold (+/-1 in each F or R experiment, +/-1.5 average, log2 scale) are coloured in 
blue. B. Venn diagrams representing the overlap of enriched proteins between meCpG, 
H3K9me3 and meCpG.H3K9me3 experiments. C-D. Scatterplots correlating the average 
enrichment ratios of the meCpG.H3K9me3 experiment with the H3K9me3 (C) and meCpG (D) 
experiments. Proteins above enrichment ratio thresholds (see A) are colour-coded as follows: 
crossed-out red circles - both experiments, meCpG.H3K9me3 – blue circles, H3K9me3 (C) or 
meCpG (D) – green circles. E. Comparison of the proteins enriched by H3K9me3 (x-axis), 
meCPG (y-axis) and meCpG.H3K9me3 (colour coded according to enrichment ratio as indicated 
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with both modifications independently. The enrichment ratios of the meCpG and H3K9me3 
binders were plotted in a scatter plot and the enrichment ratios from the combined 
meCpG.H3K9me3 experiment were overlaid as a third dimension using colour code (Figure 
4.18 E). Surprisingly, there were several transcription factors that appear to be enriched only 
when both modifications are present. These included UBP1 – a transcriptional activator that 
can in addition repress HIV-1 transcription by inhibiting TFIID binding [245]; IFI16, which can 
function as innate immune sensor for intracellular DNA [246]; several subunits of nuclear 
factor I (NFI) [196] and the trimeric nuclear transcription factor Y (NFY) [247]; YY1 – a 
ubiquitous transcription factor that may direct HAT and HDAC enzymes for activation or 
repression [248, 249]. The histone deacetylases HDAC1 and HDAC2 were also identified in 
this context. Interestingly, the meCpG-binders MECP2 and MBD4 were among those with 
high enrichment only in the meCpG.H3K9me3 dataset. Additionally, identified here were the 
known H3K9me3 binder CDYL [108], the SET, PWWP, HMG and PHD domain-containing 
probable histone methyltransferase NSD2/WHSC1 [250], the H3K4-specific demethylase 
KDM1B [228], as well as several origin recognition complex subunits [223]. Strikingly, two of 
the meCpG.H3K9me3-specific proteins were also identified in the H3K4me3 dataset: SPIN1 
– a known H3K4me3 binder [177], and TAF5/TAF2D – a subunit of TFIID [81]. 
 
4.2.2 Relationship and overlap between the interactomes of different chromatin 
modifications 
Binary comparison of the interactomes of different modifications 
As described above, the analysis of the interactomes of the ten individual chromatin 
species revealed a set of proteins enriched in multiple chromatin affinity purification 
experiments. Similar binding partners could indicate functional association; therefore the 
proteins recruited by selected pairs of modifications were compared next. Illustrating the 
similarities, differences and, most importantly, the overlap between them was the first step in 
the global analysis of the investigated interactomes. 
Both H3K9me2 and H3K9me3 have been implicated in the context of 
heterochromatin [43]. The comparison of their interactomes revealed a limited overlap of 
several highly enriched proteins, including CBX5, UHRF1, ACTL8 and DNMT1 (Figure 4.19 
A, crossed-out circles). Some known H3K9me3 binders (e.g. CBX3 and the associated 
ADNP) showed mild enrichment below threshold levels with H3K9me2, while others (e.g. 
CHAF1 subunits) were at background level. Additionally, H3K9me2 showed a tendency to 
repel binding of a large number of factors (green circles along the negative x-axis). These 
included, for example IFI16, which was enriched with meCpG.H3K9me3, and interestingly – 





Figure 4.19  Binary comparison of the enrichment ratio distributions of selected chromatin 
modifications. 
Correlation of the average enrichment ratios between H3K9me and H3K9me2 (A), H3K9me2 and 
H3K27me1 (B), meCpG and H3K9me2 (C) and H3K27me3 and H3K27me1 (D). Proteins 
enriched for only one of the modifications are coloured in green or blue, as indicated. Proteins 
above threshold levels in both experiments are represented with red crossed-out circles. 
The single protein enriched by both H3K9me2 and H3K27me1 (Figure 4.19 B), was 
UHRF1. Interestingly, a large number of the proteins enriched with H3K27me1 appeared to 
be repelled by H3K9me2 and the interactomes showed an overall negative correlation of 
enrichment ratios. These included several RNA polymerase II subunits, the insulator protein 
CTCF [201], and both activating and repressing transcription factors - ATF7 [199], IFI16 
[246], several subunits of nuclear factor I [196], TFAP2A [251]. 
UHRF1 and ACTL8 were the only two proteins enriched above threshold levels by 
both H3K9me2 and meCpG (Figure 4.19 C). One protein was excluded by both 
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enriched by both H3K27me1 and H3K27me3. Several proteins appeared repelled by 
H3K9me2 and enriched by meCpG – ATF7, as well as two subunits of the transcription 
factor complex AP-1 (JUND and FOSL2) [252]. 
While both H3K27me1 and H3K27me3 have been implicated with transcriptional 
repression [213], recent studies suggest that the monomethyl mark is found in the gene 
bodies of actively transcribed genes [43, 182]. H3K27me3 can also be found together with 
H3K4me3 at bivalent chromatin domains poised for transcription [41]. Furthermore, there is 
a recent report that suggests a role of the trimethyl modification at actively transcribed genes 
[253]. The comparison of the interactomes of the two marks revealed that the vast majority 
of proteins enriched with H3K27me1 are at or slightly above background levels in 
H3K27me3 (Figure 4.19 D, green circles). Conversely, the majority of the proteins repelled 
by H3K27me3 was near background level or slightly excluded from H3K27me1 (blue 
circles). Notably, several proteins showed strong enrichment in both experiments. These 
included UHRF1, subunits of RNA polymerase I (POLR1E) and III (POLR3D), the 
transcription factors DP-1 [226] and TEAD1 [214]. 
Several groups have demonstrated that establishing of H2Bub1 is a prerequisite for 
di- and trimethylation of H3K4, and that the mechanism behind this histone modification 
cross-talk relies on the recruitment of the specific H3K4 HMT enzymes [254-256]. 
Interestingly, there was limited overlap between the proteins enriched by H3K4me3 and 
H2Bub1 (Figure 4.20 A). These included RNA polymerase II subunit POLR2B, two subunits 
of protein phosphatase complex PTW/PP1 (PPP1R10 and TOX4), known to regulate 
chromatin structure and cell cycle progression [257, 258], as well as the chromodomain 
helicase CHD1 [67, 259]. Additionally, there was a group of factors highly enriched with one 
of the modifications and near background or moderately enriched with the other (blue and 
green circles near the positive x- and y-axes). H2Bub1 in general also showed limited 
overlap with the other modifications tested. POLR2E and POLR2L were the common 
enriched factors with H3K27me1 and ADNP with H3K9me3. 
As shown in the previous section, the comparison between meCpG, H3K9me3 and 
meCpG.H3K9me3 revealed several common interaction partners (Figure 4.18). Next, the 
overlap between the experiment utilizing meCpG.H3K9me3 chromatin and three single 
chromatin modifications was investigated. Three of the proteins prominent in almost all 
modifications screened – UHRF1, ACTL8 and CBX5, were enriched in both 
meCpG.H3K9me3 and H3K27me3 (Figure 4.20 B). These also included four ORC subunits, 
known to be associated with the repressive H3K9me3 and H4K20me3 marks [223], the 
transcription factor TFAP2A [251] and RBAP48 – a subunit of several complexes with 






Figure 4.20  Correlation of the enrichment ratio distributions of selected chromatin 
modifications. 
Comparison of the average enrichment ratios between H2Bub1 and H3K4me3 (A), 
meCpG.H3K9me3 and H3K27me3 (B), meCpG.H3K9me3 and H3K4me3 (C) and 
meCpG.H3K9me3 and H3K27me1 (D). Proteins enriched for only one of the modifications are 
coloured in green or blue, as indicated. Proteins above threshold levels in both experiments are 
represented with red crossed-out circles 
Two proteins, known to be associated with H3K4me3 (SPIN1 and TAF2D), were also 
enriched in the meCpG.H3K9me3 pull-down (Figure 4.18 and section 4.2.1). Therefore, 
further correlation between the two experiments was investigated. The two proteins 
appeared to be the only enriched above threshold levels in both experiment (Figure 4.20 C), 
however, a small set of proteins specific for H3K4me3 showed moderate enrichment below 
threshold level for the double modification as well (green circles below TAF2D). These 
included several other TFIID subunits. Additionally, as within the comparison between 
H3K4me3 and H3K9me3 (Figure 4.10), the enrichment ratios of UHRF1, HAUSP and 
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SCML2 showed similar enrichment pattern. The protein contains two MBT repeats and has 
been implicated in promiscuous binding to monomethyl lysine, while showing no binding to 
trimethylated marks [262]. However, it was also enriched with H3K9me2 and more mildly 
with H3K27me3 and wt H3 in the context of H3 Δ1-20. 
Strikingly, the enrichment ratio distributions of meCpG.H3K9me3 and H3K27me1 
showed good correlation (Pearson’s product correlation coefficient 0.67, p < 2.2e -16) 
(Figure 4.20 D). A large number of proteins appeared to be enriched above threshold levels 
in both experiments, including UHRF1, MECP2, IFI16, NFIA, CTCF, TFAP2A, ATF7 and 
YY1/INO80S. Additionally, the majority of the proteins specific for one of the modifications 
were enriched just below threshold level with the other (see blue and green circles above the 
positive x- and y-axes). On the other hand, the two interactomes did not share any proteins 
repelled by the chromatin modifications. 
 
A protein-protein interaction network of the chromatin modification interactome 
Next, a protein-protein interaction network was constructed in order to examine the 
structural interactions and functional relationships between the proteins recruited by each 
modification tested. The network was based on known relations inferred from experimental 
evidence, literature text mining and curated databases (Figure 4.21) [134, 151]. Each protein 
was represented as individual node, while interacting proteins were linked by edges. Global 
network analysis [152] revealed relatively good connectedness. 212 out of 324 nodes were 
connected with an average of 5.154 neighbours. The network diameter (that is, the distance 
or the path between the two remotest connected nodes) was 13, while the average shortest 
path length was 4.272. The clustering coefficient of the entire network, which represents the 
ratio of observed edges to the maximum number of theoretically possible edges, was 0.36. 
Visual inspection of the interaction network revealed that the individual modification 
interactomes were separated well within the network. The H3K27me1 nodes appeared to 
connect the euchromatic H3K4me3 and H2Bub1 with the heterochromatic modifications. 
Additionally, a prominent clustering was apparent for the subunits of TFIID (H3K4me3), the 
RNA polymerase II and the associated complexes NELF, DSIF, Integrator (H2Bub1) and  
 
èFigure 4.21  Protein-protein interaction network of the chromatin modification interactome. 
Interactome network constructed based on information from experiments, peer-reviewed 
publications and curated databases. Known structural and functional relationships are 
represented as edges connecting individual proteins (nodes). The weight of the edges is 
indicative of the confidence of the interaction (PPI score, as indicated). Nodes are colour-coded 
according to identification within separate experiments, and labeled using canonical gene names 
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RNA polymerase III (H3K27me1) and one or more subunits common for different datasets 
connecting them. The heterochromaic interactomes revealed less prominent clustering, with 
the exception of the highly interconnected nodes around subunits of CHAF1, GATAD2 and 
several meCpG-binding proteins, part of the meCpG/H3K9me3 related interactomes. 
However, the majority of those interactions represent individual complexes and not known 
large macromolecular assemblies. Notably, some of the proteins that were enriched with 
multiple modifications did not appear to be central members of large multiprotein complexes 
(e.g. UHRF1, ACTL8, POGZ with 6, 0 and 1 neighbours, respectively), while others showed 
enhanced connectivity (e.g. DNMT1 and CBX5 with 17 and 18 neighbours, respectively).  
 
The common heterochromatin interactome 
A major aim of this study was establishing a chromatin affinity purification approach 
for identifying a set of proteins that are associated with and conceivably important for the 
functional heterochromatin domain. The individual or comparative analyses of the 
interactomes of different chromatin modifications revealed relatively limited overlap. 
However, several proteins appeared consistently enriched or repelled throughout most of the 
datasets. In order to compare the enrichment of those prominent interactors, the proteins 
enriched or excluded in multiple experiments were identified. For this analysis, the 
enrichment ratio threshold was lowered to +/-0.5 in each individual forward or reverse 
experiment and +/-1 on average (log2 scale). As this threshold is less stringent than the one 
used previously, an additional requirement was that a protein was enriched or excluded in at 
least four out of eight chromatin modifications (excluded from the analysis here were 
H3K27me2 as it showed only two enriched proteins, and H3 Δ1-20 as it is not directly linked 
to eu- or heterochromatin). 
Strikingly, this analysis resulted in a list of 21 proteins. The enrichment ratios of these 
factors in different experiments were plotted as a heatmap with proteins as rows and 
experiments as columns, and both dimensions were clustered using Euclidean distance and 
complete linkage methods [263] (Figure 4.22 A). The majority of the proteins showed clear 
enrichment with some of the bona fide heterochromatin marks and exclusion with either the 
euchromatic H3K4me3 or with the heterochromatic H3K9me2. UHRF1, ACTL8, CBX3 and 
CBX5 were the most prominent heterochromatin modification binders. This analysis also 
revealed that H3K27me1 and H3K27me3 are most closely related as seen from the column 
dendrogram. The identical data was also visualized using line plot (Figure 4.22 B). 
Additionally, interactome network of the 21 most prominent proteins was constructed. While 
there are known connections between some of them, they do not recapitulate major 







Figure 4.22  The common heterochromatin modification interactome 
A. Heatmap showing the enrichment or exclusion of proteins found in four out of eight of the 
plotted experiments. Proteins are colour-coded according to their normalized enrichment ratios as 
indicated in the legend. Columns (modifications) and rows (proteins) were clustered using 
Euclidean distance and complete linkage methods. B. Line plot representing the enrichment 
ratios of the proteins shown in A. C. Interactome network of the proteins shown in A. Darker 
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In order to further globally compare the different datasets using the approach 
described in the previous paragraph, the enrichment ratios of all proteins above threshold 
levels from the ten experiments were plotted as a heatmap. Both the lower threshold used in 
Figure 4.22 A and the standard for this study threshold (Figure 4.23 A and B, respectively) 
were applied. Notably, on this global level there wasn’t any identifiable close relationship 
between the interactomes of the different modifications. The column dendrograms did not 
reveal close distance between the datasets, apart from the few examples with very limited 
number of data points (e.g. H3K27me2 and H3 Δ1-20 in both heatmaps). Thus on a global 
scale, the tested chromatin modifications appear to recruit distinct sets of proteins, however, 
upon closer examination of the datasets, the similar behavior of a small set of factors 





Figure 4.23  Global comparison of the quantified proteins between different chromatin affinity 
purification experiments. 
Heatmap containing all protein identified above threshold levels in at least one experiment. Lower 
threshold (A, as in Figure 4.22) or standard threshold (B) was used. The number of clustered 
proteins is indicated in each case. Proteins are colour-coded according to their normalized 
enrichment ratios as indicated in the legend. 
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4.2.3 Recruitment of SWI/SNF to H2Bub1 - investigating the interactome of a single 
modification and the specific function of a recruited complex 
The results presented in Chapter 4.2.3 were obtained in close collaboration with 
Efrat Shema and Moshe Oren (Weizmann Institute of Sciences, Rehovot, Israel). 
The experiments involving ChIP, qRT-PCR, Co-IP and transfection were performed 
by Efrat Shema. The purified SWI/SNF complex was a kind gift from Eric Allemand 
(Institut Pasteur, Paris, France). 
 
Validation of H2Bub1-dependent interactions 
Apart from the global analysis of the H2Bub1 interactome presented in the previous 
chapter, a deeper insight into the molecular mechanisms that are mediating the cellular 
functions of this modification was sought out. Multiple subunits of several macromolecular 
complexes were represented in the list of enriched proteins (colour-coded in Figure 4.24 A). 
To further validate the SILAC MS results, the recruitment of the different classes of the 
identified interactors was tested. To this aim, the chromatin affinity purification experiments 
were repeated using Western Blot detection with specific antibodies. The signals for 
RECQL5, NELFA, SUPT5H, BAF155, DYRK1A, INTS3 and MORC2 revealed preferential 
binding to the H2Bub1 containing chromatin (Figure 4.24 B, top panel), essentially verifying 
the MS results. Two of the proteins identified as non-specific binders, HDAC1 and β-tubulin, 
showed no preferential binding to either chromatin templates. Furthermore, the Western Blot 
analysis corroborated the MS results for RCC1 - a member of the small group of proteins 
showing enrichment for unmodified chromatin (Figure 4.24 B, bottom middle panel). Thus, 
the SILAC MS enrichment results for H2Bub1 were validated for all 10 proteins tested. 
Additionally, in order to exclude from further analysis any proteins that could have been 
recruited by ubiquitin alone, a SILAC pull-down experiment using biotinylated ubiquitin was 
performed. Importantly, the results showed no overlap of the limited number of identified 
interaction partners with those recovered when using chromatin reconstituted with H2Bub1 





Figure 4.24  Proteins recruited by H2Bub1. 
A. Scatterplot representing the ratios from forward and reverse pull-down experiment using 
H2Bub1 chromatin. Several prominent protein complexes are colour-coded accordingly. B. 
Validation of the recruitment of selected proteins from the H2Bub1 interactome. Affinity 
purification as in A. was repeated, the bound proteins were separated by SDS-PAGE, transferred 
on nitrocellulose membrane and immuniblotted using specific antibodies. H2A, H3 and H4 were 
used as loading controls. C. Proteins recruited by ubiquitin alone as revealed by Ub-biotin SILAC 
pull-down experiment. 
 
The SWI/SNF complex interacts with H2Bub1 in vitro and in vivo 
One of the complexes identified as preferential H2Bub1-binder was the chromatin 
remodeler SWI/SNF. This molecular machine performs ATP-dependent nucleosome 
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SWI/SNF complexes consist of a variety of proteins, including the core subunits BRG1 or 
BRM, INI1, BAF155 and BAF170. The enrichment of one of the core subunits, BAF155, was 
already reproduced using Western Blot detection (Figure 4.24 B). In order to further validate 
the recruitment of the complex, purified mammalian SWI/SNF complex [264] was incubated 
with unmodified and H2Bub1 chromatin. This revealed moderate, but nevertheless stronger 
association of four of the core subunits with the modified template (Figure 4.25 A). 
Next, this interaction was tested in vivo. For this purpose FLAG-tagged WT H2B or 
H2B resistant to ubiquitylation (mutated at lysines 120 and 125, H2B2KR) [265] were 





Figure 4.25  H2Bub1-dependent recruitment of SWI/SNF. 
A. Unmodified and H2Bub1 chromatin was incubated with purified SWI/SNF complex and the 
bound proteins were analyzed by SDS-PAGE and immunodetected using specific antibodies. B. 
HeLa cells were transiently transfected with control (empty) vector, or plasmids encoding FLAG-
tagged WT H3 or H2B2KR. 24h post-transfection, nuclear extracts were isolated and subjected to 
immunoprecipitation with αFLAG antibodies, followed by immunodetection by Western Blot using 
αBAF155 antibodies. C. HeLa cells were transfected with control siRNA oligos (siLacZ) or oligos 
directed against RNF20 (siRNF20). 24h later, the cells were transfected with plasmid carrying 








































































































































precipitated more of the BAF155 subunit, compared to H2B2KR (Figure 4.25 B, right panel). 
Additionally, WT H2B expressed in cells depleted of RNAF20, the major ubiquitin ligase for 
H2B [256], resulted in reduced association of BAF155 (Figure 4.25 C, right panel). Taken 
together, these experiments demonstrated the specific interaction of the SWI/SNF complex 
both in vitro and in vivo. 
 
RNF20-dependent genes require SWI/SNF for optimal transcription 
It was previously shown that RNF20 and H2B ubiquitylation positively or negatively 
regulate the transcription of two distinct gene sets, while having no influence on the majority 
of expressed genes [266]. Therefore, the influence of the recruitment of the SWI/SNF 
complex to H2Bub1 on the transcription of these gene sets was tested next. Several 
SWI/SNF subunits were knocked down by siRNA (Figure 4.26 A and B) and the expression 
of selected genes representative of each class was analyzed. As expected, knock down of 




Figure 4.26  RNF20-dependent genes require SWI/SNF for optimal transcription. 
A. HeLa cells were transiently transfected with control (LacZ), BRG1, BAF155 and BRM siRNA 
oligos. 48h later, total RNA was extracted and analyzed by qRT-PCR using primers specific for 
the targeted genes. mRNA levels were determined after normalization to GAPDH levels within the 
same sample and as the ratio of the signal from the same transcript in the siLacZ control sample, 
set as 1. B. The experiment presented in A was repeated using Western Blot immunodetection 
with specific antibodies as indicated. C. HeLa cells were transfected and analyzed as in A using 
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transcriptionally dependent on this ubiquitin transferase (Figure 4.26 C, left panel, compare 
control blue with violet bars). Interestingly, knock down of BRG1 and to a lesser extent 
BAF150, resulted in similar decrease in expression of this subset of genes. However, knock 
down of BRM had little effect in this regard. On the other hand, depletion of the tested 
SWI/SNF subunits did not affect the expression of RNF20-independent or suppressed genes 
(Figure 4.26 C, left panel). Thus, the SWI/SNF complex is involved in the positive regulation 
of genes whose transcription is dependent on RNF20. 
 
SWI/SNF is recruited to RNF-dependent genes 
In order to further validate the recruitment of SWI/SNF by H2Bub1, the association of 
the complex with the TSS or 5’ regions of representative genes was tested using ChIP with 
antibodies against BRG1. To this aim, the signals from control and RNF20 knock down cells 
were compared. Depletion of RNF20 resulted in significant decrease in the association of 
BRG1 with RNF20-dependent genes (Figure 4.27 A, left). In contrast, significant changes in 
the signal from RNF20-independent or suppressed genes were not observed (panel A, 
right). As expected, the knock down of RNF20 reduced the H2Bub1 levels at all tested 
genes (Figure 4.27 B). Thus, H2Bub1 recruits BRG1, and supposedly the SWI/SNF 
complex, to a subset of genes whose transcription it selectively regulates. 
Next, the rescue of the transcriptional levels of RNF20-dependent genes in cells 
depleted from RFN20 by BRG1 overexpression was tested. Again, RNF20 knock down led 
to reduced expression of the subset of RNF20-dependent genes (Figure 4.27 C, compare 
blue and red bars). Strikingly, BRG1 overexpression partially rescued the transcription of 
those genes in the RNF20-depleted cells (compare red and yellow bars), while having no 






Figure 4.27  H2Bub1-dependent recruitment of SWI/SNF to chromatin in vivo. 
A-B. Chromatin immunoprecipitation of BRG1 (A) and H2Bub1 (B) from HeLa cells transiently 
transfected with RNF20 siRNA (siRNF20) or control LacZ siRNA (siLacZ) oligos. 
Immunoprecipitated and input DNA were quantified by qPCR using primers specific for the 
indicated gene regions (x-axis). DNA levels are presented as percentage of input. C. HeLa cells 
were transfected with RNF20 siRNA (siRNF20) or LacZ siRNA (siLacZ) as in Figure 4.26. 24h 
later the cells were transfected with empty vector or plasmid carrying BRG1. After 24h the RNA 
was extracted and analyzed as in Figure 4.26. 
In summary, the SILAC chromatin affinity purification revealed that members of the 
SWI/SNF complex are associated with H2Bub1-rich chromatin. This interaction was further 
validated both in vitro and in vivo. Furthermore, the results demonstrated that it is required 
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4.3 SILAC-based internal standard strategy for relative quantification  
Relative quantification by SILAC, or any other label-based or label-free approach, is 
extremely useful when comparing different samples in a relative manner [124]. However, 
most approaches are not applicable for comparing relative enrichment between different 
experiments, especially for peptides and proteins with very high enrichment ratios. The 
dynamic range limitation in current mass spectrometers restricts accurate enrichment ratio 
estimation for peptides with high abundant peptides in one of the SILAC pairs. If the intensity 
ratio of a very high abundant light peak and a very low abundant heavy peak is greater than 
the measurable dynamic range, the enrichment ratio is calculated based on the noise in the 
spectrum instead of the heavy peak [119]. Thus, in the example given in Figure 4.28 A, the 
ratio between the light (blue) peak and the heavy (red) peak in the spectrum from 
experiment 1 or experiment 2 will result in a high arbitrary L/H ratio but both values would 
not be comparable. In the specific case of very high enrichment of a protein with two histone 
modifications and a combination of them, a synergistic effect cannot be quantified by 
comparing the three individual enrichments ratios. However, if the signals from the three 
different samples are related to a common standard peptide signal, a comparison of binding 
strength is possible. Such an internal standard should have identical physicochemical 
properties as the analytes under investigation. Synthetic heavy-labeled peptides have 
proven to be a useful standard, for example when determining the subunit stoichiometry of 
protein complexes [122]. This approach provides very accurate results but is time 
consuming and costly when applied in large-scale experiments. Therefore, a novel 
affordable method for estimative enrichment ratio comparison using the SILAC strategy was 
developed. An internal standard was derived by performing two identical series of 
experiments in parallel, one using light and the other heavy extract, and then mixing the 
eluates from one of the series and distributing them equally among the other series (Figure 
4.28 B). Thus for signals of the same peptide from different experiments in the light series, 
there would be equal amount of heavy peptide from the internal standard (Figure 4.28 C), 
and the L/H ratios should be comparable. 
 
 





Figure 4.28  Strategy for SILAC quantification using internal standard. 
A. A SILAC spectrum of a peptide highly abundant in the light form and near noise levels in the 
heavy form. B. Strategy for mixing and distributing of the internal standard. C. A theoretical 
spectrum showing the light signals from different experiments and the heavy internal standard 
with equal intensity. 
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4.3.1 Quantification of proteins binding to meCpG, H3K9me3 and a combination 
thereof 
In order to test the feasibility of the approach for comparing the enrichment to 
different chromatin modifications using internal standards, an experiment using unmodified, 
H3K9me3, meCpG and meCpG.H3K9me3 chromatin was set up. Pull-down with each of the 
chromatin species was performed using light and heavy SILAC NE. The eluates from the 
light samples were combined and distributed quantitatively between the heavy samples 
(Figure 4.29). This was termed forward experiment. Additionally, a parallel reverse 
experiment was performed where the heavy samples were mixed and distributed between 




Figure 4.29  Mixing scheme of forward internal standard experiment. 
Four chromatin species were used for pull-down from light and heavy nuclear extracts. The 
eluates from the light sample were mixed quantitatively and distributed equally between the 
heavy samples. In a reverse experiment (not shown) the heavy samples were mixed and 
distributed between the light ones. 
The enrichment ratios of several prominent meCpG (Figure 4.30 A) and H3K9me3 
(Figure 4.30 B) binding proteins identified in previous pull-downs (see section 4.2) were 
plotted as line plots and their values were compared between the individual experiments. As 
the distribution of SILAC ratios in this type of experiment with internal standard is different 
from the distribution in a typical SILAC experiment, the non-normalized ratios [119] were 
also plotted. Surprisingly, the results from the forward and reverse experiments differed 
significantly. The ratios in the reverse experiment were on average several fold higher than 
in the forward, and while the behavior of most proteins appeared similar, UHRF1 and ACTL8 
were enriched with much higher ratios in the reverse experiment. Additionally, the 
normalization changed the profile of some of the proteins mildly (for example ADNP 
Heavy
Unmodified H3K9me3 meCpG meCpG.H3K9me3
Unmodified H3K9me3 meCpG meCpG.H3K9me3
Light
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appeared slightly more enriched in the meCpG.H3K9me3 reverse experiment, compared to 




Figure 4.30  Binding profiles of meCpG and H3K9me3-specific interaction partners determined 
using SILAC internal standard. 
The ratio profiles of known meCpG (A) or H3K9me3 (B) binding proteins were plotted for 
comparison between unmodified, H3K9me3, meCpG and meCpG.H3K9me3 chromatin. The 
normalized and non-normalized ratios from forward and reverse experiments are shown. The first 
data point in each graph is a reference point set to zero. 
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In order to gain more insight into the behavior of the enrichment ratios in this 
experiment, the ratio profiles of several ribosomal proteins were plotted (Figure 4.31). 
Presumably, the ribosomal subunits are not affected by the chromatin modifications and 
behave as background proteins with constant ratios between the experiments. Interestingly, 
the ratios, both normalized and non-normalized, showed much higher spread in the forward 
experiment than in the reverse (note the different y-axis scales). Additionally, the 
normalization process performed better for the reverse experiment, adjusting the enrichment 
ratios between experiments closer to equal. Notably, the highest ratio variability for individual 
proteins in the reverse experiment was less than 0.5 ratio units, well below the effects 
observed for example for ACTL8 (Figure 4.30). Nevertheless, in order to better describe the 





Figure 4.31  Binding profiles ribosomal proteins in internal standard assay using meCpG, 
H3K9me3 and meCpG.H3K9me3 chromatin. 
The normalized and non-normalized ratios of several ribosomal proteins (PRSx and RPLx) 
quantified with high ratio counts were plotted for the forward end reverse SILAC internal standard 
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4.3.2 Control pull-down experiments using SILAC internal standards 
In the first control experiment the enrichment of proteins binding to unmodified or 
different amounts of modified species were compared. Biotinylated N-terminal histone 
peptides in unmodified or H3K9me3 form were used for simplicity. The pull-downs were 
performed using unmodified, 50% H3K9me3 and 100% H3K9me3 peptides in forward and 
reverse (Figure 4.32 A, forward experiment shown). This experiment was done in two 
replicates: in the first the proteins bound to the peptides were mixed after elution from the 
magnetic beads (“Experiment 1”), and in the second – during the last washing step of the 
pull-down (“Experiment 2”). The behavior of several known H3K9me3 binders (Figure 4.32 
B) or ribosomal proteins quantified with high ratio counts (Figure 4.32 C) were then 
compared. Importantly, all but one protein showed higher enrichment with increasing amount 
of modified peptides (panel B). However, equal and linear behavior of the different proteins 
in the three samples is not necessary expected as individual factors could have different 
modes and kinetics of binding. As observed in the experiment using chromatin (Figure 4.30), 
some proteins showed different enrichment between the forward and reverse experiments. 
Here again the values of the enrichment ratios were higher for the reverse experiment, 
however, this effect was minimized after normalization. Furthermore, normalization of the 
ratios for the ribosomal proteins resulted in near identical behavior between the experiments 
and ratio variability for individual proteins of less than 0.5 ratio units, again a number smaller 




Figure 4.32  Control peptide pull-down using different H3K9me3 modification amount and 
SILAC internal standard. 
A. Unmodified, 50% H3K9me3 and 100% H3K9me3 peptides were used for quantification of 
known H3K9me3 binders. Shown is the forward experiment where the light samples were mixed 
and used as internal standard. B. Binding profiles of known H3K9me3 interacting partners. In 
experiment 1 the proteins were mixed after elution, in experiment 2 – at the last washing step 
before elution. C. Binding profiles of ribosomal proteins, as in B. The first data point in each 































































































































































































































































































































































































Experiment 1 Experiment 2
SILAC-based internal standard strategy for relative quantification 
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A second set of control experiments was performed in order to determine the 
variability of the approach in a more reliable manner. Four parallel pull-downs utilizing only 
modified H3K9me3 peptides were done. Here, the H3K9me3 binding proteins would be 
recruited equally in the individual experiments and the variability in their enrichment ratios 
would represent the variability of the approach. The first three pairs of pull-downs were 
performed using the internal standard method, the fourth was mixed as a standard SILAC 
experiment (Figure 4.33 A). The ratios of H3K9me3-specific and ribosomal proteins 
quantified with high ratio counts (panel B) were plotted as before. The non-normalized ratios 
of both the H3K9me3 binders and ribosomal proteins showed similar pattern (panel B, left), 
indicating the usability of ribosomal proteins for internal quality control. The difference in the 
ratios of experiments “mix 1” was minimized after normalization (panel B, right). After 
normalization, the variability between different experiments was below 0.3 ratio units. Next, 
the overall distribution of the normalized protein ratios were compared for experiments “mix 
1” and “mix 3”, and “mix 2” and “mix 3” (Figure 4.33 C). Interestingly, experiment “mix 1” 
showed high variability for a set of proteins compared to “mix 3” (left panel), while the ratios 
of “mix 2” and “mix 3” correlated well (middle panel). Additionally, the normalization factor for 
mix 1 was higher than for the other experiments (data not shown). A slight bias towards 
more positive ratios was observed when comparing experiments “mix 2” and “mix 3” (Figure 
4.33 C, left panel). In order to exclude the influence of light and heavy extract variability, the 
ratio distribution of “mix 3” was compared with the ratio distribution of a mixture of equal 
amounts of light and heavy nuclear extracts. Importantly, there was no correlation between 
the two distributions. However, in this control experiment, the light samples were mixed and 
distributed between the heavy ones, therefore the bias towards higher H/L ratios might 
indicate minute loss of light sample. 
In conclusion, these preliminary results demonstrated that a SILAC approach could 
be used for internal standard-based relative comparison of enrichment between 
experiments. However, the inherent ratio variability and specific experimental steps (i.e. 
precise mixing and accurate distribution of the internal standard) require careful optimization 
and execution of the experiments for optimal performance. Additionally, following the 






Figure 4.33  Control experiment using H3K9me3 peptides to test variability of the approach. 
A. Only modified H3K9me3 peptides were used for pull-down experiments using internal standard 
(left) or standard SILAC mixing scheme (right). B. Binding profiles of known H3K9me3 interacting 
proteins (top) or ribosomal proteins (bottom). C. Differences in enrichment ratio distribution 



















































































































































































The work presented in this thesis describes the establishment of an in vitro affinity 
purification approach for the analysis of the interactomes of complex chromatin modification 
patterns based on recombinant and homogeneously modified chromatin template and 
quantitative mass spectrometry. When using two hallmark histone modifications – H3K4me3 
and H3K9me3, the approach performed comparably to a classical peptide-pull down, 
however each affinity matrix also identified a set of unique binding proteins. The chromatin 
affinity purification was further applied for the identification of the interactomes of seven 
other chromatin templates bearing different DNA or histone modifications, as well as a 
combination of two of them. Analysis of the factors recruited to individual modifications 
provided new insights into their function. Global analysis revealed moderate overlap 
between the different datasets. Nevertheless, it identified a set of factors that likely play an 
important role at the heterochromatin domain. Investigation of the molecular readout of 
H2Bub1 revealed a novel role of the SWI/SNF remodeling complex for transcriptional 
regulation of a specific set of genes. Additionally, initial experiments using a novel SILAC-
based internal standard quantification strategy showed promising results for its application in 
the direct comparison of the recruitment of factors to different chromatin species. 
 
5.1 A novel SILAC-based chromatin affinity purification strategy 
Identification of chromatin modification-binding proteins has been a focus of research 
for more than 10 years and has yielded a large number of interacting partners. In addition to 
several array-based methods [63, 100, 101], affinity purification from cellular extracts 
combined with mass spectrometry has proven to be the method of choice for de novo 
identification and characterization of these factors. However, the short peptides used in 
these assays can be synthesized only in limited lengths and as a result reflect a limited local 
histone tail surface. Therefore, the use of recombinant chromatin template for identification 
of chromatin modification-binding proteins was established, evaluated and applied in this 
study. In order to differentiate between specific and background binders, in each experiment 
the interactomes of modified and unmodified chromatin were compared quantitatively using 
SILAC labeled nuclear extracts.  
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Chromatin quality, label-swap experiments and nuclear extract synchronicity are 
crucial for optimal assay performance 
The chromatin affinity purification strategy was setup on the basis of a procedure for 
in vitro reconstitution of defined chromatin templates using salt dialysis [106, 107, 155]. 
Different histone octamer saturation levels or incomplete modification of the chromatin 
templates could lead to erroneous results. Therefore each step of the preparation of the 
template, including comparison of the modified and unmodified species (Figure 4.2 A) and 
validation of the chemical modifications (Figure 4.3), was monitored carefully to ensure 
consistent performance. 
Additionally, several critical parameters of the assay were identified. First, a label 
swap experimental design was found to be crucial for eliminating false positive interactors. In 
this set up, the specific interaction partners showed correlating enrichment ratios between 
the two experiments (termed “forward” and “reverse”), while the false positive hits from each 
experiment were identified with irreproducible, often opposite, enrichment ratios (Figure 4.5). 
There could be several explanations for this behavior. The majority of the false positive hits 
appear to be only light-labeled (red circles in upper left quadrant, Figure 4.5 A), presumably 
part of them being contaminants from the experimenter or incompletely labeled proteins with 
longer half-lives. A fraction of these false positive hits showed low summed peptide 
intensities, especially in heavy form (red circles on the positive x-axis, Figure 4.5 B), 
indicating lower abundance, which could indeed lead to false identification or quantification 
with lower accuracy [119]. A third likely reason for this behaviour are small differences in 
protein abundance between the independently prepared light and heavy nuclear extracts. A 
background protein with higher abundance in one of the extracts would appear as enriched 
with the sample incubated with this extract. Supporting this notion was the finding that highly 
asynchronous extracts showed even wider spread of enrichment ratio distribution and a 
significantly increased number of false positive hits (Figure 4.6 B). 
Two additional factors could influence the depth of protein identification coverage in 
the experiments. First, removal of DNA from the affinity purification reaction was necessary 
for optimal SDS-PAGE resolution. This prevents smear of high abundant proteins along the 
gel lane (Figure 4.7). Second, using low chromatin-per-beads ratio resulted in the binding of 
far higher number of background proteins (Figure 4.8). It is likely that this is due to lower 
saturation of the affinity beads where unspecific binding can occur at unoccupied surfaces. 
On the other hand, increasing the amount of immobilized chromatin resulted in significant 
aggregation of the streptavidin beads, presumably owing to higher order chromatin 
interactions. Therefore, an intermediate saturation level was used here as a compromise 




Comparison to peptide pull-down assay and validation of novel H3K4me3 and 
H3K9me3 interacting partners 
As a proof of principle, the novel chromatin affinity purification approach was 
compared to a classical peptide pull-down assay. Both approaches showed high specificity 
in identifying the H3K4me3 and H3K9me3 binding proteins. First, the majority of the known 
interaction partners for each modification were recapitulated (see section 4.1.3). Second, 
there was no overlap between the proteins recruited by the two modifications and therefore 
no general binding to trimethylated lysine was observed (Figure 4.10). Additionally, the 
interaction of several of the novel binders was validated using orthogonal approaches 
(Figure 4.12). Here all but one recapitulated the MS results. ACTL8 showed no or low 
specific enrichment with H3K9me3. However, this is likely due to transfection and 
overexpression artifacts as the ectopically expressed protein remained in the cytosol and 
failed to transfer to the nucleus, as shown by immunofluorescence microscopy (data not 
shown). Moreover, ACTL8 was reproducibly identified as enriched with several 
heterochromatin-associated modifications (discussed later). Therefore, despite this negative 
result, it is conceivable that ACTL8 is a true H3K9me3 associated protein. 
Both affinity approaches resulted in a similar number of recruited proteins for the two 
tested modifications, slightly higher for the peptide-based assay. It could be anticipated that 
all proteins identified with the peptide approach would be present in the set of enriched 
factors from the chromatin approach, which contains the identical N-terminal peptide in its 
structure. The chromatin experiments could in addition identify proteins whose recruitment 
depends on binding to other histone proteins or DNA. Strikingly, the overlap between the two 
approaches was limited (Figure 4.11). There are several possible causes for this 
phenomenon. First, the absolute numbers of the enrichment ratios for the chromatin-based 
experiments were on average lower than for the peptide assay (slope of the distribution of 
blue circles in Figure 4.11 A and B). Lowering the enrichment ratio threshold indeed resulted 
in higher overlap, however, the proteins specific for each approach also increased (Figure 
4.11 C). Notably, the increase was more significant for the chromatin-specific proteins. 
Second, due to steric hindrance from the far larger bait molecule in the chromatin 
experiment, higher streptavidin saturation on the surface of the beads might be achieved in 
peptide-based assay, thus providing more binding points per bead. This effect can cause the 
recruitment of higher protein amounts and subsequent better detection and identification in 
the peptide-based assay. However it does not explain the difference in the absolute values 
of the enrichment ratios. Moreover, a large proportion of the proteins unique for each 
approach were faithfully detected and identified in the other approach. Those were slightly 
above background level in the chromatin assay and around background level in peptide 
approach (solid blue circles in Figure 4.11 A and B). This, and the fact that the absolute ratio 
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values were lower in the chromatin experiments, might be the result of the additional surface 
of the histone proteins, and especially the DNA, acting not only in attractive mode, but also 
repulsively. Thus, the recruitment of selected factors, whose interaction in vitro would not be 
hindered in the case of isolated histone tails, would be lower in the chromatin approach. 
Additionally, the histone N-terminal tails might be less accessible in the chromatin context. 
At physiological salt concentrations they can interact with the surface of neighbouring 
nucleosomes mediating higher order chromatin conformations [155] and thus limiting the 
availability for interaction with additional proteins. While these effects have not yet been 
investigated widely, there is evidence from the comparison of the interaction of the 
chromodomain of HP1 with H3K9me3-modified chromatin and peptides that is supporting 
this scenario [155]. Supporting the selectivity of the chromatin approach are also the findings 
of a recent publication describing the modification-dependent interaction of BPTF with 
histones [85]. Importantly, a peptide-based approach revealed promiscuous binding of BPTF 
to three different acetyl marks, in addition to H3K4me3; however, cooperative stronger 
interaction with H3K4me3 was observed only for one of the acetyl marks (H4K16ac) in a 
nucleosome context. Finally, two recent publications reported the interactomes of H3K4me3 
and H3K9me3 using N-terminal histone peptide [75] and mononucleosome [77] pull-downs. 
The differences between these two approaches are even more striking, with the 
mononucleosome-based assay reporting far less enriched factors. 
Despite of the differences in the results from the two affinity purification approaches, 
they both recruited an overall similar number of factors. As this is the first large scale report 
comparing directly the two experimental platforms, the mechanistic nature of these 
disparities remains to be confirmed in the future. Nevertheless, the chromatin-based assay 
has some notable advantages. First, it represents a more native form of chromatin and 
offers additional histone and DNA interaction surfaces, whose attractive and repulsive roles 
are relevant in vivo. Second, modifications on DNA or in the core histone regions in the 
context of chromatin can only be investigated using a nucleosome or chromatin-based 
assay. Third, the recombinant chromatin allows studying of virtually any combination of 
chemical modifications achievable in vitro, including the conjugation of ubiquitin-like proteins. 
Fourth, in chromatin array-based format, the assay could capture interactions depending on 
more than one nucleosome (i.e. inter-nucleosome interactions, for example L3MBTL1 [86]), 
which could be of high relevance in the context of heterochromatin compaction. Fifth, 
individual nucleosomes with different modifications could be constructed into a chromatin 




5.2 Analysis of the interactomes of different modifications reveals new 
insights into chromatin function 
Following establishment and validation of the chromatin affinity purification approach, 
the interactomes of ten distinct chromatin species were further described. The main focus 
was set on heterochromatic modifications, including H3K9me2, H3K9me3, H3K27me2, 
H3K27me3, meCpG and a combination of H3K9me3 and meCpG. The other chromatin 
marks tested were the euchromatic H3K4me3 and H2Bub1, as well as H3K27me1, which 
has been associated both with euchromatin and heterochromatin. Lastly, the experiment 
utilizing H3Δ1-20 revealed several factors requiring the N-terminal H3 tail for interaction to 
chromatin. 
 
The interactomes of individual chromatin modifications 
This study expands greatly the list of proteins associated with modified chromatin. 
While some studies, carried out in parallel to this work [75, 77], have described interactomes 
of several modifications (H3K4me3, H3K9me3, H3K27me3, meCpG), others have never 
been investigated at this scale. Moreover, this is the first report utilizing chromatin arrays for 
affinity purification experiments. 
 
The euchromatic histone marks recruit large number of proteins and macromolecular 
complexes 
Interestingly, the euchromatic H3K4me3 and H2Bub1, as well as the putatively 
euchromatic H3K27me1, recruited by far the largest number of interaction partners of all 
single modifications tested. It is likely that this is not a mere coincidence or a technical 
problem, but a general feature of the interactomes of euchromatic marks. There are multiple 
protein complexes residing in active euchromatic regions, required for execution of different 
steps in the gene expression program. These processes require not only large 
macromolecular assemblies for RNA transcription (including the three RNA polymerase 
complexes, Pol I, II and III), but also multiple other components for transcriptional regulation 
and RNA processing. Indeed, these euchromatic marks appear to recruit multiple subunits of 
several protein complexes, including PolII, NELF, DSIF, SWI/SNF, INTS (H2Bub1), PolII and 
PolIII (H3K27me1) and TFIID (H3K4me3) (Figure 4.21). 
 
The euchromatic role of monomethylation on H3K27 
The fact that H3K27me1 recruits euchromatin-related factors is, to our knowledge, 
the first evidence at protein level for the involvement of this modification in active chromatin. 
What is the exact function of this mark at actively transcribed genes? It could be speculated 
that the large number of RNA polymerase subunits found here and the fact that the 




modification is enriched in the gene bodies of actively transcribed genes and depleted from 
TSS [38, 43] is related to functions in transcriptional elongation. Similarly, it is not yet clear 
whether monomethylation of H3K27 is simply an intermediate step for di- and tri-methylation 
[267], or if it has specific functional consequence in the context of transcriptional silencing. 
Notably, several proteins from the H3K27me1 interactome are linked to negative 
transcriptional regulation, including the meCpG-binding protein MECP2, UHRF1, RB1 and 
ARID4B. However, this does not necessarily implicate a heterochromatin-related signaling 
function of H3K27me1. Supporting this hypothesis is the fact that several binding partners of 
the euchromatic H3K4me3- and H2Bub1 modifications have also been related to 
transcriptional repression. For example binding of ING2 links H3K4me3 to histone 
deacetylation and gene silencing during the DNA damage response [166], while KDM5A 
binds H3K4me3 for demethylation [188]. On a global scale, the fact that in the protein-
protein interaction network (Figure 4.21) the proteins recruited by H3K27me1 are positioned 
between the euchromatic and heterochromatic interactomes supports the dual nature of the 
functionality of this modification. 
 
Proteins recruited by H3K27me2, H3K27me3 and H3K9me2 
The tested heterochromatic modifications recruited on average lower number of 
interacting partners, compared to the euchromatic marks. In line with the discussion about 
the functional requirements of euchromatin above, it is likely that lower number of proteins is 
required for maintaining a silenced and non-functional heterochromatic state. However, it is 
possible that the interactomes of H3K9me2, H3K27me2 and H3K27me3 are not complete. 
The experiment utilizing H3K27me3 did not recapitulate some of the expected polycomb 
group proteins. The majority of those were identified but with enrichment ratios lower than 
the threshold or not quantified, presumably due to lower abundance. The H3K27me2 
modification recruited two proteins, of which only one was highly enriched. While it is 
possible that the modification functions only as an intermediate step before trimethylation 
and has no other signaling roles, binding of factors related to trimethylation of H3K27 might 
be expected. Additional replicate experiments will show whether the interactomes of 
H3K27me2, H3K27me3 and H3K9me2, where the enrichment ratios showed skewed 
distribution, are broader then reported here. 
 
Chromatin array and mononucleosome-based approaches show limited overlap  
A recent publication described the interactomes of several of the modifications tested 
here using a mononucleosome-based approach [77]. The comparison with the results 
presented here reveals a very limited overlap. For example some of the discussed above 
polycomb proteins found to bind H3K27me3 by Bartke et al. were not identified by the 
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chromatin array method here. However, it revealed an additional set of factors recruited by 
H3K27me3 and not detected in the mononucleosome approach. In general a far larger 
number of proteins were unique for the chromatin array approach, including some known 
binding partners (e.g. CBX1 for H3K9me3). Some of these differences can be attributed to 
the different nature of the affinity template used. A chromatin array might stabilize the 
interaction of selected factors by inter-nucleosome binding. Nevertheless, at this point it 
cannot be excluded that the disparities are due to the different experimental procedures 
applied. Bartke et al. used nuclear extract preparations with lower protein concentration and 
analyzed the samples on an instrument with lower sensitivity and in a single technical 
replicate. Thus, direct comparison with these results is not objective and would require 
replicate experiments analyzed under identical conditions. 
 
The combinatorial effect of binding to meCpG and H3K9me3 
The analysis of the interactome of chromatin containing H3K9me3 and meCpG 
revealed the largest number of binding factors of all tested chromatin species. These 
included the majority of the proteins identified in the pull-downs with each individual 
modification (Figure 4.18 C and D), three of which (UHRF1, ACTL8 and POGZ) were 
enriched above threshold levels in all three experiments. Strikingly, more than 60 factors 
were not part of the interactomes of meCpG and H3K9me3. The experiment utilizing the 
combination of H3K9me3 and meCpG was performed with different extract preparation from 
the one used in the individual modification pull-downs. Difference in extract composition 
could explain the finding that certain proteins were identified only in the later experiment. 
However, more than 15 of the proteins highly enriched only in the combinatorial experiment 
were faithfully identified near background levels in the other two experiments (Figure 4.18 
E). Thus, the recruitment of these factors depends on both meCpG and H3K9me3. Binding 
to both modifications simultaneously could result in cooperatively stronger enrichment, either 
by direct bivalent recruitment or by bridging and stabilizing the interaction of individual 
meCpG- and H3K9me3-specific factors. The genome distributions of the two modifications 
correlate with each other at multiple heterochromatic regions (Figure 2.3), therefore 
combinatorial effect between them might be expected. However, to our knowledge this is the 
first report of such effect on protein level. These findings could provide important evidence 
supporting the histone code hypothesis, especially considering the large number of 
meCpG.H3K9me3 specific factors. Most of these proteins are involved in transcriptional 
regulation – for example the transcription factors UBP1 and YY1, HDAC1 and 2, the 
mcCpG-binding proteins MECP2 and MBD4, as well as the chromatin insulator CTCF. 
Member of this group was also the MBT repeat-containing polycomb protein SCML2. MBT 




repeat proteins can induce chromatin compaction, however so far they have been shown to 
have preference for lower methylation states [86]. 
 
The interactomes of individual modifications show limited overlap of the recruited 
factors and both positive and negative correlation trends 
In the context of the chromatin landscape, several modifications show different 
degrees of overlap and correlation in distribution. These patterns are more complex in 
actively transcribed euchromatic loci and correlate with the different gene regulatory 
elements (Figure 2.4). However, it is not yet clear what is their importance and exact 
functional consequence [268]. Heterochromatic loci, on the other hand, show more diffused 
modification distribution along large areas of silenced chromatin. Additionally, at specific 
genomic regions some of these marks show redundancy, reduction in the levels of one can 
be compensated by increase of the others [268]. Thus, recapitulating the exact recruiting 
potential and functional consequence of protein binding to individual or combinations of 
modifications is a crucial part in understanding the mechanisms of chromatin regulation. The 
analysis presented here revealed a striking degree of overlap and different correlation 
relationships between some of the individual chromatin marks. 
Apart from the case of H4K20me1/2 [76], the recruitment of proteins to sites with 
different degrees of modification has not yet been investigated in detail using large-scale 
approaches. The interactomes of H3K9me2 and H3K9me3 showed enrichment of several 
common factors, including the known H3K9me3 binders CBX5 and UHRF1. However, a 
large number of H3K9me3-specific proteins were not enriched with H3K9me2. Additionally, 
H3K9me2 repelled a wide range of proteins that were present at background level with the 
trimethyl mark. While both methylation states are widely present in large areas of silenced 
heterochromatin, it is possible that the recruitment of different factors by dimethylation of 
H3K9 is a result of distinct functional roles at other sites. Supporting this notion is the finding 
that H3K9me2 is specifically enriched in lamina-associated heterochromatic regions, and 
that the correlation with late replication timing is much stronger for regions with H3K9me2 
compared to areas with H3K9me3 [269]. The proteins enriched by H3K27me1 and 
H3K27me3 also showed limited overlap. However, owing to the distinct functions of the 
monomethyl mark at euchromatin, this finding is not unexpected. Nevertheless, some 
proteins showed high enrichment with both marks, including UHRF1, DP-1. Interestingly, 
POLR1E and POLR3D, subunits of RNA polymerase I and III, respectively, and the positive 
transcriptional regulator TEAD1, were also among these proteins. While it is surprising to 
find these factors associated with the heterochromatic H3K27me3, this finding might be 
explained with the role of this modification at bivalent chromatin domains [41], or with yet 
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unknown euchromatin-associated function. Indeed, a recent study reported the identification 
of H3K27me3 at a small fraction of promoters of actively transcribed genes [253]. 
Discrete function of individual heterochromatic marks is also evidenced by the 
comparison of meCpG and H3K9me2. While H3K9me3 and meCpG showed correlating 
enrichment ratios for several factors, including UHRF1 and ACTL8, the interactomes of 
H3K9me2 and meCpG in addition revealed a set of factors enriched by the DNA methylation 
and excluded by the histone methylation (e.g. ATF7, FOSL2 and JUND, Figure 4.19 C). 
More striking, however, is the linear correlation between the enrichment ratios of H3K27me1 
and meCpG.H3K9me3 (Figure 4.20 D). While the calculated correlation coefficient is not 
very high (R = 0.67, p < 2.2e-16), it is unusual considering the random nature of the binding 
of the background proteins centered around the origin of the graph. Apart from the large 
number of factors enriched in both experiments (e.g. UHRF1, MECP2, NFIA, CTCF), 
significant proportion of the proteins specific for one of the chromatin species appeared to be 
slightly enriched with the other. Furthermore, the interactomes of H3K4me3 and 
meCpG.H3K9me3 share two enriched proteins - the transcription initiation factor TFIID 
subunit TAF2D (TAF5) and SPIN1. Additionally, several other H3K4me3-specific TFIID 
subunits were found enriched slightly below threshold level with meCpG.H3K9me3 (Figure 
4.20). Notably, these were not identified as enriched with the individual pull-downs using 
meCpG or H3K9me3. The nature of these overlaps is unclear and cannot be easily 
explained. The combination of meCpG and H3K9me3 is a bona fide heterochromatin 
characteristic, and its role in euchromatin is very unlikely. Nevertheless, these observations 
could hint, for example, at a yet unknown link in euchromatin-heterochromatin transition. 
Alternatively, it is possible that the euchromatic factors have specific functional roles in 
hetreochromatin that are not directly related to gene expression regulation. This is supported 
by the finding that several subunits of another complex generally associated with active 
transcription - the PolIII transcriptional factor TFIIIC (GTF3C), were identified as highly 
enriched with H3K9me3, and just below threshold levels with meCpG.H3K9me3. TFIIIC, 
together with CTCF, have been found at heterochromatic loci unoccupied by PolIII in human, 
and have been implicated in higher-order chromatin organization in yeast [270]. 
Interestingly, CTCF was also identified with both H3K9me3 and meCpG.H3K9me3. 
However, the protein was depleted from meCpG chromatin, and the enrichment of CTCF 
and TFIIIC subunits was lower in meCpG.H3K9me3 compared to H3K9me3. Thus, it is 









The heterochromatic modifications recruit a limited set of common factors 
Individual binary comparison of the different chromatin species tested revealed 
limited overlap of common factors and a number of proteins unique for each experiment. 
Taken together, the interactomes did not show strong correlation of the identified factors 
globally (Figure 4.23 B), indicating in general distinct functional roles at chromatin. However, 
several proteins (e.g. UHRF1, ACTL8, CBX5) appeared in the majority of the datasets. 
Comparing the enrichment ratios of all proteins across the experiments further resulted in a 
list of 21 factors that were present in four out of eight of the interactomes. UHRF1, ACTL8, 
HAUSP, SCML2, MBD2 and MTA1L1 were enriched with the majority of the heterochromatic 
modifications and at the same time repelled by the euchromatic H3K4me3. CBX3, CBX5 
and NIPBL were not quantified in the H3K4me3 experiment but were enriched with at least 
four heterochromatic marks. All of them, except ACTL8, have been implicated with 
transcriptional repression functions. The fact that they were recruited by several distinct 
heterochromatic marks suggests that they play a central role in the establishment, 
maintenance or in general the functions of this chromatin domain. 
ACTL8, on the other hand, is a poorly studied protein. The only reported evidence 
about it at protein level originates from two large-scale studies where the factor was found to 
be ubiquytilated for degradation [271, 272]. The single annotated structural motif within the 
protein is actin-like domain. Additionally, the sequence of the protein contains a PxVxL motif, 
known to be present in factors recruited by dimers of CBX (HP1) proteins [273]. It is possible 
that ACTL8 interacts here with one of the CBX isoforms, however these proteins were not 
present in all experiments where ACTL8 was identified. Thus, it is likely that this sequence 
motif is either not involved in interaction, or participates in secondary interactions within a yet 
unknown protein complex at heterochromatin. UHRF1 was the only protein enriched in all 
experiments together with ACTL8, so recruitment by this known H3K9me- and meCpG-
binding factor is possible. However, ACTL8 was not identified in the experiments using 
H3K4me3 and H3Δ1-20, where UHRF1 was significantly depleted or enriched, respectively. 
Thus, direct recruitment of ACTL8 to chromatin is conceivable. Notably, the preliminary 
results from a SILAC internal standard approach showed remarkably strong recruitment of 
ACTL8 to the combination of meCpG and H3K9me3 (Figure 4.30). 
The rest of the proteins from this group were enriched mainly with H3K27me1, 
H3K27me3 and meCpG.H3K9me3 and depleted from H3K9me2. Some exhibited more 
complex recruitment pattern, e.g. CTCF and DP1 in addition being repelled by meCpG. 
Notably, the majority of these factors were linked to either positive or negative transcriptional 
regulation and chromatin-related processes in general. Future work will reveal whether 
these, or additional factors are also present in the interactomes of other heterochromatin 
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modifications, for example H2AK119ub1, H3R2me2a and H4K20me3 and combinations 
thereof. 
 
5.3 The interactome of H2Bub1 and the transcriptional effects of SWI/SNF 
recruitment 
The interactome of H2Bub1 chromatin revealed a large number of interacting partners, 
expanding significantly the list of known associated proteins. Notably, the recruitment of all 
proteins tested by parallel experiments with Western Blot detection validated the MS results 
(Figure 4.24 B) thus confirming the role of this modification as a signaling mark. The mode of 
recruitment to H2Bub1-rich chromatin could be mediated by several, mutually non-exclusive, 
interaction modes. First, some proteins may bind to the unique H2B-Ub conjugation 
branched peptide, similar to described antibodies [231]. Additionally, binding can be the 
result of recognition by one multi-domain factor, or individual subunits of a protein complex, 
to ubiquitin and histones and/or DNA. Weak individual interactions, for example 
characteristic of ubiquitin-binding domains [274], can thus be stabilized by cooperative 
binding. Alternatively, some complexes may recognize different chromatin conformation 
states, known to be induced by this modification [30]. Importantly, the approach showed high 
selectivity in identifying proteins recruited by ubiquitin in the context of chromatin. This is 
supported by the finding that a pull-down with biotinylated ubiquitin alone and using identical 
experimental conditions did not recapitulate any of the H2Bub1-specific proteins. 
H2Bub1 plays a role at sites of DNA damage and is necessary for double strand break 
(DSB) repair [275, 276], presumably to locally open chromatin structure and increase 
accessibility of repair proteins. The interactome of H2Bub1 revealed in addition a potential 
signaling role of this modification in DNA repair by recruitment of various DSB-related 
protein factors, including the BRCA1-A complex, RNF168, RECQL5 [277, 278]. Additionally, 
the enrichment of the nucleotide excision repair related proteins ERCC1 and ERCC4 
suggests a previously unknown role for H2Bub1 in this pathway [279].  
Insight into the role of H2Bub1 in negative transcriptional regulation is provided by the 
recruitment of two negative elongation complexes – NELF and DSIF. The expression of 
RNF20-supressed genes depends on the positive elongation factor TFIIS to overcome PolII 
stalling [266, 280]. Thus, the inhibitory role of H2Bub1 for these genes can be explained by 
the fact that NELF inhibits the binding of TFIIS to PolII [281]. 
The association of the SWI/SNF remodeling complex with H2Bub1, shown here for the 
first time, provides novel insights both for H2Bub1-dependent positive transcriptional 
regulation as well as for SWI/SNF mode of recruitment. While the activity of chromatin 
Comparative quantification of binding to chromatin modifications using a novel SILAC 
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remodeling complexes is generally indifferent to the modification status of the template, 
different histone PTMs have been implicated in recruiting/retaining them locally [282, 283]. 
The H2Bub1-mediated recruitment of SWI/SNF to the transcribed regions of RNF20-
dependent genes was required for their efficient transcription. It is conceivable that 
chromatin remodeling, resulting in a specific nucleosome pattern, is necessary for this 
process. Alternatively, SWI/SNF can exert another function at these loci, not directly linked 
to nucleosome remodeling. It is not yet clear what are the exact molecular details for the 
mechanism of SWI/SNF function here. Pull-downs using nuclear extract showed higher 
specificity for the H2Bub1 template (BAF155, Figure 4.24 B) compared to experiments 
utilizing purified SWI/SNF complex (Figure 4.25A). SWI/SNF has general affinity for 
chromatin and it is likely that additional subunits, not present in the purified complex, might 
result in higher selectivity. Furthermore, pull-downs using several individual SWI/SNF 
subunits didn’t show significant enrichment for H2Bub1 (data not shown). It is possible that 
the specific recruitment is a result of multisubunit multivalent interaction and single proteins 
do not show high affinity binding. Therefore, pull-down experiments using combinations of 
SWI/SNF subunits might reveal more in this direction. Additionally, in vitro chromatin 
remodeling assays comparing unmodified and H2Bub1 templates will show whether the 
ubiquitylation of H2B facilitates SWI/SNF remodeling action. 
 
5.4 Comparative quantification of binding to chromatin modifications using a 
novel SILAC internal standard strategy 
Absolute comparison of enrichment ratios between individual SILAC affinity purification 
pull-downs can be very beneficial, for example in determining cooperative binding for two 
chromatin modifications in combination. However, in the case of highly enriched proteins this 
is not always possible as the enrichment ratios are calculated on the basis of the detector 
noise in the mass spectrometer [119]. The SILAC spike-in strategy presented here can help 
alleviate this problem and allow direct enrichment ratio comparison between individual pull-
down experiments. When the approach was applied to compare the enrichment to 
H3K9me3, meCpG and a combination thereof it revealed striking differences between the 
absolute enrichment ratios of the forward and reverse experiments. While these disparities 
were reduced after normalization of the enrichment ratios, their values remained on average 
higher in the reverse experiment (Figure 4.30). A possible explanation is that this is a result 
of unequal nuclear extract amount and unbalanced mixing of the internal standard samples. 
Normalization would indeed at least partially reduce these differences. However, the same 
trend was observed when a control experiment using different amounts of modified 
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H3K9me3 peptide was performed (Figure 4.32). In this case normalization again reduced 
the difference significantly. The binding profiles of the highly abundant ribosomal proteins in 
all experiments, and in addition the H3K9me3-binding proteins in the peptide control 
experiment (Figure 4.33), demonstrated that normalization of the enrichment ratios results in 
near-equal values between the individual samples. The variability in each case, except for 
the forward experiment shown in Figure 4.30 and 4.31, was less than the effect of specific 
enrichment to the tested modifications. The variability shown in Figures 4.30, 4.31 and 4.33 
C is nevertheless significant. It is likely that this is a consequence of differences in the 
mixing and precise distribution of small volumes of the internal standard samples while 
diluted in SDS-PAGE sample buffer with high density. Indeed, when the internal standard 
samples were mixed in larger volumes of PD150 buffer during the last washing step, the 
variability appeared less prominent (experiment 2 in Figure 4.32 B and C). Importantly, given 
that the enrichment ratio of individual background proteins is constant between the 
compared samples, its absolute value is of lower importance (e.g. green line compared to 
the rest, Experiment 1 in Figure 4.32 C). Furthermore, all proteins with specific binding to the 
modified species are characterized with very low ratio values in the unmodified samples. 
These values are the result of the ratio between a very low background binding signal in the 
unmodified sample and relatively high signal from the internal standard. Thus, specific 
interactors could be identified based on this feature. Lastly, even with some inherent 
variability, the approach can be used in a more restricted “targeted” manner – independent 
pull-down experiments can determine the specific interactomes of individual modifications 
and the enrichment of only those proteins can be followed in and internal standard SILAC 
experiment, thus disregarding potential false positive hits. 
Following further optimization and estimation of the variability, the approach could be 
used for comparison of enrichment ratios from different SILAC pull-down experiments. Due 
to the inherent variability, the mixing and distribution of the internal standard samples is the 
most critical step of the workflow. Multiple replicates, conceivably in semi-automated fashion 
using microtiter plates, and monitoring the binding profiles of abundant background proteins 
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5.5 Conclusions and future perspectives 
 
Given the fundamental role of chromatin modifications in genome regulation and cell 
signaling, deciphering the interaction and functional protein networks associated with them is 
of utmost importance. The chromatin affinity approach presented here is promising for 
elucidation of the interactomes of single and complex patterns of chromatin modifications. 
On one hand, it provides a straightforward and practical first step in the functional 
characterization of individual modifications using a native chromatin template. Identification 
of associated proteins is an essential part of dissecting the signaling roles of modification-
specific recruitment. This was demonstrated with the example of the H2Bub1-dependent 
binding of the SWI/SNF complex for regulation of transcription. These results provided novel 
molecular insights into the function of both the H2Bub1 modification and the chromatin 
remodeling complex. Individual modification interactomes can in addition hint at novel 
general functional features of specific marks. Furthermore, the possibility to test 
combinations of different modifications in the context of chromatin can reveal important 
insights into the nature and complexity of the “histone code”. Indeed, the combinatorial 
experiment presented here showed large number of factors whose recruitment conceivably 
depends on both meCpG and H3K9me3. This result has significant implications for the 
histone code hypothesis and underlines the importance of testing further combinations of 
modifications, including additional marks not investigated here. The analysis of multiple 
interactomes on global level identified novel relationships between individual modifications 
and indicated distinct roles of functionally related marks. Additionally, taken together, this 
analysis resulted in a condensed list of proteins with potentially important roles in the 
function of the heterochromatin domain. In this respect, the detailed functional 
characterization of some of the most prominent factors, for example ACTL8, is needed. 
Lastly, the presented SILAC internal standard strategy provides a straightforward way of 
testing and quantification of combinatorial recruitment by multiple chromatin modifications. 
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Appendix 1 Proteins enriched or excluded within at least one of the chromatin affinity 
purification experiments. The leading official gene names, IPI and UniProt IDs are included 




Gene$Names IPI Uniprot H3K4me3 H3K9me3 meCpG H3K9me2 H3K27me1 H3K27me2 H3K27me3 H2Bub1 H3Δ1>20$
meCpG.$
H3K9me3
99D8.1 IPI00297779.7 P78371 >0.21 0.27 0.29 0.75 0.12 >0.50 >1.15 >0.93 >0.25 0.05
A>152E5.7 IPI00018288.1 P19387 0.80 >0.36 > >0.42 1.14 0.56 >0.35 4.26 >0.18 0.13
A18HNRNP IPI00641579.1 Q14011 1.01 >0.17 >0.20 > > 0.18 > > >0.53 1.17
A2D IPI00456363.1 Q8WWM7>3 > > > 2.34 > > > > > >0.22
AAG IPI00218495.3 P29372>2 >0.17 >0.21 0.27 >0.65 2.66 0.16 0.19 >0.04 0.26 >
ABBP1 IPI00334713.1 Q99729>3 1.03 >0.36 >0.28 0.55 1.28 0.26 0.17 0.82 >0.59 1.30
ABC1 IPI00464999.2 Q6AI08 0.16 0.44 0.23 1.39 >0.59 >1.33 >1.31 > 0.16 >0.77
ABRA1 IPI00030384.4 Q6UWZ7 > > > > > > > 3.54 > >
ACAC IPI00396015.5 Q13085>4 >0.61 >2.41 >1.23 >0.44 >1.36 0.05 0.53 >3.52 2.55 >0.53
ACF1 IPI00412415.2 Q9NRL2>1 >0.62 >0.67 0.57 >0.44 1.50 0.29 0.72 >0.41 0.18 1.78
ACTL8 IPI00329820.2 Q9H568 >2.86 2.39 2.20 2.57 > >1.10 1.76 >0.58 > 3.53
ACTR3 IPI00028091.3 P61158 > > > > > > > > > 1.29
ACTR8 IPI00025646.5 Q9H981>1 0.19 0.06 > >1.15 1.53 1.12 0.59 0.94 > 1.64
AD>005 IPI00166010.6 A5YKK6>1 >0.03 0.72 >0.19 1.54 >0.47 >1.09 >1.92 0.40 0.41 >0.50
AD>005 IPI00880052.1 A5YKK6>2 > > > > > > >1.70 > > >0.45
AD>009 IPI00856080.1 Q9UHW5>2 > > > 0.81 > > > 3.06 > >
ADNP IPI00022215.1 Q9H2P0 0.15 3.42 0.67 0.91 0.51 0.30 0.37 1.51 0.11 3.11
ADPRTL1 IPI00296909.4 Q9UKK3 > > > 1.46 >0.31 >0.83 >1.29 > 0.05 >0.25
ADTB1 IPI00940292.1 Q10567>3 >0.13 0.56 0.07 1.13 > >1.33 >1.63 0.60 0.40 >0.60
AFR1 IPI00007256.1 Q9Y6X8 0.10 > 4.02 > > > > > > 4.11
AHCTF1 IPI00979341.1 Q8WYP5>2 > > > 0.73 1.67 0.24 0.70 >1.31 >0.25 0.57
AIBP63 IPI00010486.2 Q9UPZ3>1 > > > 1.17 >0.87 >0.59 >1.99 > >0.19 >0.52
AIDD IPI00027547.2 P81605 > > > >2.04 > > > > 0.25 >
AIM IPI01011182.1 F5GX68 > 1.57 > 1.93 0.91 >0.53 1.35 >0.78 1.47 >
AIM IPI00031519.4 P26358>1 >3.53 1.13 0.56 > > > > > > 1.98
AIM IPI00220918.1 P26358>2 > 1.50 0.70 > > > > > > 1.85
AKAP10 IPI00306265.2 O43572 > > > 1.31 > >1.03 >1.68 > 0.55 >0.42
AKAP13 IPI00065931.4 Q12802>2 > > > 1.86 > > > > > >
ALL1 IPI00009286.4 Q03164>1 0.02 >0.11 >2.81 >0.56 1.65 0.70 0.45 0.29 0.63 >
AMPK IPI00220409.3 Q9Y478 > > > 1.27 > >1.01 >1.57 > 0.35 >0.74
AMPK1 IPI00410287.3 Q13131>2 > > > 1.37 >0.35 >0.89 >1.10 > 0.70 >0.37
ANAPC10 IPI00007088.6 Q9UM13 >0.57 >1.34 0.28 >0.70 > 0.06 0.13 >2.18 >0.33 0.99
ANAPC3 IPI00794278.1 P30260 >0.28 >1.24 >0.01 0.12 0.96 >0.10 0.03 >1.55 >0.07 1.02
ANAPC4 IPI00966303.1 B3KN47 0.15 >0.45 0.40 > 0.27 >0.15 >0.52 >2.19 >0.40 0.48
ANAPC7 IPI00008248.4 Q9UJX3>1 >0.26 >0.77 >0.04 0.51 0.90 >0.09 0.49 >2.15 0.15 0.82
ANAPC8 IPI00005822.2 Q9UJX2>1 >0.02 >0.98 0.17 0.93 > 0.02 0.23 >2.19 >0.51 0.41
ANCO1 IPI00914930.2 Q6UB99 > > > > > >0.13 0.46 2.32 > 0.81
ANCO2 IPI00448465.5 Q6UB98>1 > > > > > > > 2.31 > >
ANKRA1 IPI00022520.1 O14593>1 1.10 0.80 > 0.05 1.19 0.63 0.15 >0.14 0.72 1.39
ANKRD25 IPI00470559.2 Q63ZY3>1 > > > 1.31 0.01 >0.44 >1.21 > >0.08 >0.21
ANKRD52 IPI00398957.6 Q8NB46 1.28 1.65 1.44 > > > > 0.50 >0.84 >
ANKT IPI00020484.4 Q9BXS6>2 >0.05 >1.05 >0.49 >0.37 2.22 0.06 0.87 >0.76 0.53 1.16
ANP32B IPI00007423.1 Q92688>1 > > > >0.10 > 0.31 0.08 2.50 0.31 >1.14
ANX2LG IPI00183695.9 P60903 > >0.08 > >0.21 > 0.11 > >1.93 > >
AOF1 IPI00784464.1 Q8NB78>1 >0.05 1.42 0.94 0.06 0.71 0.57 >0.28 0.55 >0.21 2.33
APE IPI00215911.3 P27695 > 0.15 > >1.00 >0.04 >0.50 1.31 > >0.53 0.72
ARAP3 IPI00103380.1 Q8WWN8 > > > 1.52 > >0.77 >1.50 > 0.15 >0.26
ARC240 IPI00913988.1 Q93074>2 0.26 0.07 > 1.20 0.43 >0.24 >1.01 0.58 >0.17 0.15
ARFIP2 IPI00910034.1 B4DUZ3 > > > 2.49 > > > > >0.12 >0.77
ARG134 IPI00033143.1 Q9UBQ5 >0.10 0.16 0.46 1.13 >0.09 >0.65 >1.45 > >0.28 >0.28
ARH IPI00004758.5 Q5SW96 >0.70 0.47 0.16 1.33 >0.71 >1.15 >1.59 0.32 0.69 >0.66
ARHGAP29 IPI00152011.4 Q52LW3>1 > > > > > > >1.81 > 0.42 >0.58
ARHGEF3 IPI00385169.1 Q9NR81>2 > > > 1.24 > >0.84 >2.04 > > >0.42
ARHGEF7 IPI00900260.1 Q14155>5 > > > 1.34 > > > > > >0.36
ARID4A IPI00296069.2 P29374>1 2.19 0.49 >0.35 > > > 1.25 > > >
ARID4B IPI00328828.5 Q4LE39>1 2.17 0.40 0.02 > 1.75 0.99 0.67 1.00 >0.11 1.42
ARL1 IPI00219518.7 P40616 > > > 1.20 > >0.57 >1.43 > 0.22 >0.40





Gene$Names IPI Uniprot H3K4me3 H3K9me3 meCpG H3K9me2 H3K27me1 H3K27me2 H3K27me3 H2Bub1 H3Δ1>20$
meCpG.$
H3K9me3
ASYIP IPI00028946.2 O95197>3 1.48 >0.40 0.09 >1.80 > >0.69 > > >0.75 0.04
ATAD5 IPI00102575.5 Q96QE3>1 >0.15 >0.21 >0.84 > 1.76 0.42 0.24 >0.52 1.08 0.65
ATF1 IPI00002501.1 P18846 0.26 0.31 >0.22 >1.70 1.12 0.77 0.41 0.34 > 1.32
ATF3 IPI00002502.1 P18847>1 > > 1.77 > > > > > > >
ATF7 IPI00015147.1 P17544>1 1.12 0.14 2.14 >2.85 1.86 1.24 0.75 >0.31 0.24 2.14
ATG2B IPI00872410.3 Q96BY7 > > > > > > >1.45 > > >0.46
ATX IPI00556369.3 Q96Q15>1 > > > 1.83 > >0.94 > > > >0.19
ATXN1L IPI00900336.1 P0C7T5 > > > >1.97 > > > > > >
AUF1 IPI00028888.1 Q14103>1 1.01 >0.51 >0.34 0.43 1.81 0.50 0.31 0.35 >0.65 1.38
AUF1 IPI00220683.1 Q14103>2 > > > > > > > > > 1.35
AYP1 IPI00984287.1 E9PN81 > > > > > > > > > 1.50
BA2R IPI00645793.3 P21675>4 1.71 > > > 1.75 0.80 0.64 0.66 > >
BAF155 IPI00234252.3 Q92922 0.17 0.24 0.81 0.17 0.53 0.34 0.02 1.93 0.48 0.72
BAF170 IPI00216047.3 Q8TAQ2>1 0.26 0.19 0.58 >0.14 0.54 0.34 0.70 1.81 0.62 0.67
BAF190B IPI00514648.1 P51531>1 0.04 0.26 0.90 0.37 > 0.66 >0.32 1.74 0.70 1.43
BAF45D IPI00023322.2 Q92785 >0.36 0.42 1.20 >0.07 > 0.44 0.15 1.17 0.00 0.76
BAL2 IPI00291215.6 Q460N5>6 0.13 >2.68 >0.19 > > > > > > >
BANP IPI00956625.1 F5GZM0 0.12 0.22 >1.36 >1.69 0.92 1.02 0.83 >0.01 0.45 >
BAP1 IPI00026993.1 Q99496 0.22 0.46 >1.55 0.20 1.05 0.24 0.45 0.89 >0.31 0.05
BAP28 IPI00024279.4 Q9H583 >0.02 0.99 >2.87 0.16 0.61 0.11 0.04 1.04 >0.50 0.02
BAT1 IPI00848161.1 Q13838>1 > > > >0.09 0.15 0.24 1.43 >0.34 >0.96 >0.47
BAT2D1 IPI00083708.5 Q9Y520>7 > > > 1.80 >0.33 >0.94 >1.63 > >0.14 0.00
BAZ1B IPI00069817.2 Q9UIG0>1 0.03 0.59 >0.10 >0.41 0.76 0.45 0.66 0.45 3.08 >0.06
BBAP IPI00152503.1 Q8TDB6>1 > >1.94 >0.24 1.26 > 0.00 > > > 0.01
BCL7C IPI00447051.3 Q8WUZ0>2 >0.10 0.39 0.51 >0.47 > 0.73 > 1.77 0.26 0.96
BCLAF1 IPI00006079.1 Q9NYF8>1 1.12 > > 0.62 >0.42 0.31 0.58 0.24 >2.74 0.13
BCOR IPI00439548.1 Q6W2J9>1 0.69 0.19 >2.34 >0.91 1.48 0.72 0.28 0.76 >0.03 0.21
BEND3 IPI00741958.1 Q5T5X7 0.64 0.13 >2.52 >1.48 0.86 0.77 0.77 0.16 0.43 >0.08
BHLHB11 IPI00026559.1 P22415 0.17 0.24 >2.25 >1.22 0.72 0.75 0.23 0.46 0.30 >0.21
BHLHB12 IPI00020037.1 Q15853>1 0.36 0.18 >2.10 >1.24 0.77 0.87 0.67 0.42 0.59 >0.14
BHLHB2 IPI00021143.1 O14503 0.50 0.11 >2.21 >0.69 0.93 0.84 1.84 0.00 >0.04 >0.18
BHLHB39 IPI00030964.1 Q14469 0.82 0.36 >2.47 >0.58 0.96 0.80 0.12 0.29 0.47 >0.64
BHLHC41 IPI00009005.1 Q01664 0.61 0.13 0.09 >2.67 1.02 0.79 0.25 0.58 >0.67 1.57
BHLHD3 IPI00016177.1 Q99583 1.37 0.24 >0.89 >2.22 0.67 1.09 0.70 0.18 0.77 0.75
BHLHD4 IPI00018214.1 P61244>1 0.80 0.30 >0.67 >1.49 1.47 0.91 0.22 0.29 0.45 0.75
BHLHE8 IPI00007284.1 O15516 1.47 > > > > > > > > >
BIG3 IPI00005492.2 P61964 >0.27 >0.38 >0.55 >0.73 1.10 0.05 0.74 >0.26 1.30 0.04
BN51 IPI00215978.4 P05423 > > > >1.57 3.01 1.55 2.22 0.12 > 1.21
BNIP2 IPI00030399.2 Q12982>1 > > > 1.25 > >1.07 >1.35 > > >0.57
BOZF1 IPI00292615.3 Q96BR9>1 > > > > 2.80 0.88 > > > >
BP75 IPI00647008.1 Q9NPI1>2 0.46 >0.14 > 0.02 > 0.60 0.64 1.25 0.96 0.67
BRAF35 IPI00464951.5 Q9P0W2>1 >2.25 0.11 >0.37 >0.27 0.72 0.22 0.26 0.19 0.54 0.10
BRCC3 IPI00939471.6 P46736>1 > > > > > > > 3.44 >0.69 0.13
BRCC45 IPI00149276.1 Q9NXR7>1 >0.03 > > 0.86 > >0.30 0.05 3.10 >0.39 0.08
BRD2 IPI00797929.3 A2AAU1 >0.32 0.16 >1.57 >0.68 0.59 >0.01 >0.03 0.74 1.67 >
BRD3 IPI00014266.1 Q15059>1 1.06 >0.04 >0.02 >1.46 0.68 0.42 0.31 0.45 0.46 1.24
BRD4 IPI00440727.1 O60885>1 0.58 0.26 0.00 >1.93 0.84 0.95 0.31 1.22 0.31 1.20
BRD8 IPI00019226.2 Q9H0E9>1 1.54 > > > > > > > > 0.05
BRMS1L IPI00031653.9 Q5PSV4 2.02 0.41 >0.02 >0.46 > 0.69 0.92 1.15 0.24 1.19
BTBD12 IPI00291796.2 Q8IY92>1 > > > > > > > 3.43 > >
BTBD14A IPI00059930.1 Q96BF6 > > > 1.00 > >0.93 >2.01 > 0.18 >0.43
BTBD14B IPI00045207.2 Q96RE7 0.29 0.71 > 0.99 >0.33 >0.46 >1.15 > 0.21 >0.26
BTEB3 IPI00219691.2 Q9Y2Y9 0.11 > > >1.91 > >0.10 0.65 > 0.18 1.08
BTEB4 IPI00011115.1 Q9BXK1 0.37 0.15 0.58 >2.48 > 0.28 0.19 >0.23 >0.18 1.21
C10 IPI00016925.1 Q99622 >0.03 0.12 > 1.01 >0.44 > >2.02 0.35 >0.13 >0.26
C10orf12 IPI00166933.1 Q8N655 > > > 0.23 0.29 0.18 0.20 > 1.54 0.65
C10orf46 IPI00410319.1 Q86Y37>1 > > > 1.87 > > >1.77 > 0.14 >0.57
C11orf23 IPI00719725.1 Q5H9R7>5 1.73 1.45 1.22 > > > > 0.54 > >
C11orf30 IPI00981684.1 Q17RM7 2.09 >0.22 >0.09 0.58 1.29 0.66 0.77 >0.63 0.58 >
C12orf11 IPI00550986.4 Q9NVM9 > > > >0.65 0.80 0.25 >0.33 3.99 >0.22 0.19
C12orf14 IPI00639887.3 B7Z287 1.24 0.17 >0.05 > > > >0.10 0.81 0.32 0.56
C13orf8 IPI00064212.2 Q96JM3 > 3.40 0.34 1.21 0.83 0.27 >0.22 0.96 >0.38 1.15
C14orf117 IPI00784739.1 Q6PJG2 0.36 >0.63 0.18 >1.12 2.52 0.41 0.20 >0.81 >0.37 1.16
C14orf125 IPI01013086.1 Q86XA9>1 >0.15 0.68 0.01 1.36 >0.39 >0.77 >1.52 > >0.12 >0.44
C14orf151 IPI00895800.3 Q27J81>1 0.33 0.43 > 1.33 >0.60 >1.50 >1.44 0.11 0.48 >0.74
C14orf46 IPI01025516.1 Q52LA3 0.54 > > > > > > > > 1.21
C14orf92 IPI00006586.1 O94842 1.59 > > >1.59 0.25 >0.19 > 2.23 >0.29 0.07
C15orf25 IPI00018198.3 Q9NVX0>1 > > > 1.10 > >0.83 >1.38 > >0.09 >0.16
C15orf44 IPI00306017.3 Q96SY0>1 1.06 0.07 0.21 >0.12 0.78 0.10 >0.27 3.41 >0.42 0.21
C16orf88 IPI00554560.4 Q1ED39 > >0.87 >0.30 > 2.40 0.23 0.77 >0.71 0.80 >
C17orf1 IPI00025202.6 O95466>2 3.10 >0.90 >0.25 >1.31 >1.19 >0.56 >0.16 0.14 >1.10 >






Gene$Names IPI Uniprot H3K4me3 H3K9me3 meCpG H3K9me2 H3K27me1 H3K27me2 H3K27me3 H2Bub1 H3Δ1>20$
meCpG.$
H3K9me3
C17orf96 IPI00246649.7 A6NHQ4 >1.65 0.99 > 0.35 > 0.21 1.19 0.11 1.20 >
C18orf21 IPI00845453.1 Q8TBS0 1.39 >0.15 >0.11 > > > > > > >
C18orf37 IPI00413363.1 Q6PI98>1 0.22 0.09 0.52 >1.25 > 1.19 0.56 0.74 >0.42 1.84
C19orf62 IPI00101987.6 Q9NWV8>1 > > > > > > > 3.89 >0.42 0.00
C19orf7 IPI00187011.4 Q9UPT8 > > > >0.39 > > > 2.83 > >0.09
C1orf103 IPI00479789.2 Q5T3J3>1 > 5.39 > > > > > > > >
C1orf112 IPI00178512.7 Q9NSG2>1 > > > 0.84 >0.55 >1.09 >1.85 > 0.02 >0.22
C1orf149 IPI00009373.3 Q9HAF1>3 0.93 >0.03 >1.02 0.21 > 0.15 >0.25 0.66 1.33 >0.07
C1orf174 IPI00844507.2 Q8IYL3 0.10 >0.22 >0.05 >0.32 1.13 >0.15 > >1.31 > >
C1orf193 IPI00418336.3 Q68E01>2 > > > >0.21 0.39 0.12 >0.06 4.89 0.07 0.01
C1orf24 IPI00328350.6 Q9BZQ8 > > > 1.29 > >0.55 >1.12 > >0.07 >0.65
C1orf73 IPI00743871.2 Q9NVH2>1 0.58 > 0.56 >0.49 0.74 0.21 >0.43 4.21 >0.18 0.09
C1orf77 IPI00719040.1 Q9Y3Y2>3 0.44 >0.29 >0.17 0.88 > 0.15 >0.04 >0.38 >1.17 >1.18
C20orf1 IPI00008477.1 Q9ULW0 0.07 >0.30 0.20 >0.20 1.93 0.08 0.07 >1.06 >0.20 0.65
C20orf154 IPI00032496.2 Q9UJA3>1 2.33 >0.19 >0.06 > > 1.37 0.00 >0.16 >0.52 1.17
C20orf158 IPI00619921.3 Q9BTC0>4 1.63 0.03 >1.32 0.32 0.67 0.34 0.74 >1.26 >0.85 0.24
C20orf167 IPI00057097.3 Q9H147 0.14 >0.41 0.00 >0.99 2.54 0.54 0.61 >0.83 >0.56 0.98
C20orf20 IPI00019451.3 Q9NV56 1.31 0.35 0.37 >0.09 > 0.47 0.21 0.79 0.25 0.83
C20orf88 IPI00152692.2 Q8TEA8 > > > > > > > > > 2.20
C20orf94 IPI00046188.4 Q5VYV7 > > > > > > > 2.50 > >
C21LRP IPI00030770.1 O95456>1 >0.34 > > 1.58 > >0.75 >1.51 > 0.12 >0.16
C22orf18 IPI00031566.3 Q9NSP4>1 >0.17 0.07 > 0.91 > > >1.85 > 0.43 >0.41
C2orf3 IPI00418340.6 P16383>1 > > > 1.11 > >1.04 >1.48 > 0.01 >0.48
C5orf7 IPI00298935.5 Q7LBC6>1 > > > 1.37 >0.55 >0.57 >1.81 > >0.19 >0.22
C6orf61 IPI00014977.5 Q9NXL9>1 3.00 0.21 0.32 > > 1.44 0.30 >0.05 >0.57 1.57
C6orf90 IPI00007729.1 Q9UMY1>1 1.84 >0.32 >0.72 0.02 1.36 0.48 0.21 0.30 >0.25 >0.49
C7orf26 IPI00043294.1 Q96N11>1 0.29 0.27 0.11 >0.46 > >0.12 >0.72 4.17 >0.36 0.14
C8orf33 IPI00867735.1 Q9H7E9>2 > > > > > > > 2.37 > >0.16
C8orf35 IPI00550272.3 Q9NVR2 0.84 > > >0.52 0.08 0.16 >0.52 3.97 >0.30 >0.06
C8orf52 IPI00375653.5 Q75QN2>1 > > > 0.43 0.32 >0.22 >0.96 3.96 >0.51 >0.17
C8orf55 IPI00171421.3 Q8WUY1 0.81 > > >1.30 > >0.85 > > > >0.12
C9orf142 IPI00030968.4 Q9BUH6>1 0.19 0.01 0.60 >1.44 1.21 > > 0.46 > >0.20
C9orf80 IPI00000330.5 Q9NRY2>1 0.27 >0.04 > >0.41 > > >0.32 4.76 > 0.04
CAF IPI00023177.4 Q13111>1 0.56 2.80 0.24 >0.14 >0.43 0.17 0.11 > 0.61 1.23
CAF1 IPI00006552.2 Q9UIV1 >0.38 0.35 0.18 1.67 >0.46 >1.23 >1.92 0.28 0.21 >0.49
CAF1A IPI00011857.1 Q13112 0.04 2.59 >0.32 >0.45 >0.25 0.33 0.61 >0.13 0.18 1.32
CAGF28 IPI00973545.1 Q6ZW49>6 > > > 1.07 0.30 >0.32 >1.37 1.41 0.50 >0.32
CAGH32 IPI00167535.7 Q96L91>1 1.57 0.11 >0.24 0.90 0.66 >0.20 >0.61 0.47 >0.07 0.49
CALIF IPI00295501.1 Q9UFF9 >0.69 0.13 > 1.63 > > >1.96 > 0.35 >0.58
CAMSAP3 IPI00176702.4 Q9P1Y5>1 > > > 1.04 0.24 >0.29 >1.13 0.63 0.41 >0.58
CANPL1 IPI00011285.1 P07384 > > >0.54 >1.93 >0.96 >0.39 > >0.40 > 0.46
CASKIN2 IPI00103516.2 Q8WXE0>1 > > > > > >0.87 >1.39 > 0.39 >0.23
CAT53 IPI00298731.2 Q96QC0 1.73 0.20 > >0.58 0.14 >0.41 >1.32 1.63 >0.40 >0.34
CATX11 IPI00008708.5 O76021 >0.71 >0.65 0.24 0.96 0.52 >0.76 0.74 >1.64 1.14 0.26
CBX IPI00878669.2 P83916 > 4.03 0.97 1.35 > > 0.10 > > 3.60
CBX3 IPI00297579.4 Q13185 0.01 3.80 1.14 1.45 > 0.44 >0.57 0.81 >0.16 3.57
CBX5 IPI00024662.1 P45973 0.05 4.35 > 2.50 > > 2.25 > > 4.26
CCDC111 IPI00065356.2 Q96LW4 2.20 >0.36 > > > > > >0.08 > >
CCDC120 IPI00181265.2 B4DFC1 > > > 0.60 > > >1.33 > 0.67 >0.37
CCDC86 IPI00012199.1 Q9H6F5 >0.34 >1.01 0.05 >0.52 2.36 0.05 0.40 >1.89 0.27 1.17
CDABP0017 IPI00879210.1 Q9Y5Q8>3 0.48 1.53 > > > > > > > 1.08
CDC36 IPI00005011.1 Q9NZN8>1 > 0.47 > 0.81 >0.46 >0.93 >1.78 0.10 0.42 >0.41
CDCA5 IPI00879287.1 B5MBX0 >0.25 0.08 0.04 0.36 1.35 >0.06 0.15 >1.48 0.41 0.73
CDK2AP1 IPI00022340.1 O14519 >1.22 >0.25 2.40 > > > 0.14 0.97 > >
CDYL IPI00293963.4 Q9Y232>1 >0.03 1.21 0.21 0.95 1.52 0.70 0.62 0.05 >0.31 2.59
CEBPB IPI00289773.3 P17676 0.63 0.30 0.42 >1.84 0.49 1.02 0.69 0.08 >0.36 1.04
CENPE IPI00296365.4 Q02224>1 > > > > >0.64 > >1.23 > 0.70 >0.25
CENPI IPI00552142.1 Q92674>1 > > > > > > >1.36 > 0.64 >0.35
CGI>120 IPI01020803.1 F8VVA7 0.07 0.22 0.54 1.35 >0.30 >0.82 >1.97 >0.06 0.19 >0.38
CHC1 IPI00001661.3 P18754>2 >0.35 >0.86 0.10 >0.26 1.49 >0.09 0.83 >2.65 0.05 0.72
CHD1 IPI00297851.1 O14646>1 3.18 0.68 >0.77 0.83 0.38 0.51 0.61 1.57 >0.70 >0.58
CHD3 IPI00465222.2 E9PG89 > >0.10 1.77 0.59 > 0.09 0.53 1.34 0.05 2.44
CHD4 IPI01012026.1 F5H2G1 >0.86 0.92 1.78 > > > > > > 2.31
CHD8 IPI00398992.7 Q9HCK8>1 1.72 > > 0.66 0.90 0.40 >0.18 0.07 >0.55 0.69
CHEK1 IPI00909845.2 B4DT73 > > > 0.25 > >1.32 >1.10 > > 0.25
CHET9 IPI00299526.7 Q15022 >1.53 0.89 >0.95 >0.48 0.56 0.24 0.59 0.42 1.27 1.17
CHRAC1 IPI00010158.3 Q9NRG0 >0.08 0.20 0.56 >0.48 0.49 0.03 0.11 >0.55 > 1.55
CIC IPI00045360.4 Q96RK0 > > > >1.62 1.44 0.83 > > > >
CIP150 IPI00164719.11 Q4ADV7>1 > > > 1.34 > >1.17 >1.44 > > >0.62
CIRH1A IPI00239815.9 Q969X6>1 >0.42 0.69 >2.75 0.62 0.46 0.17 0.37 0.59 >0.39 0.03





Gene$Names IPI Uniprot H3K4me3 H3K9me3 meCpG H3K9me2 H3K27me1 H3K27me2 H3K27me3 H2Bub1 H3Δ1>20$
meCpG.$
H3K9me3
CMAS IPI00303158.3 Q8NFW8>1 >0.01 >0.47 0.27 >0.85 2.29 >0.02 2.20 >0.61 >0.59 1.44
CNBP IPI00430812.6 P62633>1 1.07 >0.31 >0.85 >0.70 1.36 0.44 0.30 0.05 >0.12 0.99
CNOT10 IPI01014565.1 Q9H9A5>1 >0.23 0.25 >0.26 1.00 >0.71 >1.00 >2.02 0.67 0.24 >0.33
CNOT3 IPI00005015.1 O75175>1 > > > 0.61 >0.43 >1.22 >1.68 > 0.49 >0.46
COBRA1 IPI00103483.1 Q8WX92 > 0.51 > 1.09 >0.74 >0.53 >0.70 3.02 0.08 >0.21
COPA IPI00295857.7 P53621>1 1.71 0.32 >0.02 > > > > > > >
COPG IPI00783982.1 Q9Y678 0.57 0.25 0.27 0.95 >0.43 >0.56 >1.54 >0.06 >0.18 >0.14
COPG2 IPI00002557.1 Q9UBF2 > 0.40 > 0.59 >0.45 >0.64 >1.38 > 0.01 >0.30
CPSF1 IPI00026219.4 Q10570 1.69 0.12 >0.75 >0.11 >0.27 >0.17 0.75 1.82 >0.55 >0.60
CPSF100 IPI00419531.2 Q9P2I0 1.24 0.00 >0.54 >0.28 > >0.23 0.29 1.70 >0.42 >0.19
CPSF3L IPI00063404.8 Q5TA45>1 0.44 > > >0.81 1.13 0.44 0.50 3.99 0.07 0.14
CREB1 IPI00027713.1 P16220>1 0.42 0.13 >0.10 >2.08 1.21 1.31 0.77 0.00 0.24 1.19
CREM IPI00337364.4 Q03060>9 >1.10 >0.01 >0.06 >1.54 > > > > > 1.38
CREM IPI00748922.3 Q03060>6 0.46 0.17 0.22 >1.76 > 0.90 0.18 >0.10 >0.05 1.26
CRM1 IPI00298961.3 O14980 >0.06 0.73 >0.05 1.43 >0.27 >1.40 >1.68 0.64 0.12 >0.49
CSDA IPI00031801.4 P16989>1 > > >0.02 0.10 1.83 0.54 0.37 > >0.44 1.81
CTCF IPI00027988.1 P49711 0.32 >0.03 >1.11 >2.48 3.29 0.72 0.60 >0.62 >0.35 1.57
CTNND1 IPI00182540.7 O60716>3 > > > 0.38 0.07 >0.27 >2.00 0.35 >0.61 0.13
CTTN IPI00029601.6 Q14247 > > > 0.71 > >0.41 >1.33 > 0.50 >0.31
CUTL1 IPI00419894.1 P39880>3 >0.06 >0.26 0.63 >1.46 0.93 0.88 0.71 0.88 0.64 1.20
CVAK104 IPI00396218.2 Q6P3W7 >0.20 0.80 > 1.27 >0.35 >0.66 >2.28 > >0.04 >0.15
CXXC2 IPI00185326.1 Q8NHM5>1 0.15 >0.17 > > 1.41 0.59 0.47 0.48 >0.23 >
CXXC8 IPI00166009.2 Q9Y2K7>1 >0.32 0.54 >4.66 >0.44 0.19 0.01 0.21 0.25 0.19 >0.32
DADB>100D22.1>
002
IPI00607575.2 B7Z7J5 0.40 0.64 > 1.21 0.00 >0.42 >1.13 >0.11 0.03 >0.06
DBI1 IPI00015922.2 Q9UL03>1 0.99 0.48 0.30 >0.05 0.74 0.08 >0.42 4.16 >0.18 >0.02
DCAF7 IPI00006754.1 P61962 > > > 0.65 0.04 >0.31 >0.80 3.22 >0.16 >0.46
DCC1 IPI00299884.4 Q9BVC3 > > > 1.29 > >0.57 >1.21 > > >
DDX36 IPI00027415.3 Q9H2U1>1 0.15 >0.06 >0.51 0.14 3.12 0.30 0.17 0.32 >0.28 1.16
DDX47 IPI00023972.5 Q9H0S4 0.01 >0.04 0.03 0.37 >0.29 0.59 1.84 >0.43 > 0.64
DDX52 IPI00032423.3 Q9Y2R4 >0.18 >0.08 >0.40 0.86 0.44 >0.64 >1.27 0.03 1.22 >0.43
DEAF1 IPI00216889.5 O75398>1 >0.22 0.23 >4.01 >0.52 >0.24 0.57 0.61 0.93 0.15 >0.69
DEK IPI00020021.3 P35659 >0.13 >0.03 >0.02 >0.87 4.00 0.24 0.55 >0.31 >0.18 0.97
DFS70 IPI00028122.1 O75475>1 0.17 0.06 >0.17 >0.40 1.47 >0.23 0.93 >0.35 >0.09 1.08
DGCR1 IPI00217560.3 P54198>1 1.15 > > >0.26 0.73 0.61 >0.15 0.19 0.32 >
DGT6 IPI00719210.1 Q7Z4H7>1 > > > 1.75 > >0.82 >1.97 > 0.09 >0.53
DIA IPI01015143.1 O60879>1 > > > 1.63 > >0.86 >1.45 > 0.14 >0.52
DIAP1 IPI00936125.3 Q6URC4 > > > 1.41 >0.18 >0.46 > > >0.09 >0.37
DIAPH3 IPI00942390.1 C9JDG0 > 0.71 > 1.42 >0.97 >1.02 >2.14 > 0.34 >0.57
DMAHP IPI00410575.2 Q8N196>1 > > 2.13 > > > > > > 1.78
DNAJC9 IPI00154975.3 Q8WXX5 >0.21 >0.06 0.22 >0.16 2.20 0.27 0.23 >0.38 0.00 1.17
DNM2 IPI00218889.3 P50570>2 > > > 1.38 > >0.57 > 0.27 > >
DP1 IPI00029095.1 Q14186 0.71 >0.09 >1.63 >1.70 2.10 1.07 2.04 >0.30 0.31 1.16
DP2 IPI00029096.1 Q14188>1 > > > > 1.87 > 0.97 >0.09 > >
DPY30 IPI00028109.1 Q9C005 0.35 0.07 >1.55 > > > 0.00 >0.10 > >
DR1 IPI00008991.1 Q01658 0.82 0.00 > >1.57 > > 0.10 > >0.05 >
DUC1 IPI00329605.6 P20585 0.80 > > > 1.41 0.76 0.38 >0.13 0.16 1.76
DXS254E IPI00005658.3 P11441 > > > 1.46 >0.72 >0.74 > > >1.13 >0.21
DXS9928E IPI00030098.5 Q14320 > > > 1.40 >0.50 0.12 0.18 > 0.03 >0.02
DYRK IPI00014344.1 Q13627>1 > > > > > >0.18 > 3.40 > >
E1AF IPI00017382.4 P43268 > > > > > > >1.33 > > 0.07
E2F3 IPI00743509.2 O00716 > > > >1.55 2.11 0.78 0.74 >0.15 0.48 1.18
E2F3 IPI01011332.1 Q24JQ3 0.58 >0.26 >1.70 > > > > > > >
E2F6 IPI00289560.3 O75461>1 1.67 1.55 > 0.41 > > > 0.61 > 1.34
E4BP4 IPI00290562.4 Q16649 0.43 >0.04 >0.10 >0.83 1.34 1.18 1.29 >0.03 >0.09 >
E4F IPI00184135.6 Q66K89 > 0.26 > >2.52 2.17 > > > > >
ECHDC1 IPI00302688.7 Q9NTX5>1 > > > 0.97 > >0.30 >2.03 > 0.32 >0.07
EDC3 IPI00018009.2 Q96F86 > > > 1.51 > > > > > 0.10
EDC4 IPI00376317.4 Q6P2E9>1 > > > 2.11 > > > > >0.21 >0.75
EED IPI00432040.1 O75530>2 >1.45 0.96 >0.97 0.14 0.87 0.35 1.07 >0.07 1.35 1.75
EFO1 IPI00552279.5 Q5FWF5>1 >0.21 > 0.16 >0.52 1.60 0.10 0.01 >1.57 0.04 0.88
EIF2B2 IPI00028083.1 P49770 > > > 1.19 > >0.55 > > >0.33 >0.52
EIF2G IPI00297982.7 P41091 > >0.07 > 0.12 0.50 >0.43 2.24 >0.18 0.42 1.11
EIF4E2 IPI00744211.2 O60573 0.39 >0.03 0.12 1.61 >0.73 >0.43 >1.74 0.38 0.09 >0.54
ELF4 IPI00170744.1 Q99607 > > > >1.94 > 0.49 > > >0.26 0.91
ELP1 IPI00293735.2 O95163 > 0.39 > 1.10 >0.40 >0.64 >0.77 > 0.10 >0.64
EMC19 IPI00301364.3 P63208>1 >0.25 0.38 >2.40 > > > > > > >
ENO1 IPI00465248.5 P06733>1 >1.20 >0.30 > > 0.35 >0.04 2.49 > >0.71 >
EPC1 IPI00018823.1 Q9H2F5>1 1.85 > > > > 0.64 > 1.86 > >
EPC2 IPI00141118.6 Q52LR7 1.82 > > > > > >0.58 > > >






Gene$Names IPI Uniprot H3K4me3 H3K9me3 meCpG H3K9me2 H3K27me1 H3K27me2 H3K27me3 H2Bub1 H3Δ1>20$
meCpG.$
H3K9me3
ERCC11 IPI00219179.6 Q92889 0.96 > > 1.11 > 1.12 >0.42 2.40 >0.13 >
ERCC2 IPI00029728.3 P18074 0.36 >0.09 0.21 >1.85 0.99 1.19 0.81 >0.45 >0.06 0.33
ERF IPI00032936.4 P50548 0.61 0.32 >0.53 >0.10 1.21 0.56 >0.10 >0.16 >0.01 0.35
ESP1 IPI00397474.2 Q14674>1 > > > > > >0.31 >1.75 > > 0.00
ESYT1 IPI00746655.1 Q9BSJ8>2 2.27 0.02 > >0.10 >0.85 >0.59 > > >0.43 >0.47
EXP IPI00021692.2 Q9NR56>1 > > > 1.32 > > >1.49 > >0.46 >0.53
EYA3 IPI00015990.2 Q99504>1 > > > > > > > 0.33 >0.18 1.35
EZF IPI00167069.2 O43474>3 > 0.20 1.29 > 1.09 0.98 0.63 >0.07 > 1.81
EZH2 IPI00947357.1 Q15910>1 > > > 0.01 0.54 0.26 0.76 0.58 1.35 >
EZH2 IPI00376787.4 Q15910>2 >1.45 0.85 >1.01 > > > > > > 1.26
FACE IPI00030252.1 Q9HB96 1.87 0.39 >0.23 0.18 0.22 > >1.39 >0.38 > >0.10
FAM91A1 IPI00152671.7 Q658Y4 > 0.45 > 0.57 0.05 >0.80 >1.17 > >0.23 0.08
FAM96A IPI00030985.1 Q9H5X1 > > >0.43 >1.25 >0.76 >0.62 > > > >
FANCF IPI00009290.3 Q9NPI8 2.02 0.85 0.02 0.78 > > >0.61 > >0.24 >0.95
FBI1 IPI00026317.3 O95365 >0.17 >0.02 0.70 >0.57 0.66 0.43 0.53 0.26 0.00 1.43
FBL12 IPI00015011.1 Q9NXK8>1 0.68 0.26 2.20 > > > > >1.28 > >0.31
FBL6 IPI00166767.3 Q8N531>1 > > >1.02 > 2.78 0.84 0.30 > >0.81 2.20
FBX3 IPI00296789.2 Q9UK99>1 >0.23 > >0.75 >0.29 0.09 0.49 1.15 >0.34 0.21 0.05
FEN1 IPI00026215.1 P39748 0.01 >0.21 > 0.46 >0.11 0.28 0.43 >0.46 0.06 1.42
FHOD1 IPI00001730.3 Q9Y613 > > > 1.28 > >0.44 >1.29 > > >0.17
FIGNL1 IPI00335421.4 Q6PIW4>1 > > > 0.69 >0.47 >0.83 >1.66 > 0.25 >0.46
FIZ1 IPI00045801.4 Q96SL8 > > > >1.28 1.31 0.75 0.87 >0.57 >0.59 3.57
FKHL16 IPI00401044.2 Q08050>3 > > > > > > >1.42 > 0.43 >
FKSG13 IPI00176903.2 Q6NZI2>1 > > > >0.78 0.37 0.70 2.34 > >0.01 0.28
FOSL2 IPI00011593.1 P15408>1 0.57 0.20 2.45 >1.82 > > > 0.78 > 1.72
FOXK1 IPI00556645.3 P85037>1 0.85 0.21 >0.34 >1.77 1.38 1.01 0.69 0.38 0.26 1.02
FOXK2 IPI00006029.2 Q01167>1 1.13 0.21 >0.43 >1.89 0.75 1.16 0.67 0.17 0.45 1.04
FPGS IPI00016745.1 Q05932>1 > 0.40 > 0.77 > > > > > >1.96
G2E3 IPI01026109.1 Q7L622 >0.79 >0.12 >0.64 0.19 > >1.86 >0.64 0.54 0.10 >0.06
GARNL1 IPI00456722.3 Q6GYQ0>2 > > > 1.92 > > > > 0.36 >
GATAD1 IPI00171123.4 Q8WUU5 1.36 >0.06 0.21 >0.09 1.42 0.23 0.31 >0.90 0.45 0.81
GATAD2A IPI00478128.2 B5MC40 >1.18 >0.26 1.84 >0.27 0.55 0.57 0.41 0.92 0.68 2.18
GATAD2B IPI00103554.1 Q8WXI9 >1.19 >0.24 2.07 0.11 0.55 0.41 0.40 1.14 0.55 2.07
GIGYF2 IPI00784233.2 Q6Y7W6>1 0.41 0.38 0.32 1.23 >0.08 >0.21 >1.13 0.60 0.25 >0.45
GLYR1 IPI00647648.3 Q49A26>2 > > > >0.90 1.74 0.33 0.56 >1.35 0.66 >
GMDS IPI00030207.1 O60547 > > > 1.59 >0.69 >0.87 >1.13 > 0.12 >0.56
GMIP IPI00292376.4 Q9P107 > > > 1.57 >0.44 >0.50 >1.73 > >0.03 >0.42
GPN1 IPI00027035.2 Q9HCN4 > > > 1.49 >0.54 > >1.35 2.79 0.17 >0.52
GPS2 IPI00012301.1 Q13227 > > > 0.58 > > > 1.73 > >0.11
GRL IPI00022282.3 P04150>1 > > > 0.99 >0.51 >0.88 >1.54 > 0.48 >0.28
GRWD IPI00027831.1 Q9BQ67 0.79 > > 0.14 > >0.29 0.20 2.22 >0.15 >0.14
GTBP IPI00384456.4 P52701>1 1.00 >0.02 0.57 >0.28 1.33 0.80 1.09 0.09 >0.20 1.34
GTF2A1 IPI00004350.1 P52655>1 2.62 > > > > > > > > >
GTF2A2 IPI00004353.1 P52657 1.97 0.00 > > > > > > > >
GTF2D1 IPI00022831.1 P20226 1.61 0.58 0.35 >0.25 1.13 0.68 0.39 0.25 0.02 0.37
GTF2E1 IPI00019977.2 P29083 2.70 > > >0.38 1.48 0.51 0.22 > 0.13 0.66
GTF2H4 IPI00016839.1 Q92759 0.09 >0.16 0.09 >0.81 1.40 1.09 1.88 >0.40 >0.48 0.65
GTF3C1 IPI00414482.3 Q12789>2 > 1.88 > 1.26 0.67 0.05 0.02 > >0.27 1.06
GTF3C3 IPI00015806.3 Q9Y5Q9>1 0.87 1.52 > 0.73 0.48 0.15 >0.22 0.70 >0.39 0.98
GTF3C4 IPI00016725.2 Q9UKN8 > 1.29 > 0.65 0.68 0.16 0.21 0.44 >0.27 1.20
GYG IPI00180386.5 P46976>1 > > > > > > >1.72 > > >
H1FX IPI00021924.1 Q92522 >0.25 >0.12 0.02 >0.02 2.49 0.25 0.20 >0.41 0.37 1.21
HAP3 IPI00013217.1 P25208 0.54 0.47 0.53 >0.78 > 0.79 0.35 0.09 0.81 1.74
HARP IPI00386311.2 Q9NZC9 1.94 0.39 >0.68 0.08 2.38 1.22 0.32 >0.12 > 1.34
HARS IPI00021808.3 P12081 > > > > > > > > > 1.29
HAUSP IPI00003965.5 Q93009 >2.45 1.35 1.24 1.79 >0.22 >0.70 0.99 0.97 1.39 3.08
HCFC2 IPI00002469.1 Q9Y5Z7 >0.05 > >2.07 > 1.22 > > 0.62 > >
hCG_1742080 IPI00470473.2 Q5VW26 > 0.40 > >3.21 > 1.90 > > > 2.00
hCG_1744585 IPI00796462.1 B5MDF5 >0.41 >0.16 0.18 0.22 1.13 >0.09 0.32 >2.43 0.08 0.45
hCG_1810992 IPI00953051.1 B2R8A7 2.28 > > 0.08 > 0.38 > 1.04 > 0.36
hCG_1811093 IPI00165068.1 Q96AN2 > > > > > > > > > 2.13
hCG_1812148 IPI00871372.2 D3DS86 0.03 > > 1.65 > 0.12 > > > 0.01
hCG_19946 IPI00032355.3 Q5T1Z8 >0.36 0.77 > 1.63 >0.67 >1.47 >2.07 0.79 1.15 >0.72
hCG_29955 IPI00900285.1 B1A8Z5 0.24 0.45 0.40 0.20 0.84 0.55 0.27 1.82 0.31 0.81
hCG_32740 IPI00941474.3 A8K4Q3 > > 2.59 > > > > 1.40 > 2.29
hCG_37170 IPI00009453.2 Q96SH1 0.46 0.07 0.94 >2.82 1.80 1.48 1.89 >0.72 >0.20 2.05
hCG_37966 IPI00027454.5 F5GXF0 > > > 0.55 >0.55 > >1.45 0.27 0.75 >0.33
HD IPI00002335.1 P42858 > > > 1.34 > >0.30 > > > >
HDAC1 IPI00013774.1 Q13547 >0.02 0.00 1.17 >0.25 1.38 0.65 0.81 0.24 0.22 1.84
HDAC2 IPI00289601.10 Q92769 >0.22 >0.04 1.18 >0.18 1.39 0.66 0.77 0.33 0.17 1.86





Gene$Names IPI Uniprot H3K4me3 H3K9me3 meCpG H3K9me2 H3K27me1 H3K27me2 H3K27me3 H2Bub1 H3Δ1>20$
meCpG.$
H3K9me3
HELLS IPI00010590.2 Q9NRZ9>1 > > > 1.19 0.08 >0.72 >1.40 > 0.09 >0.20
HIP12 IPI00024417.1 O75146 >0.52 0.40 > 1.61 >0.48 >1.32 >0.76 > 0.44 >0.73
HMBOX1 IPI00956180.1 Q6NT76>5 0.30 0.40 1.25 >2.74 2.05 1.46 0.99 >0.40 0.41 2.34
HMG14 IPI00554761.2 P05114 >0.11 >0.35 0.08 0.07 1.17 >0.05 >0.06 >1.80 0.20 0.33
HMG17L3 IPI00220484.3 O00479 > 0.20 > 0.18 > > > >1.55 0.06 >
HMG20A IPI00018924.3 Q9NP66>1 >2.24 >0.08 >0.02 >0.25 >0.47 0.36 0.28 0.15 1.67 >0.44
HMG2L1 IPI00455982.1 Q9UGU5 1.03 >0.73 >1.03 >0.85 1.89 0.66 1.07 >0.74 1.22 1.05
HNRNPU IPI00479217.1 Q00839>2 1.29 0.10 >0.18 > > > > > > >
HOMEZ IPI00941497.2 B4DX80 > > 3.75 > > > > > > 4.06
HRX2 IPI00218823.4 Q9UMN6>1 >0.15 0.31 >3.06 >0.59 0.90 0.72 0.76 >0.43 >0.23 >0.02
HSF1 IPI00024071.1 Q00613>1 > > > 2.12 > > >2.44 > 0.26 >0.46
HSP60 IPI00784154.1 P10809 > > > 1.55 >0.12 >0.56 >1.15 > >0.12 >0.16
HSP75 IPI00030275.5 Q12931 > > > 1.59 >0.99 >1.04 >1.59 > 0.40 >0.40
HSPC130 IPI00164949.4 Q8IXH7>1 0.12 0.23 > 1.50 >0.10 >0.53 >0.83 3.15 >0.04 >0.04
HSPC144 IPI00383163.5 Q9P016>1 >1.65 0.06 > > 0.39 0.05 0.42 >0.82 0.03 1.11
HSPC189 IPI00009777.3 Q9P0T4 > 2.26 > > > > > > > 3.03
HSPC301 IPI00387159.3 Q9NXR8>1 1.79 > > > > 0.61 > 0.82 > >
HUSSY>29 IPI00007089.1 O95478 > > > > > > > > > >1.86
IDH3B IPI00304417.7 O43837>1 > > > 1.52 > > > > > >
IDN3 IPI00026466.9 Q6KC79>2 > > > 2.10 0.19 >0.14 1.17 1.79 >0.21 2.66
IDN3 IPI00436632.1 Q6KC79>1 0.64 2.48 > > > > > > > >
IFI16 IPI00003443.3 Q16666>1 >0.11 >0.15 0.38 >2.37 2.69 >0.01 0.27 >0.25 1.33 2.10
IFI16 IPI00217474.7 Q16666>2 >0.43 >0.12 0.43 >2.14 2.86 0.02 0.24 >0.22 1.40 2.06
IGKJRB IPI00030177.3 Q06330>1 > > 1.01 > > > > > > 1.89
ING1 IPI00099385.1 Q9UK53>2 1.56 0.35 >0.25 > 0.90 0.95 0.80 1.06 > >
ING1 IPI00014324.3 Q9UK53>1 > > > > > > > > > 1.19
INO80 IPI00008091.2 Q9ULG1 0.34 >0.07 0.27 >1.54 1.71 1.25 1.00 0.97 >0.29 1.50
INO80S IPI00014513.1 P25490 0.60 0.02 1.32 >0.70 1.81 0.24 0.18 0.00 >0.16 1.82
INRF2 IPI00106502.5 Q14145 > > 2.73 > > > > > > >
INTS1 IPI00876931.1 Q8N201 1.05 0.47 >0.16 >0.09 0.48 0.22 >0.68 4.31 >0.22 0.02
INTS12 IPI00060379.1 Q96CB8 1.15 0.33 >0.04 >0.26 0.69 0.30 >0.51 4.47 >0.14 0.01
INTS2 IPI00477759.2 Q9H0H0 0.56 > > 0.45 >0.21 >0.45 >0.82 4.52 >0.01 >0.47
INTS4 IPI00446765.2 Q96HW7>1 0.21 0.75 0.53 0.24 0.30 >0.36 >1.35 4.25 0.52 >0.19
INTS5 IPI00304676.5 Q6P9B9 0.77 0.68 0.33 0.40 0.13 >0.34 >0.98 4.38 >0.39 >0.18
INTS9 IPI00290514.1 Q9NV88 0.46 > > >0.52 > 0.44 0.09 4.31 0.10 0.24
IPO12 IPI00395694.1 Q9Y5L0>2 1.77 0.07 >0.77 0.08 0.00 >0.53 >0.66 >0.77 >0.44 >0.23
IPOA7 IPI00747764.3 B4DWX3 > > > 0.52 0.32 >0.19 >0.50 1.69 0.01 0.07
IRA1 IPI00002922.5 Q9BZK7 1.27 0.20 0.11 >0.05 1.04 0.45 0.08 1.20 >0.39 0.67
IRAK2 IPI00304986.5 O43187 > > > > > >0.83 >1.74 > 0.81 >0.34
JADE3 IPI00006077.1 Q92613 0.63 > > 0.38 0.82 0.12 0.21 0.49 2.00 >0.50
JARID1A IPI00021363.3 P29375>1 2.06 >0.03 > > > 0.91 0.48 > > >
JNKK2 IPI00745806.3 O14733>3 >1.60 0.38 > > > > > > > 0.04
JUN IPI00008965.1 P05412 0.65 > 1.82 >2.12 > > 1.02 > >0.47 1.66
JUND IPI00289547.4 P17535 0.89 0.31 2.20 >2.11 1.35 > > > > 1.79
KAISO IPI00465140.3 Q86T24 > > 3.50 0.82 > > >0.78 > 0.06 0.80
KBRAS2 IPI00021124.3 Q9NYR9>1 > > > 0.79 > >0.58 >1.30 >0.07 >0.09 >
KDP IPI01012075.1 F5H2M7 > > > 2.28 > > > > >0.39 >0.03
KHNYN IPI00829596.3 O15037 > > > 0.75 > > >1.44 > 0.81 >0.54
KIAA0007 IPI00937477.1 Q15061 >0.50 0.87 >2.87 0.56 0.45 0.31 0.42 0.86 >0.47 0.08
KIAA0017 IPI00300371.5 Q15393>1 1.48 >0.06 0.02 0.10 >0.55 >0.09 >0.10 0.61 >0.22 >0.77
KIAA0035 IPI00216654.2 Q14978>2 >0.40 0.57 >0.34 0.16 >0.05 >0.31 0.02 1.92 0.02 >
KIAA0035 IPI00908873.1 Q14978>3 >0.53 0.56 >0.31 > > > 0.34 1.73 > >
KIAA0042 IPI00299554.3 Q15058 1.08 0.27 > 1.19 >0.22 >0.89 >1.22 0.21 0.71 >0.44
KIAA0099 IPI00551014.1 Q14671>1 > > > 0.72 > > >2.04 > 1.24 >0.81
KIAA0170 IPI00552897.2 Q14676>1 0.01 >0.68 >0.20 0.44 0.93 0.59 0.88 >2.55 >0.55 0.38
KIAA0211 IPI00022460.2 Q92610 > > > > > > > 3.36 > >
KIAA0295 IPI00307591.5 O15014 > > > > > > > 4.03 >0.39 >
KIAA0309 IPI00444046.4 Q6ZRS2>1 >0.87 >0.18 >1.77 > > > > > > 0.44
KIAA0370 IPI00465296.2 Q96QU8 > > > 1.24 0.08 >0.82 >1.33 > >0.04 >0.77
KIAA0395 IPI00301844.2 Q9H4I2 >0.13 > 3.58 > > > > 0.82 > 3.45
KIAA0406 IPI00011702.4 O43156 0.04 0.46 0.16 1.04 >0.82 >1.13 >1.06 > >0.20 >0.70
KIAA0414 IPI00022264.1 O43298 >0.05 0.09 > >3.00 1.25 >0.06 > >0.53 > 2.88
KIAA0425 IPI00477949.1 Q5VZL5>1 > 2.47 > > > > > > >0.14 1.17
KIAA0459 IPI00847831.1 Q5T2D3 > > > > > > > 4.09 > >
KIAA0461 IPI00410717.2 Q7Z3K3>1 > 3.20 2.22 > > > >0.69 > > 2.57
KIAA0570 IPI00297593.4 Q70CQ2>1 > > > 1.44 > >1.29 > > > >0.19
KIAA0650 IPI00890837.1 A6NHR9>1 > 3.76 > 1.58 0.32 0.03 0.37 >0.29 > 1.47
KIAA0663 IPI00328306.9 O75152 > > > > > > > > >1.29 >1.12
KIAA0700 IPI00607589.1 O75182>2 2.66 0.44 > >0.55 > 0.53 0.60 >0.05 > 0.84
KIAA0764 IPI00006651.1 O94864>1 2.17 > > 0.30 > > > > > 0.18






Gene$Names IPI Uniprot H3K4me3 H3K9me3 meCpG H3K9me2 H3K27me1 H3K27me2 H3K27me3 H2Bub1 H3Δ1>20$
meCpG.$
H3K9me3
KIAA0783 IPI00472782.1 O94880>1 >2.33 >0.15 >0.07 >0.46 >0.11 >0.08 >0.19 0.72 2.36 >0.62
KIAA0791 IPI00026625.1 O75694>1 >0.25 0.50 >0.49 1.22 >0.49 >1.00 >1.60 0.02 0.38 >0.69
KIAA0852 IPI00455518.5 Q9Y6X9>1 > > > 0.72 > > 0.29 4.28 0.29 >0.32
KIAA0886 IPI00298289.1 Q9NQC3>2 > > > >1.33 >1.58 >0.43 > > > >0.40
KIAA0886 IPI00478442.3 Q9NQC3>5 1.96 >0.30 >0.58 > > > > > > >
KIAA0892 IPI00000656.2 Q9Y6X3>1 0.73 2.82 0.33 0.95 > 0.10 0.39 1.61 >0.33 2.14
KIAA0913 IPI00877106.1 A7E2V4>4 > > > 1.18 >0.65 >1.26 >2.07 > 0.85 >0.39
KIAA0997 IPI00007273.3 Q9Y2K1>1 0.60 > > >1.72 1.45 0.99 0.82 >0.13 0.74 >
KIAA1057 IPI00902614.2 Q9UPU5 > > > 1.66 >0.16 >0.55 >0.59 > >0.21 >0.16
KIAA1090 IPI00218240.3 O96028>1 >0.28 0.11 >0.43 > > 0.56 1.02 >0.42 0.49 1.93
KIAA1111 IPI00480187.2 Q9UPP1>1 4.15 > >0.07 > 1.04 >0.17 > 0.73 0.33 >0.25
KIAA1115 IPI00873586.3 Q9UPN7 1.15 1.47 1.19 1.49 > >0.66 > > >0.57 >0.04
KIAA1125 IPI01008745.1 Q9ULU4>13 > > 1.42 > 0.90 1.15 > 3.22 > >
KIAA1148 IPI00868787.1 Q9HCD6>1 > > > 0.69 0.06 >0.30 >1.37 1.13 >0.03 >0.25
KIAA1196 IPI00074893.1 Q96KM6 >0.48 >0.45 0.62 > 1.88 0.16 0.15 >0.40 >0.24 2.13
KIAA1197 IPI00008200.2 Q9ULM3 1.46 0.05 >1.02 >0.55 0.67 0.70 0.80 0.12 0.31 0.41
KIAA1205 IPI00855833.1 Q9ULL5>3 0.04 2.01 > 0.90 0.81 > > > > 1.74
KIAA1227 IPI00008137.1 Q9ULJ3>1 2.62 >0.31 > >2.05 2.18 1.39 >0.92 >0.34 0.36 1.15
KIAA1231 IPI00398772.4 Q9NQV6>6 > > > > > > 1.38 > > 2.67
KIAA1266 IPI00165357.4 Q9BTC8>1 >0.85 >0.13 1.59 >0.01 0.89 0.54 0.80 0.53 0.66 2.03
KIAA1291 IPI00640703.3 Q9HAV4 2.00 0.54 >0.13 0.27 >0.43 >0.68 >0.71 0.48 >0.22 >0.51
KIAA1429 IPI00036742.6 Q69YN4>1 1.62 >0.02 >0.08 0.65 0.07 >0.07 0.01 1.12 >1.01 >0.48
KIAA1441 IPI00395813.1 Q8N1G0>1 > 0.03 > >0.11 > > > 2.86 > 0.78
KIAA1452 IPI00220045.3 Q9NVU0>1 > > > >1.67 2.74 1.26 0.85 0.51 >0.07 0.77
KIAA1523 IPI00292750.3 Q96QT6>1 2.74 > > > > 0.84 > > 0.91 1.10
KIAA1584 IPI00149044.9 Q6N043>1 > > > > > > > > > 3.90
KIAA1649 IPI00440688.4 Q9BY77>1 1.15 >1.20 0.00 0.16 2.34 0.80 0.04 >0.93 >0.21 >0.33
KIAA1665 IPI00289667.3 Q9Y535>1 > > > >1.22 2.26 1.26 0.55 > >0.62 1.07
KIAA1728 IPI00173946.8 Q9C0D5>1 0.21 0.52 > 1.37 >0.01 >0.59 >2.06 > 0.15 >0.30
KIAA1741 IPI00304589.5 Q9C0C2>1 > > > 1.52 >0.18 >1.18 >1.55 > 0.37 >0.57
KIAA1797 IPI00748360.2 Q5VW36 > > > 1.66 > >0.90 >1.53 > >0.18 >0.41
KIAA1798 IPI00306511.2 Q96JM7>1 >0.13 0.07 >1.75 > > > > > > 0.09
KIAA1978 IPI00217661.4 Q8IY67>2 0.45 >0.38 0.40 0.51 >0.68 >0.15 >1.51 >0.14 0.39 >0.46
KIAA1991 IPI00456899.2 Q8NCN4 > > > 0.04 0.68 0.08 >1.13 3.02 0.18 0.07
KIAA2030 IPI00785015.3 Q6ZU65>1 1.71 > 0.79 > 0.50 0.94 0.14 0.27 0.29 0.27
KIF4 IPI00178150.5 O95239>1 0.52 0.50 > >0.43 1.14 >0.37 0.85 0.21 0.91 0.96
KPNA1 IPI00303292.2 P52294 0.48 0.52 0.44 1.02 0.38 >0.25 > 1.98 0.07 0.41
L14 IPI00303813.5 Q9H8H0 >0.57 0.65 >2.79 >0.03 0.60 0.36 0.42 1.09 >0.41 >0.03
LAP2 IPI00216230.3 P42166 >0.19 1.29 >1.05 >1.37 >0.61 0.36 >0.09 2.33 >1.72 0.28
LATHEO IPI00294402.1 Q9UBD5>1 0.01 1.47 0.36 0.55 0.34 0.52 2.29 >0.38 0.02 2.48
LATHEO IPI00374747.5 Q9UBD5>2 > > > 1.38 > 0.34 2.02 > > 2.49
LBP1 IPI00005018.3 Q9NZI7>1 0.89 0.27 0.23 >2.03 1.42 1.12 0.92 0.05 > 1.90
LIG1 IPI00219841.6 P18858 > > > 1.38 > 1.71 >1.52 > >0.17 >0.36
LP3587 IPI00031633.4 Q9BQ15>1 > > > >0.45 > > > 4.68 > >
LRWD1 IPI00069309.6 Q9UFC0 0.16 1.45 0.50 0.87 0.67 0.73 3.05 >0.73 >0.05 2.97
LSF IPI00037599.3 Q12800>1 0.74 0.35 >0.11 >2.16 1.52 1.25 1.01 0.03 >0.04 1.99
LYT10 IPI00845373.1 Q00653>1 > > > 1.16 1.36 1.18 1.77 >0.40 >0.44 1.59
MADH5 IPI00017730.1 Q99717 > > > 0.87 > >0.27 >1.99 > > 0.28
MAFF IPI00099497.2 Q9ULX9 > >0.23 2.41 >1.60 1.38 0.71 > > > 2.19
MAFG IPI00007311.1 O15525 0.69 0.70 2.15 >1.43 > > > > > 2.19
MAFK IPI00031018.2 O60675 0.09 >0.06 2.26 >1.28 > 1.48 > > > 1.93
MAP3K7IP3 IPI00166840.4 Q8N5C8>1 > > > > > > >1.51 > 0.10 >0.29
MBD2 IPI00434623.1 Q9UBB5>1 >1.37 >0.64 2.45 0.56 1.10 0.64 0.82 0.85 0.64 2.79
MBD3 IPI00439194.1 O95983>1 >0.96 >0.15 0.37 0.51 0.94 0.49 >0.08 1.49 0.48 0.55
MBD4 IPI00426728.3 O95243>2 >0.39 >0.47 1.16 >0.08 1.81 0.04 0.68 >0.68 >0.11 >
MBD4 IPI00426727.1 O95243>1 > > > > > > > > > 2.33
MBTD1 IPI00784023.1 Q05BQ5>1 2.32 > > 0.10 > > > > > >
MECP2 IPI00645192.4 P51608>2 > > > >1.77 1.68 0.25 0.63 >0.64 0.01 3.91
MEIS2 IPI00023696.1 O14770>1 > > > > > > > > > 1.53
MEN1 IPI00182106.5 O00255>2 >0.12 0.02 >2.06 >1.05 0.86 0.57 0.53 >0.26 0.16 0.02
MGMT IPI00028618.2 P16455 >2.06 >0.65 > 0.26 > > 0.34 > 0.30 0.96
MIZ1 IPI00556634.1 Q13105>2 0.46 0.04 > > 1.55 1.11 > 0.29 > >
MLN70 IPI00013895.1 P31949 >1.31 0.24 > > >1.09 > > > > >
MORF4L1 IPI00550968.3 A5D8W6 1.36 0.38 0.26 0.39 > >0.03 0.39 0.11 0.15 0.40
MSH2 IPI00017303.1 P43246 0.86 0.08 0.69 >0.42 1.90 0.53 0.10 >0.16 >0.25 1.67
MTA1L1 IPI00171798.1 O94776 >1.19 >0.23 2.27 0.03 0.42 0.49 0.29 1.05 0.61 2.31
MTF2 IPI00291983.8 Q9Y483>1 >1.01 0.71 >1.63 >0.22 0.92 0.13 0.80 0.07 1.15 >
MUS81 IPI00289454.3 Q96NY9 > > > 0.14 2.34 0.39 1.12 >0.42 > >
MUTYH IPI00414235.1 Q9UIF7>3 > > > >2.25 2.38 0.46 0.80 >0.93 0.06 >
MUTYH IPI00414236.7 Q9UIF7>2 > > > > > > > > > 2.35





Gene$Names IPI Uniprot H3K4me3 H3K9me3 meCpG H3K9me2 H3K27me1 H3K27me2 H3K27me3 H2Bub1 H3Δ1>20$
meCpG.$
H3K9me3
NAK IPI00293613.2 Q9UHD2 > > > 0.59 >0.29 >0.83 >1.27 > 0.47 >0.31
NELFA IPI00394679.3 B3KM78 > > > 1.15 >0.19 >0.33 >0.59 3.52 0.03 >0.08
NELFE IPI00000858.2 B4DYX9 > > > >0.44 0.14 0.21 0.11 2.91 0.06 0.42
NFI IPI00029795.1 P08651>1 > > > >3.32 2.39 0.93 0.30 >0.22 >0.19 >
NFI IPI00218041.1 P08651>5 > > > > > > > > > 1.95
NFIA IPI00163319.3 B4DS53 0.47 0.07 > >2.83 2.60 > > > >0.33 1.97
NFIX IPI00218260.3 Q14938>1 > 0.00 > > > 1.31 > > > >
NFYA IPI00333568.1 P23511>1 0.75 > 0.94 > 1.11 0.63 0.70 0.36 0.67 1.61
NFYC IPI00071697.1 Q13952>1 0.69 0.30 0.82 >0.97 1.41 0.75 0.80 0.28 0.50 1.74
NIRF IPI00044681.1 Q96PU4>1 > 3.95 > > > > > > > 4.50
> IPI00980612.1 No_ID10 0.23 >0.27 1.25 > > > > > > >
> IPI00181352.2 A8K1B6 > >0.50 > 1.34 >0.23 >0.55 >0.73 0.27 0.00 >
> IPI01011704.1 A8K1E1 0.82 >0.71 >0.69 >0.93 1.38 0.54 0.14 >0.06 0.28 1.75
> IPI00979371.2 B4E3V7 > > > > > > > 3.20 > >
> IPI00945820.1 C9JYP6 > > > 1.21 > > >1.78 > 0.05 >0.50
> IPI00514550.1 E9PEQ4 0.31 >0.27 1.24 > > > > 0.24 > >
> IPI00879166.1 E9PHA7 >1.47 >0.40 1.03 >0.32 0.70 0.71 0.34 1.25 1.05 >
> IPI00925034.4 F2Z2U4 1.26 0.25 >0.43 0.83 0.26 >0.37 >0.21 0.39 >0.17 0.53
NOC4L IPI00031661.1 Q9BVI4 1.89 >0.09 >0.36 0.54 1.05 0.78 >0.47 >0.10 0.16 >0.12
NR2B1 IPI00418394.2 P19793 > > > 1.93 0.13 >0.79 >1.49 > 0.04 >0.02
NR2C2 IPI00749258.1 P49116>1 0.86 0.11 >0.65 0.69 1.50 0.09 0.37 >0.38 > >0.20
NR2C2 IPI00332451.3 P49116>2 > > > 0.25 1.59 0.17 0.53 >0.67 0.44 >
NSEP1 IPI00031812.3 P67809 0.40 >0.14 >0.41 0.44 2.65 0.69 0.35 0.06 >0.36 1.46
NSPC1 IPI00902987.2 Q9BSM1>1 >0.10 >0.04 >2.47 >0.28 0.41 0.60 0.19 0.54 >0.32 >0.30
NUBP2 IPI00644674.1 Q9Y5Y2 >1.04 0.24 > 1.71 >0.65 >0.91 >1.66 > 0.05 >0.42
NUP358 IPI00221325.3 P49792 >0.03 >0.02 > 1.88 > >1.07 > 0.03 >0.16 0.03
OBFC2A IPI00059434.2 Q96AH0>1 0.73 0.08 0.34 >1.35 > 0.44 0.37 4.24 0.12 0.38
OCR IPI00550655.4 Q9Y657 4.90 > > > > > > > > 1.75
OK/KNS>cl.5 IPI00885108.1 Q86TB9>1 > > > 1.45 >0.61 >1.07 >2.27 > 0.08 >0.31
ORC1 IPI00013215.2 Q13415 >0.09 0.87 0.43 > > 1.16 > >0.54 > >
ORC2 IPI00013216.1 Q13416 0.06 1.46 0.44 1.00 0.25 0.58 2.67 >0.48 0.07 2.71
ORC5 IPI00015143.1 O43913 0.09 1.21 0.60 0.47 0.50 0.11 2.41 >0.76 0.18 2.02
ORP10 IPI00032971.2 Q9BXB5 > > > 1.47 > >0.68 >1.40 > 0.54 >0.36
PAF53 IPI00550638.2 Q9GZS1>2 > > > > 2.26 1.12 2.01 >1.57 > >
PAGA IPI00000874.1 Q06830 >1.29 >0.09 >0.26 >0.47 0.29 0.20 0.72 > >0.47 0.53
PCL1 IPI00973445.1 B4DI51 > > > > > 3.87 4.91 > > >
PCL3 IPI00157837.5 Q5T6S3>1 >2.47 1.26 >1.12 > > 0.80 1.97 0.32 > >
PCNA IPI00021700.3 P12004 >0.13 0.25 1.59 >1.28 0.21 0.49 0.39 0.05 0.39 1.00
PDE3A IPI00291205.4 Q14432 > > > 1.58 >0.12 > >2.15 > 0.16 >0.40
PGDH3 IPI00011200.5 O43175 1.32 >0.16 >0.05 >0.13 >0.06 0.03 >0.59 >0.14 >0.46 0.09
PHF23 IPI00063434.2 Q9BUL5>1 3.05 > > > > > > > > >
PI4KA IPI00070943.4 P42356>1 > > > > > > >1.66 > > >0.35
PIR51 IPI00093253.3 Q96B01>1 > > > > > > > 2.59 > 0.10
PKN2 IPI00002804.1 Q16513 > > > 1.76 > > >1.88 > 0.30 >0.43
PKNOX1 IPI00220929.4 P55347>1 > > > > > > > > > 1.56
PLEKHG4 IPI00025442.2 Q58EX7>1 > > > > > > >1.63 > > >0.78
PMS2 IPI00746337.2 P54278>1 > > > 1.06 0.22 >0.63 >1.26 > >0.15 0.28
PNO1 IPI00024524.4 Q9NRX1 > 0.21 > 1.72 > >0.68 >2.04 > 0.48 >0.47
POLD IPI00655631.2 E7EVW0 > > > 0.81 >0.42 >0.45 >1.50 > 0.05 >0.40
POLM IPI00002325.1 Q9NP87 > > > > 1.74 > 0.73 > > >
POLR1C IPI00005179.1 O15160>1 > > 0.08 >0.95 2.30 1.05 0.86 >0.68 >0.20 0.46
POLR2 IPI00031627.4 P24928 0.67 >0.09 > >1.52 1.59 0.82 0.45 3.73 > >
POLR2B IPI00027808.1 P30876 1.57 0.25 > >0.65 0.25 0.17 >0.32 4.07 0.21 >0.19
POLR2D IPI00007283.1 O15514 0.49 > > > > > > 3.21 > >
POLR2E IPI00291093.3 P19388 0.58 >0.06 0.13 >1.64 2.37 1.11 0.72 2.05 >0.02 0.81
POLR2G IPI00218895.6 P62487 0.72 >0.25 > >1.15 > 0.86 > 3.89 >0.02 0.74
POLR2J1 IPI00003310.2 Q9H1A6 0.66 >0.38 > >0.49 > > > 3.35 > >
POLR2L IPI00003311.1 P62875 > > > >0.91 1.88 0.86 0.39 2.17 >0.10 0.41
POLR3A IPI01015730.1 F5H7E9 > > > >1.46 2.57 1.12 1.33 0.22 >0.10 >
POLR3B IPI00301346.3 Q9NW08 > > > >1.10 2.49 1.20 0.54 > > 0.67
POLR3C IPI00007948.2 Q9BUI4 > > > >1.28 2.79 0.94 1.13 >0.16 >0.06 0.60
POLR3F IPI00100245.1 Q9H1D9 > > > >2.03 2.54 1.41 0.88 > >0.45 1.19
POLR3G IPI00968202.1 O15318 > > > >1.14 2.85 1.23 0.51 > >0.38 >
PPP2CA IPI00008380.1 P67775 0.78 > 0.09 >0.27 0.69 0.04 >0.24 4.59 >0.12 >0.11
PPP2CB IPI00429689.3 P62714 > > > > > > > 3.80 > >
PPP2R1A IPI00554737.3 P30153 0.24 0.31 0.03 0.21 0.34 >0.26 >0.48 3.95 >0.39 >0.04
PPP2R1B IPI00335449.3 P30154>2 > > > 0.31 >0.08 >0.26 > 3.57 >0.39 >0.15
PPT1 IPI00514424.4 E9PES1 > > > 1.55 > >0.62 >1.91 > 0.38 >0.39
PRO2134 IPI00018110.1 Q15544 1.93 > > > > > > > > >
PSEC0006 IPI00328985.1 Q86W42>1 0.63 0.09 >0.14 0.33 >0.55 >0.22 0.43 0.93 >1.20 >1.49






Gene$Names IPI Uniprot H3K4me3 H3K9me3 meCpG H3K9me2 H3K27me1 H3K27me2 H3K27me3 H2Bub1 H3Δ1>20$
meCpG.$
H3K9me3
PSME3 IPI00219445.1 P61289>2 >0.47 0.65 0.53 1.50 >0.51 >0.66 >1.59 >0.18 >0.08 >0.51
PUR1 IPI00023591.1 Q00577 0.74 >0.94 > >0.79 1.98 1.21 0.65 0.49 >0.51 2.02
PURB IPI00045051.3 Q96QR8 0.85 >0.40 >1.49 >1.26 2.34 0.80 0.47 0.64 >0.39 1.96
PYCR1 IPI00550882.3 B4DMU0 > > > 1.59 > > >1.81 > 0.07 >0.46
RAD18 IPI00024579.2 Q9NS91 0.13 > >0.40 0.16 > 0.26 >0.02 2.09 >0.34 0.18
RAD54B IPI00018281.1 Q9Y620 >0.26 0.74 > 0.80 >0.18 >1.12 >1.76 > 0.80 >0.51
RAP80 IPI00384342.3 F8VQY2 > > > > 0.91 > > 3.49 > 0.56
RB1 IPI00302829.5 P06400 0.30 0.02 >1.54 >0.52 1.85 0.27 0.25 0.09 0.30 0.85
RBAP46 IPI00395865.4 Q16576 >0.40 >0.06 1.84 >0.68 1.07 0.78 1.92 0.62 0.50 2.19
RBAP48 IPI00328319.8 Q09028>1 >0.43 0.42 1.46 >0.65 0.80 0.75 1.87 0.36 0.35 1.78
RBBP5 IPI00478230.2 Q15291>1 >0.07 0.10 >2.37 >0.46 1.04 0.57 0.56 0.10 0.10 0.18
RCD1 IPI00023101.1 Q92600 >0.22 0.50 0.16 1.79 >0.62 >1.04 >1.78 0.29 0.04 >0.61
RECQ1 IPI00178431.12 P46063 > > > >0.88 1.50 0.32 0.43 > 0.44 1.29
RECQL5 IPI00185769.3 A5YM55 > > > > > > > 3.57 > >
REPA1 IPI00020127.1 P27694 0.64 >0.11 >1.07 >0.78 1.06 1.17 0.65 >0.02 >0.14 1.05
REPA2 IPI00646500.1 P15927>3 0.49 >0.01 >0.68 >0.25 1.23 1.19 0.17 >0.13 >0.27 1.01
RFX5 IPI00009303.1 P48382 1.25 0.74 0.92 >0.10 1.56 0.66 0.40 >0.25 0.64 1.02
RFXAP IPI00010890.1 O00287 1.12 0.85 0.84 >0.70 1.26 0.65 >0.20 0.19 0.63 1.25
RING1 IPI00641330.1 Q06587>1 0.48 0.31 >1.07 >0.41 1.16 0.93 1.84 0.29 >0.11 0.44
RNF114 IPI00032955.1 Q9Y508>1 1.66 >0.03 0.21 > > > > > > >
RNF168 IPI00217899.1 Q8IYW5 0.06 > > > > > > 3.06 > >
RNF95 IPI00010948.2 Q12899 > 3.01 > > > > > > > >
RP11>101E13.2>
006
IPI00642374.1 Q5LJA9 0.39 0.11 0.23 >1.27 1.14 0.91 0.45 1.27 >0.54 1.21
RP11>114F7.3 IPI01011375.1 Q5SVK8 > > > 1.34 > >0.93 >1.68 > 0.39 >0.48
RPL34 IPI00219160.3 P49207 > > > 0.64 > > > > 0.20 >1.37
RSBN1 IPI00019999.2 Q5VWQ0>1 > > > > > > > 4.09 > >
RSBN1L IPI00925255.1 Q6PCB5>1 > > > > > > > 4.38 > >
RTTN IPI00645947.4 Q86VV8>1 > > > 1.14 >0.42 >0.97 >1.56 > >0.07 >0.51
SAMD1 IPI00395474.1 Q6SPF0 >0.16 0.26 >2.19 >0.59 >0.18 0.38 0.31 >0.33 0.04 >0.09
SAP130 IPI00002220.4 Q9H0E3>2 1.60 0.38 0.14 > > 0.92 0.45 0.96 0.59 >
SAP30 IPI00022019.1 O75446 1.22 0.33 0.04 >0.25 0.75 0.90 0.34 0.98 0.10 1.30
SAP45 IPI00607645.5 Q9H7L9 1.82 0.27 >0.04 >1.16 0.83 0.88 0.83 0.72 0.17 1.38
SAP49 IPI00017339.1 Q15427 0.81 > >0.30 >0.42 > 0.44 1.60 0.08 >0.50 0.27
SCML2 IPI00328688.3 Q9UQR0>1 >3.22 >0.10 >1.11 1.54 > >0.18 1.07 1.62 0.93 2.40
SEP1gene IPI00657805.1 Q8IZH2>1 > > > 1.26 >0.08 >0.25 >1.26 > 0.63 >0.38
SIN3A IPI00170596.1 Q96ST3 1.61 0.34 >0.07 >1.12 1.00 0.77 1.17 1.17 0.43 1.24
SIX4 IPI00006525.3 Q9UIU6 0.64 0.06 1.39 >0.65 1.29 0.74 0.27 0.67 >0.54 1.80
SP3 IPI00025807.2 Q02447>1 > > > >1.51 > > > > > >
SPK IPI00023344.2 Q92797>1 1.52 0.32 >0.03 0.61 >0.39 >0.73 >0.88 1.33 >0.27 >0.56
SPT4H IPI00002895.1 P63272 > > > 0.28 > > > 6.30 > >
SPT5 IPI00298058.1 O00267>1 > > > > > 0.39 > 4.41 > >0.04
SRBD1 IPI00171087.7 Q8N5C6>1 >0.02 >0.10 0.46 >0.57 2.60 >0.24 0.35 >0.57 0.64 1.96
STX5 IPI00744834.2 Q13190>1 > > > 1.82 >0.88 >1.37 >1.74 > 0.48 >0.49
TADA1 IPI00060046.1 Q96BN2 1.22 >0.05 > 0.44 > > >0.35 > >0.03 >0.05
TAF10 IPI00030364.1 Q12962 1.63 0.25 > >0.62 > 1.47 0.06 > > 0.89
TAF12 IPI00002806.1 Q16514>1 1.85 > > >1.22 > > > > > >
TAF1A IPI00024263.1 Q15573>1 > > > > > 1.45 > > > >
TAF1B IPI00291416.6 Q53T94>1 > > > > > 1.47 0.74 > > >
TAF1C IPI00246842.5 Q15572>1 > > > > 1.90 1.32 0.61 > > >
TAF2C IPI00413755.1 O00268 2.60 > > > > 0.99 0.33 > > 1.46
TAF2D IPI00298925.2 Q15542>1 2.36 >0.06 > >1.77 2.43 1.02 0.65 0.28 0.90 2.07
TAF2E IPI00944951.1 B4DT11 2.27 >0.10 > >2.57 1.47 1.23 0.52 0.13 0.84 1.13
TAF2F IPI00018111.1 Q15545 3.03 > > > > > > > > >
TAF2G IPI00002993.1 Q16594 1.78 0.15 0.03 0.09 0.51 0.37 >0.62 0.18 0.23 0.07
TAF3 IPI00853240.1 Q5VWG9 2.72 > > > > > > > > >
TAF8 IPI00065313.2 Q7Z7C8>2 1.26 >0.10 >0.09 >1.05 0.49 0.65 0.25 0.20 0.21 >
TAF9B IPI00642105.1 Q9HBM6 1.78 0.12 > 0.28 > 0.23 > > 0.18 0.02
TARDBP IPI00025815.2 Q13148>2 1.12 >0.32 0.05 0.81 >0.60 >0.18 >0.03 0.16 >0.45 0.45
TBC1D15 IPI00793999.2 E9PH93 > > > 1.11 >0.52 >0.30 >1.64 > >0.33 >0.12
TCF13 IPI00002901.5 P28347 >0.10 >0.19 0.23 >2.41 2.17 1.06 2.04 >0.22 >0.64 1.53
TCF4 IPI00221009.1 Q9NQB0>7 > > > >1.78 1.34 0.93 0.46 >0.65 > >
TCF6 IPI00020928.1 Q00059 >0.58 0.28 >0.13 >0.81 1.98 0.16 0.32 >0.46 0.53 1.06
TCHH IPI00015869.2 Q07283 > > > > > > > > > 2.04
TCOF1 IPI00815944.2 Q13428>3 1.05 1.11 >1.11 > > > > > > >
TEM6 IPI00658152.1 Q68CZ2>1 > > > 0.66 > >0.44 >1.34 > 0.27 >0.41
TGIF IPI00297138.2 Q15583>1 1.57 0.91 1.77 > > > > 0.79 > 1.53
THOC3 IPI00063729.4 Q96J01 0.58 > 0.41 0.67 > >0.15 >0.08 > >0.97 >1.07
TIGD1 IPI00043467.4 Q96MW7 > > > >1.85 > > > > > 1.96
TIM13B IPI00001589.1 Q9Y5L4 0.50 >0.02 >2.14 >0.37 0.25 0.43 >0.02 > 0.14 >0.05









Gene$Names IPI Uniprot H3K4me3 H3K9me3 meCpG H3K9me2 H3K27me1 H3K27me2 H3K27me3 H2Bub1 H3Δ1>20$
meCpG.$
H3K9me3
TOP3 IPI00013378.1 Q13472>1 1.61 0.31 >0.32 >0.47 1.48 0.60 0.25 >0.20 0.00 0.89
TRIO IPI00657953.2 O75962>1 > > > 1.73 > >0.61 >1.32 > > 0.00
TRIP12 IPI00783250.1 Q14CF1 >0.26 >1.06 >0.42 >0.19 1.93 0.34 0.30 >1.87 >0.07 0.67
TRIP12 IPI00032342.4 D4HL82 >0.23 >0.78 >0.28 0.15 2.00 0.25 0.29 >1.63 >0.04 0.62
TTF2 IPI00290812.2 Q9UNY4>1 0.39 >0.32 0.54 0.07 1.32 0.04 >0.37 >0.09 0.34 >0.16
UBCH5C IPI00749013.2 P61077>2 > > > > > > > > > 3.11
UFD1L IPI00873326.3 C9JS35 > > > 1.14 > > > > >0.45 >0.12
UHRF1 IPI00797279.1 A8K024 >2.36 2.54 1.77 3.17 1.58 >0.32 2.66 0.02 2.75 3.98
UNQ9342/PRO34
047
IPI00152695.2 Q6UXN9 1.24 >0.01 >0.06 >0.38 >0.55 >0.11 >1.18 2.08 >0.38 >0.43
USP3 IPI00002330.2 Q9Y6I4 > > > 0.10 > >1.81 > > > 1.55
UTP15 IPI00152708.4 Q8TED0 >0.09 0.61 >2.78 >0.04 0.86 0.33 0.59 0.60 >0.32 0.09
WDR18 IPI00032533.3 Q9BV38 0.81 0.20 0.04 0.17 >0.35 0.03 0.48 0.40 >0.13 >1.13
WDR3 IPI00009471.1 Q9UNX4 > > > > 0.01 > >1.66 > > >0.46
WDR36 IPI00169325.1 Q8NI36 > > > 0.84 >0.34 >0.36 >1.86 > 0.10 >0.14
WDR75 IPI00217240.1 Q8IWA0 >0.53 0.65 >2.61 > 0.91 0.34 0.49 1.94 >0.47 0.19
WEE1 IPI00025830.1 P30291 > > > >2.04 0.41 0.33 >0.84 0.60 > >0.16
XRCC1 IPI00002564.4 P18887 >0.09 0.03 >0.28 >1.57 0.38 1.10 0.72 0.12 >0.16 >0.47
ZBP89 IPI00010833.1 Q9UQR1 0.81 > > >2.14 0.79 0.41 >0.05 0.39 >0.61 1.19
ZBTB14 IPI00307325.2 O43829 0.52 0.56 > >1.57 2.14 0.69 1.12 >0.39 0.68 0.19
ZBTB15 IPI00026277.8 O15156 >0.38 >0.23 0.41 >0.82 0.96 0.53 0.54 0.37 0.10 1.60
ZBTB9 IPI00060141.3 Q96C00 > > > 0.22 1.77 > > > > >
ZFP276 IPI00847391.2 Q8N554>1 >0.59 > >1.04 > 2.28 0.38 0.41 > >0.15 >
ZFP38 IPI00001344.4 Q9Y5A6 0.38 0.10 >2.12 > 1.64 0.58 0.79 >0.54 >0.59 >
ZFP64 IPI00018906.6 Q9NPA5>1 0.02 > > > 1.73 0.88 0.74 >0.15 >0.01 >
ZHX1 IPI00293086.2 Q9UKY1 0.41 0.14 3.96 > 0.74 0.40 0.96 1.45 0.45 3.73
ZKSCAN4 IPI00005191.2 Q969J2 >0.07 >0.29 0.28 >1.45 2.64 0.20 1.07 >0.61 0.22 1.76
ZMYM3 IPI00641109.1 A6NHB5 > 2.53 > 0.95 > 0.28 0.72 0.60 >0.17 1.91
ZNF131 IPI00658062.1 P52739>1 0.22 0.13 >3.99 >1.38 0.76 0.93 0.51 0.34 0.76 >0.02
ZNF580 IPI00478837.1 Q9UK33 >0.36 1.47 > > > > > 0.20 > 2.74
ZNF691 IPI00301583.3 Q5VV52>1 >0.05 0.16 0.30 >1.51 1.26 0.16 0.57 >0.17 >0.28 1.41
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